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1.1. SCHIZOPHRENIA 
1.1.1. Epidemiology, symptoms and aetiology  
Psychotic phenomena are abnormal mental states involving loss of contact with reality. The 
understanding of its triggering agents has been the spotlight of numerous attempts 
throughout recorded history, tracing back to Plato and Aristotle era. Even many observations 
have noted similarities between three major, still partially known, processes namely dreams, 
hallucinogenic drug states, and psychosis. Thus, Kant stated “The lunatic is a wakeful 
dreamer”. Shopenhauer wrote “A dream is a short-lasting psychosis, and a psychosis is a long-
lasting dream”. Freud simply marked “A dream, then, is a psychosis” (Fischman, 1983). A 
different current of thought states that schizophrenia is the price that humans pay for 
language (Crow, 2000). Therefore, the understanding of the aetiology and course of psychosis 
has become the cornerstone for the better understanding of the disease, crucial to develop 
effective treatments. 
 
The German psychiatrist Emil Kraepelin (1896) was the first to describe schizophrenia as a 
neurodegenerative disease, introducing the term “dementia praecox” in the book “Psychiatrie: 
Ein Lehrbuch für Studirende und Aertze”. He undertook extensive research on psychiatric 
symptomatology classification, psychiatric degenerative processes and risk factors that 
predispose to the development of the disease. The reputable Swiss psychiatrist Paul Eugen 
Bleuler understood the illness as a neurodevelopmental disorder stating the term 
“schizophrenia” for the first time in a conference in 1908. Bleuler thought that “dementia” was 
an effect not directly caused by the underlying biological process and made great efforts to 
understand the complexity of the disease (Bleuler, 1978). 
 
After more than a century of studying schizophrenia, the causes of the disorder remain poorly 
understood. Pharmacological treatments have been in wide use for nearly half a century, yet 
there is little evidence that these treatments have substantially improved the course of the 
disease for many patients with schizophrenia. Such unsatisfactory results lead to rethink 
schizophrenia as a neurodevelopmental disorder with psychosis as the latest stages, and that 
could be potentially prevented gaining insight into its aetiology. 
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Schizophrenia is a chronic and disabling mental illness that affects roughly 0.7% of the 
population worldwide (Faludi et al., 2011). Although the incidence is relatively low (McGrath et 
al., 2008), its chronicity makes the disease burden greater, being ranked as one of the top ten 
causes of long-term disability (Murray & Lopez, 1996; Carr et al., 2003; Mueser & McGurk, 
2004). The onset of the disease is most commonly during adolescence or early adulthood (16-
30 years) (Mueser & McGurk, 2004). A later age of onset in females has been reported 
(Hambrecht et al., 1992; Jablensky et al., 1992; Häfner et al., 1993; Castle et al., 1995; 
Takahashi et al., 2000; Venkatesh et al., 2008), likely due to gonadal hormones and their 
interactions with neurotransmitters (Halbreich & Kahn, 2003). 
 
To establish reliable criteria for diagnosing schizophrenia and closely related behavioral 
disorders, the guidelines most commonly used by psychiatrists are the Tenth Revision of the 
International Classification of Disease (ICD-10) (World Health Organization, 1992), and the Fifth 
Edition of the Statistical Manual of Mental Disorder (DSM-5) (American Psychiatric Association, 
2013). 
 
Schizophrenia symptoms are grouped into three main categories: 
• Positive symptoms: visual, auditory (most frequently), olfactory or tactile 
hallucinations, and false beliefs (delusions). These symptoms tend to occur in 
episodes, separate by full or partial remissions. Neuroleptic drugs are generally more 
effective for positive than negative symptoms. Acute exacerbations of these symptoms 
might be precipitated by major life events or critical family atmosphere. 
 
• Negative symptoms: apathy (no interest or unwilling to initiate or follow through on 
plans), emotional blunting (e.g. immobile facial expression, monotonous voice tone), 
anhedonia (lack of pleasure), social withdrawal and alogia (impoverished language). 
These symptoms are typically continuous rather than episodic, although do not affect 
all schizophrenic patients. 
 
• Cognitive impairment: difficulties in attention and concentration, learning, memory, 
and executive functions (e.g. abstract thinking and problem solving). 
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The study of the aetiology of schizophrenia has been the focus of intensive research for 
decades, albeit is poorly known so far. However, both genetic and environmental factors 
appear to be key players in the emergence of the disease. While some researchers understand 
schizophrenia as a neurodevelopmental disorder, having its roots in early brain development 
followed by neurological and behavioral abnormalities since childhood (Bender, 1947; Watt, 
1978); others converge towards a neurodegenerative hypothesis of schizophrenia as a 
“dementia praecox” with a progressive downhill course (Pino et al., 2014). Nevertheless, both 
theories are synergic rather than exclusive, inasmuch as they can individually explain 
phenomena observed in different stages of the illness (Berlim et al., 2003; Gupta & Kulhara, 
2010). 
 
1.1.1.1. Genetic risk factors 
 
Kraepelin already mentioned that about 70% of his patients with dementia praecox had a 
family story of psychosis. Compelling evidence posits the importance of genetic factors in the 
development of schizophrenia. Siblings or offspring of first degree schizophrenic patients are 
up to ten times at higher risk than the general population, reaching up to 46% higher 
probability of developing the disease when both parents are affected, and 85% when a 
monozygotic twin is affected (McGuffin et al., 1995; Cardno et al., 1999). That risk decreases in 
second and third degree relatives of schizophrenia, but it is still higher than in the general 
population. 
 
A substantial number of candidate genes underlying genetic risk for schizophrenia has been 
postulated using genome wide association studies (GWAS) and copy number variation studies 
(CNV) (Lee et al., 2012), including: neuregulin-1 (NRG1), catechol-O-methyl-transferase 
(COMT), brain derived neurotrophic factor (BDNF), disrupted in schizophrenia-1 (DISC1), N-
methyl-D-aspartate (NMDA) receptor subunit (NR1), regulator of G protein signaling 4 (RGS4), 
Dysbindin, Reelin, phosphodiesterase 4B (PDE4B) (Berry et al., 2003; Di forti et al., 2007; Gray 
& Roth, 2007; Carpenter & Koenig, 2008; Lu et al., 2011) (Figure 1). 
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However, over 60% of schizophrenic patients have no first or second degree relatives with the 
disorder (Bleuler, 1978), pointing out that environmental factors may also play an important 
role. 
 
1.1.1.2. Environmental risk factors 
 
Several biological and psychosocial factors have been posited to play a role in the emergence 
of schizophrenia (Broome et al., 2005). Maternal viral infections (Mednick et al., 1988; Barr et 
al., 1990; Shi et al., 2003; Brown & Derkits, 2010; Moreno et al., 2011b), obstetric 
complications (Goodman, 1988; Thomas et al., 2001; Cannon et al., 2002), maternal nutritional 
deficits (Andrews, 1990; Susser et al., 1996; Mackay et al., 2017), paternal age (Messias et al., 
2007), and cannabis use (Bangalore et al., 2008; Wilkinson et al., 2015) among others, have all 
been suggested to increase the risk of the illness. 
 
In terms of sociodemographic factors, Bruce and co-workers (1991) demonstrated that lower 
social classes are at higher risk for a number of psychiatric disorders, including schizophrenia. 
People living in urban regions would also be at higher risk than those living in rural areas (Peen 
Fig. 1- Hypothetical schematic picture of various putative candidate genes, which confer susceptibility to develop schizophrenia, 
including DISC-1, Dysbindin, NMDA, NRG1, RGS4, and PDE4B. Other abbreviations are: Glu (glutamate), DA (dopamine), 5-HT2A
(serotonin 2A receptor, 5-HT2AR), mGluR5 (metabotropic glutamate 5 receptor), D1 (dopamine receptor 1), ErbB4 (ErbB-type 
tyrosine kinase receptor B4), cAMP (cyclic adenosine monophosphate), Gq/Gs (G proteins), PSD95 (postsynaptic density protein 
95), D-ser (D-serine) (Adapted from Gray & Roth, 2007). 
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& Dekker, 1997; Marcelis et al., 1999; McGrath et al., 2004; van Os, 2004; Krabbendam & van 
Os, 2005; Spauwen et al., 2006). Even some authors have reported that season of birth can 
influence the incidence of developing schizophrenia, positing winter and early spring as the 
season with higher risk to develop the disease (Mortensen et al., 1999; Dean & Murray, 2005).   
 
There is controversy about the incidence variation of schizophrenia across countries. The 
influential study of the incidence of schizophrenia among 10 countries, the WHO 10 Nation 
Study, points schizophrenia as an egalitarian disorder, affecting equally to the population all 
over the world. However, prognosis is better in developing countries patients than in 
developed countries (Jablensky et al., 1992). Elevated rates are present in some ethnic 
minorities, likely attributable to the stress of being a minority, which could lead to increased 
vulnerability to schizophrenia in biologically predisposed individuals (Boydell et al., 2001). 
Conversely, others support that schizophrenia rates vary internationally (McGrath, 2005; 
Messias et al., 2007).  
 
A relatively new theory in vogue to explain processes of schizohrenia links neuroinflammation 
with higher risk of developing schizophrenia (Müller et al., 2015; Pasternak et al., 2016). In this 
sense, pro-inflammatory cytokines could lead to structural neuroanatomic alterations in 
regions of the brain implicated in schizophrenia (Ellman et al., 2010). Even changes in intestinal 
microbiota composition, as a factor to yield inflammation, have been postulated to confer risk 
of schizophrenia, through a gut-brain axis. Increased incidence of gastrointestinal barrier 
dysfunction, food antigen sensitivity, inflammation, and metabolic syndrome found in 
schizophrenic patients may be influenced by the gut microbiota composition (Nemani et al., 
2015; Rogers et al., 2016; Dinan & Cryan, 2017). 
 
1.1.2. Antipsychotic treatment 
Antipsychotic drugs are the keystone in the treatment and management of schizophrenia. To 
date, none of them cure the disease, but they greatly reduce the symptoms, especially the 
positive symptoms, and bestow on patients a better quality of life. 
 
Dating back to 1950s, the French doctor Henri Laborit serendipitously discovered the drug 
chlorpromazine when looking for sedative drugs to treat states of shock. Later on, the French 
psychiatrists Jean Delay and Pierre Deniker proved its intrinsic antipsychotic effects 
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suppressing hallucinations and delusions in psychotic patients. That was the beginning of the 
modern pharmacological era. From that time on, increasing efforts have been made to 
discover new antipsychotic treatments. The “first-generation antipsychotics” or “typical 
antipsychotics”, known also as “neuroleptics”, encompass chlorpromazine, fluphenazine, 
haloperidol, loxapine, perphenazine, thioridazine, thiothixene and trifluoperazine. They can 
effectively treat positive symptoms, but their efficacy in treating negative and cognitive 
symptoms is limited. They all block dopamine D2 receptors, even those located in the 
nigrostriatal core, increasing the risk of developing extrapyramidal side effects (EPS) (e.g. 
bradykinesia, tremor and rigidity). This generation of drugs can also impair cognitive and 
emotional symptoms. Thus, its use has been declined in the last few years, being replaced by 
the “second-generation antipsychotics”. 
 
Shortly after clozapine was approved by the Food and Drug Administration (FDA), in 1990, the 
era of “atypical antipsychotics” - also termed “second-generation antipsychotics” - began. 
Clozapine stood out as an effective psychotic treatment, ameliorating positive symptoms, even 
in antipsychotics non-responder patients (Carpenter & Koenig, 2008; Swartz et al., 2008; Van 
Sant & Buckley, 2011), improving cognitive impairment (Meltzer, 1999), and sharply reducing 
the rate of suicide attempt, the main case of premature death in schizophrenic patients 
(Meltzer, 2001). However, the dark side of clozapine that restricts its prescription as a first 
choice is the risk of suffering fatal agranulocytosis, estimated to occur among 1-2% of treated 
patients in the first months under treatment (Alvir et al., 1993). That was how clozapine gave 
way to other atypical antipsychotic drugs as first choice use such as quetiapine, risperidone, 
olanzapine, aripiprazole, asenapine, lurasonide, paliperidone and ziprasonide, with similar 
pharmacological properties, but without agranulocytosis risk. Normal doses of these drugs 
produce little or no EPS, but other kind of side effects, mainly metabolic adverse effects which 
comprise weight gain, raising blood sugar, cholesterol and triglyceride levels (Melkersson & 
Dahl, 2004). 
 
Meltzer (1989) postulated the hypothesis that what really confers effectiveness to 
antipsychotic treatments is the serotonin 2A receptor (5-HT2AR) and dopamine D2 receptor 
blockade ratio (5-HT2AR:D2), since high ratios would trigger negative symptoms, whereas low 
ratios would evoke positive symptoms. Atypical antipsychotic drugs are characterized by their 
low affinity to block D2 receptors as well as their profile as 5-HT2AR antagonists. The optimal 
occupancy of D2 receptor appears to be crucial to balance efficacy and side effects (Meltzer, 
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1989; Meltzer et al., 1989). These drugs are able to block D2 receptor transiently (termed the 
“fast-off-D2 theory”), sufficient to exert antipsychotic effects with few or no EPS (Seeman, 
2014). They are also antagonists at 5-HT2AR, able to modulate dopamine (DA) neuronal firing 
in areas such as dorsal striatum, prefrontal cortex (PFC), and nigrostriatum. The ability to 
enhance dopaminergic activity in the former areas might explain their efficacy for negative and 
cognitive symptoms (likely related to prefrontal dopaminergic hypoactivity). The increased in 
DA release in nigrostriatal areas may balance the D2 antagonism, resulting in milder EPS 
(Kessler et al., 2005). Animal studies have revealed that 5-HT2AR antagonists have 
antipsychotic-like effects (Varty et al., 1999). However, a subsequent clinical trial confirmed 
that the selective 5-HT2AR antagonist M100907 was more effective than placebo at treating 
schizophrenia, but did not show significantly greater efficacy than the typical antipsychotic 
haloperidol in neuroleptic-responsive patients (de Paulis, 2000; Halberstadt & Geyer, 2013b). 
Even M100907 could worsen negative symptoms of schizophrenia and withdrawal syndrome 
triggered by chronic drug use (Semenova & Markou, 2010). Ritanserin, a drug with high affinity 
at 5-HT2AR and serotonin 2C receptor (5-HT2CR) and much lower affinity at D1, α1- and α2-
adrenoceptors (Leysen et al., 1985) has never marketed for clinical use as antipsychotic alone, 
but it could be useful as an adjunctive treatment strategy for the negative symptoms of 
schizophrenia (Akhondzadeh et al., 2008). Recently, a selective 5-HT2AR inverse agonist 
(pimavanserin, ACP-103) which does not block D2 receptros (Stahl, 2016), has been reported to 
reverse psychosis-like behaviors associated with Parkinson’s disease (Ballanger et al., 2010; 
McFarland et al., 2011; Sarva & Henchcliffe, 2016; Bozymski et al., 2017). 
 
α-Adrenoceptors, α1 and α2, are other target receptors of some atypical antipsychotics. It has 
been shown that risperidone can antagonize α2-adrenoceptors, and this antagonism could 
likely be a plus in its efficacy as antipsychotic (Raja, 2009). Dopamine D1 and D3 receptors, as 
well as the 5-HT2CR antagonism, confer properties that may also play a role in their efficacy, as 
well as the agonist effects at serotonin 1A receptor (5-HT1AR) (Horacek et al., 2006). 
 
According to the Practice Guideline for the Treatment of Patients with Schizophrenia, Second 
Edition (American Psychiatric Association, APA, 2010), the appropriate treatment of 
schizophrenia depends on the phase of the disorder: 
 
• Acute phase: the aim is to treat psychotic symptoms, prevent harm and control 
disturbed behavior. Frequently higher doses of antipsychotics are employed. Oral 
medication is mostly preferred, albeit non-adherent patients with recurrent relapses 
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are candidates for long-lasting antipsychotic injectables. Special care must be taken to 
protect patients from suicidal intentions. Lifetime risk of suicide among schizophrenic 
patients is 12-25 times greater than in the general population (Meltzer, 2001; Dutta et 
al., 2010). Sometimes co-treatment with other kind of drugs such as benzodiazepines 
is required. 
 
• Stabilization phase: dosage is monitored to prevent adverse effects, and improves 
adherence to treatment in order to promote the recovery, minimize relapses and let 
patients return to a normal life. 
 
• Stable phase: treatment is usually life-long maintained at a minimal effective dose, 
regularly monitored to ensure controlled symptom remission and adverse side effects. 
While most of schizophrenic patients improve with antipsychotic treatment, there is a 
minority of adherent patients who do not respond to medications, termed “treatment 
resistant patients”. By contrast, a few of them seem not to need it (Harvey & 
Rosenthal, 2016). Adjuvant psychosocial interventions are also recommended in all 
phases of schizophrenia. 
 
1.1.3. Animal models of schizophrenia 
Animals are widely employed to mimic physiological or pathophysiological processes occurred 
in humans with the ultimate goal of gaining insight into the biology, pathophysiology and 
treatment of a human disease. Animal models serve as tools for studying psychiatric disorders, 
inasmuch as they allow the use of research methods which are impossible to undertake in 
humans for ethical reasons. Many approaches are employed to generate animal models, such 
as genetic engineering, brain lesions, environmental manipulations, prenatal drug exposures, 
optogenetic tools or pharmacological treatments (Nestler & Hyman, 2010; Jones et al., 2011). 
 
However, the main limitation of the use of animal models to study psychiatric disorders is the 
uniquely human nature of psychiatric diseases, with a strong subjective component. Thus, the 
effects observed in humans cannot be directly reproduced in animals. For this reason, animal 
models are generated as proxies for specific signs or symptoms linked to an illness. 
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The validity and reliability of animal models must be evaluated using established criteria 
guidelines. There are three types of validators (Figure 2): 
 
• Construct validity: animals must present the etiological processes of the illness (e.g. 
knocking out a specific gene that potentially confers susceptibility to develop a disease 
in humans) (Chadman et al., 2009). 
 
• Face validity: indicates the plausibility to reproduce anatomical, behavioral, 
biochemical, neuropathological features and/or neurochemical abnormalities of the 
human disease. 
 
• Predictive validity: ability of the pharmacological effective treatment in humans to 
revert the signals and symptoms evoked in that animal. It allows the discovery of 
potential novel therapeutic approaches. 
 
 
 
Many different animal models of schizophrenia have been created and postulated to lend pro-
psychotic properties, although modeling psychosis in animals remains controversial since is 
difficult to evaluate psychosis-like states in the absence of verbalization. Various genetically 
modified mice, knocking down candidate genes (e.g. DISC1, NRG1, erbB4, Dysbindin and 
Reelin), or overexpressing specific proteins (e.g. Munc 18-1), have been reported to resemble 
behavioral components of schizophrenia (Carpenter & Koenig, 2008; Jones et al., 2011; 
Urigüen et al., 2013). Other approaches that have triggered positive and negative symptoms as 
well as cognitive deficits of schizophrenia include: environmental-based interventions, such as 
Fig. 2- Schematic diagram of the three types of validators necessary for creating animal models of schizophrenia. 
Based on Jones et al., (2011). 
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post-weaning social isolation; virus analogue administration to pregnant mice using 
polyinosinic-polycytidilic acid (poly(I:C)); pharmacological approaches; or brain lesions, such as 
in ventral hippocampus (Carpenter & Koenig, 2008; Jones et al., 2011; Koh et al., 2016; 
MacDowell et al., 2016).  
 
The most common pharmacological approaches to recapitulate symptoms of schizophrenia in 
healthy humans and rodents include the use of NMDAR antagonists (e.g. PCP, ketamine and 
MK-801), hallucinogenic 5-HT2R agonist drugs (such as psilocybin, (±)-DOI or lysergic acid 
diethylamide - LSD -), monoamines uptake inhibitors (such as amphetamine and cocaine), and 
the primary active component of cannabis, ∆9-tetrahydrocannabinol (THC) (Steeds et al., 
2015). They all produce psychotic symptoms and cognitive disturbances in healthy humans and 
rodents (Quednow et al., 2012; Hanks & González-Maeso, 2013; Steeds et al., 2015; Talpos et 
al., 2015; De Gregorio et al., 2016). However, it is important to note that, in contrast to drug 
models, schizophrenia is chronic, neurodevelopmental, and episodic, with different symptom 
domains predominating at different stages. Therefore, any purely pharmacological model is 
likely destined to be incomplete in the extent to which it can represent the full picture of 
schizophrenia.  
 
In humans, the psychostimulants amphetamine and cocaine, the dissociative anesthetics PCP 
and ketamine, the hallucinogenic 5-HT2AR agonists LSD and psilocybin, as well as THC have 
been reported to induce psychotic states in healthy individuals and exacerbate psychotic 
episodes in people with existing schizophrenia (Lahti et al., 1995; D’Souza, 2007; Koethe et al., 
2009; Morrison et al., 2009; Morrison & Stone, 2011). Positive symptoms induced by these 
drugs include agitation, anxiety, visual hallucinations and illusions, which are similar to 
symptoms seen in the first psychotic episode of the illness (Hyde et al., 1978; Fletcher & 
Honey, 2006). Acute doses of ketamine in healthy volunteers induce schizophrenic-like positive 
and negative symptoms, and may also lead to impairments in cognitive functions that 
resemble schizophrenia (Morgan et al., 2004; Krystal et al., 2005; Deakin et al., 2008; Stone et 
al., 2012). However, there are several dissimilarities between the ketamine-, THC- and 
hallucinogenic 5-HT2AR agonists-induced states and schizophrenia (Koethe et al., 2006; Steen 
et al., 2006). For instance, auditory hallucinations are one of the most common symptoms in 
this disease, but the hallucinations and illusions experienced following acute administration of 
the latter drugs are more commonly visual (Abi-Saab et al., 1998; Klosterkotter et al., 2001; 
Steen et al., 2006; Geyer & Vollenweider, 2008). On this basis, it has been suggested that, 
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rather than modeling chronic schizophrenia, acute ketamine or hallucinogenic 5-HT2AR agonist 
drugs administration may induce a state closer to the prodrome/early stages of schizophrenia 
(Klosterkotter et al., 2001; Corlett et al., 2007).  
 
On the other hand, chronic PCP and ketamine users have persistent schizophrenia-like 
symptoms (Krystal et al., 1994; Jentsch & Roth, 1999), and such patients may display a 
symptomatic profile that can so closely resemble schizophrenia (Abi-Saab et al., 1998). 
Reported symptoms triggered by chronic consumption of PCP and ketamine include paranoid 
delusions, persistent cognitive deficits, and greater incidence of auditory than visual 
hallucinations (Jentsch & Roth, 1999). Depressive and dissociative symptoms also increase with 
persistent use of ketamine (Morgan et al., 2004). The chronic abuse of these substances 
produces biochemical brain changes that are similar to those seen in schizophrenia patients.  
Chronic ketamine users have reduced PFC grey matter volume (Liao et al., 2011) and 
decreased blood flow in the frontal cortex, similar to that seen in schizophrenia (Hertzmann et 
al., 1990). Moreover, dopamine D1 receptors are upregulated in the frontal cortex of patients 
with schizophrenia and in chronic ketamine users (Narendran et al., 2005). This upregulation is 
associated with cognitive impairment and dopaminergic hypofunction (Narendran et al., 
2005). 
 
Individuals with a family history of schizophrenia appear to be at greater risk of schizophrenic 
symptoms following LSD consumption, and it has been suggested that LSD use may lead to an 
earlier onset of this disease (Vardy & Kay, 1983).  
 
In rodents, amphetamine, hallucinogenic 5-HT2AR agonists, and NMDAR antagonists 
administration have been reported to yield hyperlocomotion and repeated (“stereotyped”) 
behaviors, including sniffing, chewing, head-weaving, backpedalling and turning, that may be 
related to the positive symptoms of psychosis. All these families of drugs produce negative 
symptoms (such as delusions in terms of basic associative learning processes, immobilization in 
the forced swim test, and social withdrawal) (Corbett et al., 1995; Sams-Dodd, 1998a,b, 1999; 
Corlett et al., 2007; Jenkins et al., 2008; Marona-Lewicka et al., 2011). Acute and repeated 
administration of the latter recreational drugs have been reported to develop also cognitive 
impairments, including spatial working memory (Schneider & Koch, 2003; Beraki et al., 2009; 
Rubino et al., 2008; Realini et al., 2009), and attentional disturbances (Corlett et al., 2007). 
Acute and chronic treatment with PCP, THC and hallucinogenic 5-HT2AR agonists in rodents 
impair prepulse inhibition (PPI), a marker of sensory gating impairment also described as 
altered in patients with schizophrenia (Jackson et al., 1994; Kitaichi et al., 1994; Ogren and 
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Goldstein, 1994; Jentsch & Roth, 1999; Schneider & Koch, 2003; Jones et al., 2011; Steeds et 
al., 2015). Notably, hallucinogenic 5-HT2AR agonists disrupt PPI through direct stimulation of 
the 5-HT2ARs (Aghajanian & Marek, 2000; Quednow et al., 2012).  
 
One of the most used behavioral proxies performed in rodents for human hallucinogen effects 
is the drug-induced “head twitch” response (HTR) (Halberstadt & Geyer, 2014). The first 
description of a drug-elicited HTR was reported in 1956 by Keller and Umbreit, following 
intravenous administration of LSD to mice. They described an easily observed and quantifiable 
response similar to the reflexive response observed when the ear is touched or pinched (the 
pinna reflex response), or following LSD administration (which became ‘permanent’ in a subset 
of mice following an injection of indole followed by LSD). In their words: “The response 
consists of a rapid and violent head shaking. . . The head-twitch response does not occur in 
normal mice, and with a little experience the response is easy to detect. Independent 
observations by different workers are remarkably consistent, so that provided a suitable tool 
for the behavioral studies” (Canal & Morgan, 2012). HTR is well defined as a rapid side-to-side 
rotational head movement that occurs in rats and mice after injection of psychedelic 
compounds, such as LSD, (±)-DOI, 2,5-dimethoxy-4-methylamphetamine (DOM) or 2,5-
dimethoxy-4-bromoamphetamine (DOB) (serotonergic agonists with high affinity for 5-HT2AR 
(Halberstadt & Geyer, 2011; Canal & Morgan, 2012; Canal et al., 2013), PCP (Hori et al., 2000), 
and other GPCR selective agonists (Vollenweider et al., 1998; González-Maeso et al., 2003; 
Moreno et al., 2011a). Head-twitches in rats are sometimes referred to as wet-dog shakes 
because in that species the behavior frequently involves the head, neck, and trunk (Bedard & 
Pycock, 1977). There is a body of evidence aiming at the 5-HT2AR as the main responsible for 
the occurrence of hallucinations in humans and the associated animal behavioral paradigms as 
HTR (Pranzatelli, 1990; Willins & Meltzer, 1997; González-Maeso et al., 2003; González-Maeso 
et al., 2007; Quednow et al., 2012; Kometer et al., 2013; Halberstadt, 2015). Notably, despite 
the fact that lisuride is a 5-HT2AR agonist, studies indicate that lisuride does not evoke HTR 
(González-Maeso et al., 2003; González-Maeso et al., 2007; Halberstadt & Geyer, 2010). Based 
on the behavioral inactivity of lisuride in this paradigm, it appears that the HTR has utility as a 
behavioral screen that can distinguish hallucinogenic versus non-hallucinogenic 5-HT2AR 
agonists (Geyer & Vollenweider, 2008). In recent years, HTR has become one of the few 
behaviors that can reliably distinguish hallucinogenic and non-hallucinogenic 5-HT2AR 
agonists, a behavioral response antagonized by 5-HT2AR antagonist antipsychotic drugs 
(González-Maeso et al., 2007).  
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Another proxy for schizophrenia in rodents is a deficit in PPI. PPI describes the phenomenon in 
which a weak initial stimulus (the prepulse) inhibits the startle response that is elicited by a 
strong stimulus. Deficient PPI is thought to demonstrate impaired sensorimotor gating that 
occurs in schizophrenia, but also in several other neuropsychiatric disorders (Sipes & Geyer, 
1994; Powell et al., 2009; Vollenweider et al., 2007; Halberstadt & Geyer, 2010). Hallucinogens 
affect PPI in humans and rodents (Halberstadt & Geyer, 2013a; Hanks & González-Maeso, 
2013).  
 
In the present Doctoral Thesis, three types of genetically modified mice, animals lacking 
mGluR2, mGluR3 or 5-HT2AR, were used to gain insight into the pathophysiology of 
schizophrenia. Pharmacological approaches administering the psychedelic drug 2,5-dimethoxy-
4-iodoamphetamine ((±)-DOI) have been used to mimic psychosis-like effects in mice, 
evaluating HTR.  
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1.2. NEUROTRANSMISSION NETWORKS: FOCUS ON DOPAMINE AND 
NOREPINEPHRINE 
1.2.1. From DA and NE synthesis to synapse: a brief understanding  
DA and norepinephrine (NE) - also termed noradrenaline (NA) - belong to a group of 
neurotransmitters termed catecholamines, due to the presence of a catechol ring and an 
amine side chain. The above catecholamines together with serotonin comprise the family of 
monoamines, in view of the existence of a unique amine group in their structures. They are 
neurotransmitters, endogenous chemicals released from synaptic vesicles into the synaptic 
cleft, where they interact with receptors on the target cells. 
 
Tyrosine is the precursor amino acid (AA) for the synthesis of both monoamines. It is mainly 
provided with the dietary intake, albeit a small proportion is derived from hydroxylation of 
phenylalanine by the action of the liver enzyme phenylalanine hydroxylase. Tyrosine is 
transported by blood, can cross the blood-brain-barrier (BBB), and is finally taken up into 
neurons. Dopamine is synthesized in the cytoplasm of dopaminergic neurons by the action of 
two enzymes, the rate-limiting factor tyrosine hydroxylase (TH), and the aromatic L-amino acid 
decarboxylase (AADC), in this case DOPA descarboxylase (DDC) (Figure 3). Once DA is 
synthesized, it is translocated 
by the vesicular monoamine 
transporter (VMAT) into 
storage vesicles. DA can be 
further turned into NE inside 
the vesicles by the enzyme 
dopamine-β-hydroxylase (DBH) 
(Südhof & Starke, 2008). DA 
and NE can be synthesized and 
released from dendrites, as 
well as from terminal regions. 
 
Vesicle membrane contains an 
H+-ATPase, which maintains 
the proton gradient that 
Fig. 3- Representative picture of DA synthesis, storage, release and 
metabolism. DA is synthesized from the amino acid tyrosine by two steps 
involving TH and DDC enzymes. Once synthesized DA is stored in axon 
terminals vesicles or can be degraded by action of MAOA. Once DA is 
released in the synaptic cleft can act at postsynaptic receptors, be 
metabolized by MAOA, MAOB and COMT or re-uptaken back into the 
presynaptic neurons through DAT. 
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energizes VMAT and preserves an acidic intravesicular environment. An action potential is 
generated by Na+ entrance through the opening of its voltage-dependent channels, which 
depolarizes the membrane potential and triggers the activation of voltage-dependent K+ 
channels, which leads to K+ efflux. Upon the arrival of an action potential (input), which is 
initiated in a cell body and travels along the neuron to the terminal nerve, a change in 
membrane protein conformation allows the influx of Ca2+, which is a key part to trigger the 
fusion of vesicles with the neuronal membrane and the neurotransmitter release (output) into 
the synaptic cleft, a process termed exocytosis (Hilfiker et al., 1999; Westfall et al., 2002).  
During this process, there is a fusion between the membranes of the vesicles and the cell 
membrane of the presynaptic neuron, which involves the action of certain proteins (SNARE 
proteins) to mediate the docking process, including: synaptobrevin, synaptotagmin, SNAP-25, 
syntaxin, and N-ethylmaleimide sensitive factor (NSF) (Südhof, 2004). 
 
Once neurotransmitters are released and remain in the synaptic cleft they can target receptors 
on postsynaptic neurons, but also can fall prey of metabolic enzymes: monoamine oxidase 
isoforms (MAO) – MAOA located primarily in mitochondria of NE and DA neurons but also in 
glial cells and astrocytes, and MAOB located in glial cells and astrocytes -, and COMT - located 
in glia and in the external membrane of postsynaptic neurons -. Degradation metabolites of DA 
include: 3,4-dihydroxyphenyl-acetic acid (DOPAC), 3-methoxytyramine (3-MT), and 
homovanillic acid (HVA). On the other hand, when NE is degraded generates the following 
metabolites: normetanephrine, DOPAC, vanillylmandelic acid (VMA), 3-methoxy-4-
hydroxyphenylethyleneglycol (MOPEG), and epinephrine (E) (Rang et al, 2007). Determination 
of the DOPAC/DA concentration ratio is a useful method to estimate rapid changes in neuronal 
activity. Released DA and NE in the synaptic cleft can be reuptake into synapses vesicles in the 
presynaptic neuron by the DA transporter (DAT) or the NE transporter (NET), respectively 
(Südhof & Starke, 2008). 
 
 
1.2.2. Main DA-containing nuclei and projection pathways  
DA has been largely associated with physiological and neuropathological processes such as 
arousal, stress, reward, social behavior, drug addiction, depression, and schizophrenia, among 
others (Graybiel, 2000; Vetulani, 2001; Dunlop & Nemeroff, 2007; Kress et al., 2013; Cho & 
Sohal, 2014; Laman-Maharg & Trainor, 2017). 
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The majority of the DA-containing neurons are clustered in two principal areas in the midbrain: 
the substantia nigra (SN) and the ventral tegmental area (VTA) (Tritsch & Sabatini, 2012). DA 
neurons appear to be capable of storing and releasing DA from somatodendritic areas in the 
SN (Cheramy et al., 1981) and in the VTA (Kalivas & Duffy, 1991) in a calcium-dependent, 
tetrodotoxin (TTX)-sensitive manner.  DA can be released by axonal and somatodendritic sites 
and both mechanisms can be regulated by similar factors, although somatodendritic release is 
less influenced by action potential generation and less responsive to some releasing agents 
(Kalivas & Duffy, 1991).  
 
Ascending dopaminergic projections constitute the main DA pathways: the nigrostriatal 
pathway, which arises from the SN and innervates predominantly the striatum (caudate-
putamen); and the mesocorticolimbic pathway, which originates in the VTA and projects to the 
frontal cortex (FC) through limbic areas such as amygadala (A), nucleus accumbens (NAcc) and 
hippocampus (Albanese & Minciacchi, 1983; Sesack et al., 1995; Taylor et al., 2014) (Figure 4). 
The mesocorticolimbic system can be further subdivided into two subsystems, depending on 
the location of the dopaminergic cell bodies within the VTA, and the projecting areas. Thus, 
dopaminergic cells arising from the VTA projecting to the NAcc comprise the mesolimbic 
system, which is largely associated with reward, motivation and social behavior (Kim et al., 
2016; Laman-Maharg & Trainor, 2017); whereas projections arising from the VTA to cortical 
structures comprise the mesocortical system, thought to be involved in the modulation of 
cognitive functions (Tzschentke, 2001; Alex & Pehek, 2007). The nigrostriatal dopaminergic 
system has been classically associated with the control of voluntary movement.  
 
Another important dopaminergic loop in the brain is the hypothalamo-hypophyseal pathway, 
which transmits DA from the arcuate nucleus (infundibular nucleus) of the hypothalamus to 
the pituitary gland via DA release into the median eminence and subsequent circulation 
through the hypophyseal portal system (Björklund et al., 1968). This pathway regulates the 
secretion of certain hormones, such as prolactin, from the pituitary gland. Hypothalamus acts 
as a negative regulator of prolactin secretion in the pituitary systems, through the release of 
the neurotransmitter DA. Moreover, prolactin itself regulates the secretion of the inhibitory 
factor, DA (Grattan, 2015). MacLeod and co-workers (1970) demonstrated that dopaminergic 
agonists were effective at suppressing prolactin secretion in vivo, as well as the ability of DA as 
an inhibitor of prolactin secretion from pituitary glands. Supporting evidence were later found 
when DA receptors were identified on lactotroph cells in the anterior pituitary (Mansour et al., 
1990), and after observing that mice lacking D2 receptors are hyperprolactinemic (Kelly et al., 
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1997; Saiardi et al., 1997). Altogether, clearly demonstrates the crucial role of DA in 
suppressing endogenous prolactin secretion. 
 
Dopamine exerts its effects by interaction with the dopamine D1 family receptors (comprising 
the D1 and D5 subtypes) and the D2 family receptors (comprising the D2, D3, and D4 subtypes). 
While activation of D1 family receptors are thought to trigger excitatory effects, D2 family 
receptors appear to display a pharmacological inhibitory profile. Presynaptic somatodendritic 
D2 receptors located on dopaminergic neurons in the VTA play an important role as 
autoreceptors. Activation of these receptors inhibits the cell firing and the DA release in the 
VTA. Conversely, their blockade enhances DA activity (Adell & Artigas, 2004). 
 
DA neurons exhibit at least three electrophysiological patterns of activity along which they are 
capable of activating postsynaptic transmitter release: a change from inactive to 
spontaneously discharging state, an increase in the rate of spontaneous spike discharge, and 
an alteration from single-spiking to a burst-discharge mode of activity. An additional state, 
involving depolarization block, occurs when an abnormally large demand, typically mediated 
by an exogenous pharmacological agent, causes the system to be overdriven to the inactivity 
state. DA neurons have been shown to be under a number of complex regulatory influences. 
Firstly, the membrane properties that drive spike activity in the DA neuron enable it to fire 
spontaneously in the absence of afferent activation, and to accommodate rapidly to 
maintained excitatory influences and regain its basal level of activity. Secondly, 
dendrodendritic interactions appear to underlie synchronization of activity as well as provide 
autoreceptor-mediated local feedback modulation of the neuron activity. Thirdly, the 
influences of afferent and feedback processes apparently play a minor role when the system is 
in a basal state, but provide a substantial impact on the discharge pattern and level of activity 
when the system is challenged pharmacologically or physiologically. 
 
These multiple homeostatic factors appear to act in concert to enable the DA neuron to 
maintain a basal level of activity and compensate for maintained changes. It seems that the 
discharge of DA neurons is not involved in the maintenance of long-term changes in the 
midbrain, but instead only alters its activity state phasically in response to short-term demand 
(Hollerman & Grace, 1990). Hence, by preserving basal states of electrophysiological activity, 
the DA neuron conserves the dynamic range of electrophysiological response that can be 
rapidly drawn upon when required by the system. In fact, the ability of the DA system to 
maintain basal activity levels when faced with a tonic demand but respond rapidly with a 
massive phasic increase when required is consistent with the behavioral studies showing that 
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DA neuron discharge is only altered when the system is changing state, as occurs with the 
learning of a novel stimulus paradigm. On the other hand, when DA system is driven in a 
manner such that the biochemical compensations are inadequate to respond to the demand 
(resulting in a tonic activation of DA cell firing - for instance, with chronic neuroleptic 
treatment or near maximal DA depletions - or if one of the primary regulatory responses is 
thwarted (- for instance, administering a DA blocker to a system recovered from a lesion -), the 
ultimate consequence appears to be depolarization blockade of DA cell discharge and a 
reinstatement of the deficit state (Hollerman et al., 1992). However, under conditions in which 
the DA system appears to be showing an abnormal increased responsivity, such as 
schizophrenia (Grace, 1991), the induction of depolarization blockade may result the most 
effective way to refrain behaviorally mediated activation of this system (Grace, 1991; 
Hollerman et al., 1992; Grace, 1993). 
 
Immunohistochemistry assays have also revealed that some DA neurons, especially in the 
hypothalamus, co-express γ-aminobutyric acid (GABA) and glutamate receptors, and might 
thus operate with more than one neurotransmitter or neuropeptide (Yamaguchi et al., 2015). 
 
Although most of the neurons in the VTA are dopaminergic, this nucleus also contains 
GABAergic and glutamatergic neurons (Geisler & Wise, 2008; Stuber et al., 2012). Many 
afferent projections converge in the VTA displaying regulatory roles in the activity of this 
nucleus. Optogenetic approaches have allowed the identification of excitatory projections to 
the VTA arising from lateral hypothalamus, medial frontal cortex (mFC), lateral habenula, 
 
Fig.4- Schematic distribution of dopaminergic efferent projections in the rat brain. A: amygdala, S: septum, 
VTA: ventral tegmental area, SN: substantia nigra, EC: entorhinal cortex, PC: piriform cortex, ACC: anterior 
cingulate cortex, AON: anterior olfactory nucleus, CC: corpus callosum, FC: frontal cortex, OB: olfactory 
bulb, OT: olfactory tract, pc: pars compacta, PRC: perirhinal cortex (from Sara, 2009). 
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pedunculopontine tegmental nucleus (PPTg), and inhibitory afferents arising from NAcc, 
amygdala and the bed nucleus of the stria terminalus (BNST) (Stuber & Mason, 2013; Yau et 
al., 2016). Dopamine cells also receive convergent afferents from the dorsal raphe nucleus 
(DR) (Phillipson, 1979), and 5-HT axon terminals can synapse onto DA neurons modulating its 
activity (Hervé et al., 1987). Indeed, the VTA contains one of the highest levels of 5-HT of the 
limbic system (Pessia et al., 1994). 
 
  
1.2.3. Main NE-containing nucleus and projection pathways  
The locus coeruleus (LC) - also termed A6 pontine noradrenergic cell group - is a small nucleus 
(comprising roughly 1500 neurons in rats) considered as the main source of noradrenergic 
neurons in the mammalian brain. Immunohistochemistry assays have revealed a vast amount 
of TH enzyme containing neurons mainly in the posterior levels of the LC, and most of these 
neurons also contain DBH, presumably being noradrenergic neurons (Swanson, 1976; Debure 
et al., 1992). LC is depicted adjacent to the fourth ventricle in the pontine brainstem (Maeda, 
2000). The region surrounding the LC is termed pericoerulear area (peri-LC), which is densely 
populated by NE neuron dendrites from the LC (Luppi et al., 1995) and is a convergence site of 
terminal projections arising from various brain areas (Aston-Jones et al., 1991). LC neurons 
have long branched dendrites which can make axo-somatic, axo-dendritic and dendro-
dendritic, and rarely axo-axonic synapses (Shimizu & Imamoto, 1970; Groves & Wilson, 1980). 
Even the axon collaterals of a single noradrenergic neuron can reach separated areas of the 
brain. 
 
LC innervates and supplies NE throughout the central nervous system (CNS). It can modulate 
the activity of a high number of brain areas, standing out as a critical component of the neural 
architecture. Thus, it has been considered to play a role in a variety of physiological processes 
(e.g. sleeping, arousal, memory, and attention), behavioral impairments, mental diseases (e.g. 
attention-deficit hyperactivity disorder, depression, insomnia, narcolepsy, pain modulation, 
and stress-related disorders) or opiate withdrawal, among others (Singewald & Philippu, 1998; 
Vandergriff & Rasmussen, 1999; Berridge & Waterhouse, 2003; Llorca-Torralba et al., 2016). 
 
NE neurons can fire following tonic and phasic activity patterns. Tonic activity is characterized 
by relatively low-frequency (between 1 Hz-15 Hz), sustained and regular discharge patterns. 
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On the contrary, phasic discharge rates are observed (generally in response to salient sensory 
stimuli) with a relatively short latency (15-70 ms), and are comprised of a brief burst of 2-3 
action potentials followed by a more prolonged period of suppression of discharge activity 
(300-700 ms). Phasic discharge has been associated with sustained attention in tests of 
vigilance (Berridge & Waterhouse, 2003). 
 
Other putative neuropeptides have been found in LC neurons, and they might also play a role 
as modulators acting in this area. Some of them display stimulatory effects, such as 
vasopressin, substance P, adrenocorticotropin hormone and corticotropin-releasing factor; 
whereas galanin, somatostatin, neuropeptide Y and enkephalin exert depressant effects (Olpe 
& Steinmann, 1991). 
 
Although LC is the most important noradrenergic area, there are also some noradrenergic 
nuclei in the medulla oblongata involved in autonomic and endocrine regulations (termed A1, 
A2 and A5), which together with the A7 pontine cluster constitute the lateral tegmental group 
of NE cells (Guyenet, 1991). 
 
NE neurons have ramified axons that project to a number of brain areas, such as neocortex - 
including FC -, raphe nuclei, thalamus, amygdala, hippocampus, hypothalamus, spinal cord and 
other nuclei (Austin & Takaori, 1976; Foote et al., 1983; Florin-Lechner et al., 1996) (Figure 5). 
LC is posited as the sole provider of NE in the FC and hippocampus, both areas highly 
implicated in cognitive and affective processes (Conrad et al., 1974; Foote et al., 1983; 
Berridge & Waterhouse, 2003). 
 
Studies in monkeys have revealed a stratified distribution within the neocortex. While all six 
cortical layers possess NE innervation, the densest DBH-labelled fibers have being found in 
cortical layers III and IV, whereas layer I receives sparse innervation (Lewis et al., 1987). In rats, 
all cortical layers seem to be enriched in DBH-immunoreactive axons, although there are some 
morphological and geometrical distinct patterns in each layer (Grzanna et al., 1978). Layers IV 
and V appears to be terminal fields of NE neurons (Grzanna et al., 1978; Morrison et al., 1978). 
Electron microscopic histochemical techniques have provided new data on the presence of 
numerous monoaminergic axo-dendritic synapses in layer IV of somatosensory cortex in 
immature rats (Molliver & Kristt, 1975). 
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NE released in terminal areas can bind α- (α1 and α2) and β-adrenoceptors. Activation of α1 and 
β-adrenoceptors generally leads to excitatory responses in the follower cells, whereas α2 
triggers inhibitory effects. α2-Adrenoceptors are densely located in the LC acting as 
autoreceptors. Its activation evokes decreases in the firing rate of LC neurons and in the 
release of NE (Fernández-Pastor & Meana, 2002; Samuels & Szabadi, 2008). GABAA, NMDA, 
non-NMDA glutamate, and muscarinic receptors in the LC also play roles in controlling the 
activity of NE neurons (Kawahara et al., 1999). 
 
A wide array of areas projecting to the LC has been reported so far. Tract-tracing and 
electrophysiology studies have allowed a better understanding of the afferent fibers projecting 
to the LC. The two major afferent inputs arise from the excitatory nucleus paragigantocellularis 
(PGi) and the inhibitory nucleus prepositus hypoglossi (PrH), both located in the rostral 
medulla, which project toward peri-LC zones and to the LC proper (Aston-Jones et al., 1991; 
Luppi et al., 1995). Additionally, other minor projections mainly to the pericoerulear area have 
been found, arising from forebrain structures such as the cortex, the central nucleus of the 
amygdala, the medial, lateral and magnocellular preoptic areas, the BNST, and the 
dorsomedial, paraventricular and lateral hypothalamic areas. 
 
 
 
 
 
 
 
 
 
Fig. 5- Schematic distribution of noradrenergic efferent projections in the rat brain. LC: Locus coeruleus, S: septum, 
EC: entorhinal cortex, AON: anterior olfactory nucleus, AP-VAB: ansa peduncularis–ventral amygdaloid bundle 
system, BS: brainstem nuclei, CC: corpus callosum, CER: cerebellum, CTT: central tegmental tract, CTX: cortex, DB:
dorsal bundle, DPS: dorsal periventricular system, F: fornix, FR: fasiculus retroflexus, H: hypothalamus, HF: 
hippocampal formation, ML: medial lemniscus, MT: mamillothalamic tract, OB: olfactory bulb, PRC: perirhinal 
cortex, PT: pretectal area, RF: reticular formation, SC: spinal cord, ST: stria terminalis, T: tectum, TH: thalamus.
(from Sara, 2009). 
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From the brainstem, afferent projections have been found arising from the periaqueductal 
gray area (PAG), the raphe nuclei, the VTA, the reticular formation, vestibular, solitary tract 
and lateral reticular nuclei. In particular, the areas of catecholamine cell groups A1, A2 and A5 
appeared to contain many reactive cells. Labeled neurons were also observed in the fastigial 
nuclei and in the marginal zones of the dorsal horns of the spinal cord (Cedarbaum & 
Aghajanian, 1978; Luppi et al., 1995). 
 
LC neurons receive vast excitatory amino acid (EAA) inputs, primarily originating from the PGi, 
(Aston-Jones et al., 1991). The EAA antagonist kynurenic acid is able to block PGi-induced 
activation of the LC neurons (Ennis & Aston-Jones, 1988). The NMDAR antagonists AP5 or AP7 
were not effective in either response, indicating that PGi-induced EAA activation of LC neurons 
probably takes place at a non-NMDAR in the LC. There are also some fibers arising from the FC 
to the peri-LC region (Luppi et al., 1995). Stimulation of neurons in the FC leads to an activation 
of LC neurons through EAA inputs acting at NMDAR and non-NMDAR, such as α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors (Jodo & Aston-
Jones, 1997). Another region implicated in LC neurons activation is the PAG in the midbrain. 
Electrical stimulation in PAG was found to be able to vastly stimulate neurons in the peri-LC 
(Ennis et al., 1991).  
 
Conversely, low frequency stimulation of the other major input to the LC, the GABAergic 
nucleus PrH, potently inhibit LC neurons discharge, presumably via GABAA receptors located in 
the LC.  Microinfusion with the GABAA receptor antagonist bicuculline antagonizes this effect 
(Ennis & Aston-Jones, 1989). 
 
The LC also receives noradrenergic inputs from the A1, A2, A5 catecholaminergic cells groups 
as well as the contralateral LC (Cedarbaum & Aghajanian, 1978), and there are extensive 
recurrent axon collaterals within the nucleus (Aghajanian et al., 1977). Any of these structures 
may be capable of releasing NE. 
 
Noradrenergic activity has been largely proven to be regulated by α2-adrenoceptors located on 
NE neurons in the LC, controlling NE release and cell firing (Cedarbaum & Aghajanian, 1976; 
Jorm & Stamford, 1993; Van Gaalen et al., 1997; Mateo et al., 1998; Kawahara et al., 1999) in 
terminal areas. The peri-LC zone, but not the LC proper, is densely innervated by 5-HT 
projections, presumably arising from the DR (Aston-Jones et al., 1991). α2-Adrenoceptors may 
act in synergy with 5-HT1ARs on serotonergic neurons located in the peri-LC, since the 
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inhibition of the LC firing rate by an agonist at α2-adrenoceptors is potentiated by the 
simultaneous administration of a 5-HT1AR agonist, having no effect on the firing rate when the 
serotonergic agonist is administered (Ruiz-Ortega & Ugedo, 1997). α2-Adrenoceptors are 
widely expressed in the LC, FC, thalamus, hippocampus, striatum, amygdala, hypothalamus, 
vestibular nuclei and spinal cord, among others (Pazos et al., 1988; Meana et al., 1989; Pascual 
et al., 1992; Nicholas et al., 1993; Talley et al., 1996), concretely in dendrites, presynaptic axon 
terminals, and astrocytes (Lee et al., 1998). The α-adrenoceptor subtype α2A, and not the 
closely related α2B/C-adrenoceptors, seems to be the one that modulate NE release and cell 
firing in the rat LC (Callado & Stamford, 1999; Fernández-Pastor & Meana, 2002). 
 
Extracellular NE in the LC seems to be released from somatodendritic areas of NE neurons 
(Fernández-Pastor et al., 2005), but also from noradrenergic afferents from other nuclei such 
as the A5 and the A7 nuclei (Luppi et al., 1995) and from collateral axons (Aghajanian et al., 
1977; Ennis & Aston-Jones, 1986). LC expresses a high density of NE reuptake binding sites 
(Tejani-Butt, 1992; Ordway et al., 1997), which leads to increased extracellular NE 
concentrations in the LC after the administration of the NE reuptake inhibitor antidepressant 
desipramine (Mateo et al., 1998). NE concentrations in the LC decrease after local infusion of 
Ca2+-free medium, and with the infusion of the sodium channel blocker TTX, whereas increased 
via KCl-induced depolarization. Altogether points out that the extracellular NE released in the 
LC seems to follow an impulse flow-dependent vesicular exocytosis pattern (Fernández-Pastor 
et al., 2005). The presence of NE release in somatodendritic areas plays a crucial role in 
regulating noradrenergic transmission in terminal areas via feedback inhibition trough 
α2A-adrenoceptors.  
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1.3. NEUROBIOLOGY OF SCHIZOPHRENIA 
 
Several neurotransmitter systems and functional networks within the brain, as well as brain 
structures, have been found to be altered in patients with schizophrenia. The threshold 
question is whether these alterations cause the development of the disease or are 
consequences of the illness progression or treatment. Below, the most important findings and 
hypotheses in schizophrenia neurobiology are briefly presented.  
 
1.3.1. Morphological brain alterations  
PFC has long been implicated in the neuropathology of schizophrenia, especially in the 
manifestation of negative and cognitive symptoms, since PFC plays an important executive role 
in working memory, attention, motivation and impulse control (Callicott et al., 2000; Selemon 
& Zecevic, 2015). In fact, lesions of this brain region in animals and humans produce the latter 
impairments (disruption in working memory, reduced impulsive choice related to reward, 
enhancing environmental stimuli, and behavioral restraint) (Fritts et al., 1998; Eagle et al., 
2008; Barbey et al., 2013). However, unilateral frontal lesions retain some working memory 
function, likely due to functional compensation by the intact hemisphere (D’Esposito et al., 
2006). It is thus not surprising that abnormalities in PFC have been largely associated with 
schizophrenia and other psychiatric disorders (Aghajanian & Marek, 2000; Alex & Pehek, 
2007). 
 
It is well-established that schizophrenic patients exhibit enlarged ventricles, especially in the 
lateral and third ventricles (Johnstone et al., 1976; Weinberger et al., 1979; Murray et al., 
1985; Buckley, 2005; Kempton et al., 2010; Olabi et al., 2011; Sayo et al., 2012). The size of the 
ventricles increase progressively after the onset of the illness (Kempton et al., 2010), as the 
whole brain gray matter is reduced over time in patients with schizophrenia (Olabi et al., 
2011). 
 
Grey matter comprises neuronal cell bodies, dendrites lacking myelin, glial cells, synapse 
processes and capillaries. It is distributed in various areas of the brain, such as the surface of 
the cerebral cortex, cerebellum, thalamus, hypothalamus, basal ganglia-putamen, globus 
pallidus, NAcc, and SN. Magnetic resonance imaging (MRI) and voxel-based morphometry 
studies have disclosed grey matter loss in cortical areas, and impaired neuronal networks in 
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schizophrenic patients, although no differences in total brain volume were found (Andreasen 
et al., 1994; Buchanan et al., 1998; Crespo-Facorro et al., 2000; Honea et al., 2005; Narr et al., 
2005; Gutiérrez-Galve et al., 2010; Rosso et al., 2010; Torres et al., 2013; Yang et al., 2014). 
Hippocampus, amygdala, thalamus and insula are other regions shown to be reduced in 
schizophrenia (Wright et al., 2000; Shepherd et al., 2012).  
 
Positron emission tomography (PET) studies have unmasked abnormalities in FC, thalamus and 
cerebellum in patients with schizophrenia while performing cognition tasks, likely reflecting 
disturbances between cortical and subcortical networks (Andreasen, 1997). Increases in 
regional cerebral blood flow and glucose metabolism in the FC of acute unmedicated patients 
have been found (Cleghorn et al., 1989; Parellada et al., 1994). Morphological studies in 
postmortem brains of schizophrenic patients have revealed differences in cellular distribution 
likely attributed to altered neuronal migration early in brain development, loss of pyramidal 
cells, malformed cell structure, and decreased number of GABA interneurons (Faludi et al., 
2011; Schmidt & Mirnics, 2015). The FC is an area entrusted with cognitive and emotional 
functions. Thus, these alterations might explain the functional disturbances in thinking, 
socializing and behaving that schizophrenic patients face. 
 
1.3.2. Impaired neurotransmission systems in schizophrenia 
Albeit the aetiology of schizophrenia remains still obscure, many lines of evidence aims at 
abnormalities in neurotransmission systems as agents thereof. DA has long been studied and 
associated with the disease; however, over the past few decades other systems such as 
serotonergic, noradrenergic, GABAergic, glutamatergic or cholinergic, have been suggested to 
play a role in the disease.  
 
1.3.2.1. Dopaminergic system in schizophrenia 
 
The most lasting neurotransmission hypothesis to explain the aetiology of schizophrenia is the 
dopaminergic hypothesis. In 1957, Arvid Carlsson and co-workers aimed at DA as the main 
neurotransmitter involved in this disease. Initially, an overall hyperdopaminergia in the brain 
was stated, thought to be responsible for the psychotic symptoms. This model emerges mainly 
due to the observations that the clinical effects of typical antipsychotics (chlorpromazine, 
haloperidol and similar drugs) were derived from the postsynaptic D2 receptors blockade, 
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positioning DA and the dopaminergic hypothesis in the spotlight as the main neurotransmitter 
involved in schizophrenia. Moreover, some recreational drugs which increase DA activity, such 
as amphetamine or cocaine, can induce psychotic symptoms (Carlsson & Lindqvist, 1963; Davis 
et al., 1991; Howes & Kapur, 2009; Faludi et al., 2011).  
Soon afterwards, the theory was reformulated, aiming at subcortical hyperdopaminergia 
(mostly in striatum and NAcc, based on the high concentrations of DA terminals and D2 
receptors in these regions) and cortical hypodopaminergia. According to this explanation, 
there could be an increased activity of mesolimbic DA pathways potentially responsible for the 
positive symptoms of the disease, whereas insufficient DA signaling in frontal cortical regions 
may explain the negative symptoms (Carlsson, 1959; Graybiel, 2000; Carr et al., 2002; Carlsson 
& Carlsson, 2006; Brisch et al., 2014).  
It has been posited that there could exist two different subpopulations of D2 receptors, so that 
D2 receptors are not the same in the striatum, responsible of extrapyramidal effects, and in the 
PFC, predicting as antipsychotic effects. The overall occupancy of D2 receptors by antipsychotic 
drugs is higher in temporal cortex than in striatum (Xiberas et al., 2001).  
The reason to explain the above differences could be that D2 receptors in striatum could be 
synaptically located and in the cortex the distribution could be predominantly extrasynaptic 
(Carlsson & Carlsson, 2006). Extrasynaptic receptors are those not activated during low-
frequency synaptic events, and can be found in the cell body, the dendritic shaft, the neck of 
the dendritic spine and also adjacent to the postsynaptic density (perisynaptic). It has been 
reported that the same receptor can lead to opposite effects depending on its synaptic or 
extrasynaptic location by the activation of different intracellular signaling pathways 
(Hardingham & Bading, 2010). Extrasynaptic D2 receptors are located on the dopaminergic 
neuron itself and they have high capacity for up- and downregulation. Moreover, extrasynaptic 
receptors are more responsive than postsynaptic receptors (Carlsson & Carlsson, 2006). 
 
Elevated DA synthesis, higher tonic and phasic DA release and increased postsynaptic D2 
receptor binding in striatum of drug-naïve patients are described. Conversely, diminished 
extrastriatal D2 receptor binding has been observed in patients with schizophrenia, especially 
in the thalamus, an area highly implicated in this disease (Hirvonen & Hietala, 2011). Recently, 
it has been reported by PET studies that schizophrenic patients have lower extracellular DA 
concentrations in the PFC and other extrastriatal regions, due to a deficit in the capacity for DA 
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release (Slifstein et al., 2015). Furthermore, postmorten brains of schizophrenic patients have 
reduced DA innervations in the dorsolateral PFC (Laruelle, 2014). Studies in schizophrenics 
have suggested a relationship between low cerebrospinal fluid (CSF) homovanillic acid, a 
measure of DA activity in the PFC, and poor working memory. Negative and cognitive 
symptoms seem to be resistant to D2 blockers. Imaging techniques revealed that the PFC 
impairment might be responsible of these symptoms. It seems that D1 receptor is upregulated 
in the FC of schizophrenic patients, likely due to chronic DA depletion. Such upregulation was 
correlated with a poor achievement on a working memory assignment. However, D1 receptor 
antagonists do not have antipsychotic activity, even worsen positive symptoms (Laruelle, 
2014). Indeed, some of the key benefits of clozapine to improve cognition and negative 
symptoms are attributed to the ability to increase dopaminergic activity in the PFC and its 
potent D1 receptor occupancy (Meltzer, 1989). 
 
The dopaminergic hypothesis supports that excessive stimulation of D2 receptors in the 
striatum could be responsible of positive symptoms. Moreover, the blockade of D2 receptors in 
the anterior striatum, but not those in the ventral striatum, is correlated with therapeutic 
effects. However, the continuous blockade of D2 receptors in the ventral striatum could 
worsen negative symptoms (Laruelle, 2014).  
 
However, this DA hypothesis seems not to be sufficient to explain the disease, inasmuch as 
negative and cognitive symptoms have been shown to be resistant to DA receptor blockers. In 
addition, 30% of schizophrenic patients do not adequately respond to typical antipsychotic 
drugs, suggesting that other neurotransmitter systems must be also involved in the 
pathophysiology of the illness (Faludi et al., 2011). In fact, DA synthesis is under the inhibitory 
control of D2 receptors in neuron terminals (el Mestikawy et al., 1986; Santiago & Westerink, 
1991). Ichikawa and Meltzer (1995) suggest that 5-HT2Rs in the striatum may have a 
facilitatory effect on the amphetamine-induced DA release, at least in part, via their ability to 
modulate DA synthesis regulated by D2 autoreceptors. 
 
The latest versions of the dopaminergic hypothesis recognize an indirect associative 
connection between DA and glutamate. Preclinical and clinical data suggest that dysfunction of 
DA systems in schizophrenia may be triggered by a deficit in NMDA receptor function. 
Psychoactive drugs, such as ketamine, a NMDA blocker, are able to indirectly increase DA 
release. It has been found that co-administration of ketamine and amphetamine in healthy 
I. Mollinedo Gajate 
30 
 
humans, can induce a striatal DA release similar to that exhibit in schizophrenia patients 
(Kegeles et al., 2000; Howes & Kapur 2009). It is now understood that DA has a modulatory 
role on glutamate performance. Thus, changes in DA function might affect NMDA activity, and 
vice versa (Laruelle, 2014). 
 
Administration of NMDAR antagonists, cocaine and amphetamine, modulates 
neurotransmission systems in the brain toward increased DA release in the rat FC, striatum, 
and VTA (Quarta & Large, 2011; Matsumoto et al., 2014; Paasonen et al., 2017). Whereas 
Matsumoto and co-workers (2014) did not observe changes in extracellular DA concentrations 
after (±)-DOI injection (5 mg/kg i.p.) in rats, others have reported enhanced DA release (2.5 
mg/kg i.p.) in rat FC (Pehek et al., 2001). NMDA blockers have direct effects on the D2 receptor 
and 5-HT2R, since it has been reported that ketamine displays very similar affinity at the 
NMDA receptor and D2 sites with a slightly lower affinity for 5-HT2R (0.5 µM, 0.5 µM and 15 
µM respectively), whereas PCP shows similar affinity for the NMDA and 5-HT2R sites, with a 
slightly lower affinity for the D2 site (2 µM, 5 µM and 37 µM respectively) (Kapur & Seeman, 
2002). 
 
Interestingly, acute administration of antipsychotic drugs exerts similar pattern of DA release 
than propsychotic drugs. Microdialysis experiments have shown that systemic administration 
of the antipsychotic drugs haloperidol and clozapine enhance DA outflow in the NAcc, 
striatum, and rat FC (Moghaddam & Bunney, 1990). Likewise, chronic treatment with clozapine 
increases extracellular basal concentrations in the FC (Yamamoto & Cooperman, 1994). 
 
1.3.2.2. Noradrenergic system in schizophrenia 
 
This catecholamine has received only marginal attention as an aetiologic factor of 
schizophrenia throughout decades. It was as early as 1971 when NE was posited to be involved 
in the pathophysiology and long-term downhill course of the disease (Stein & Wise, 1971; 
Tissot, 1975). Nevertheless, introduction of atypical antipsychotics appears to have awakened 
interest in NE dysfunction again. Practically all clinically effective neuroleptic drugs act on more 
than a single type of neurotransmitter receptor, including DA, NE, 5-HT, acetylcholine or 
histamine, among others. Regarding NE receptors, the majority of antipsychotics display 
antagonism at α-adrenoceptors (Minzenberg & Yoon, 2011). 
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Neuromelanin is a dark pigment structurally related to melanin, expressed in large quantities 
in catecholaminergic cells of the substantia nigra pars compacta and LC, giving dark color to 
the structures. This compound is assumed to be an indicator of cathecolaminergic neuronal 
activity, though it was thought to serve no pivotal functions until recently (Usunoff et al., 
2002). In 1980, Kaiya discussed the possibility of an interaction between DA and NE in 
schizophrenia patients after seeing that they displayed a high negative correlation in melanin 
content between the substantia nigra and the LC. 
 
Yamamoto and Hornykiewicz (2004) provided compelling evidence of the implication of the 
noradrenergic system in the pathophysiology of the illness. Studies in postmortem brain have 
shown increased levels of NE in schizophrenic patients. Likewise, plasma and CSF of these 
patients exhibit higher NE concentrations. NE controls a wide range of brain functions, being 
crucial in sleep-wakefulness cycles, arousal, attention, novelty-oriented behavior, anxiety, fear, 
aggressiveness, stress, memory, learning, psychomotor behavior and many neuroendocrine 
functions. 
 
The noradrenergic theory supports the involvement of a noradrenergic system overactivity to 
be responsible for positive symptoms; whereas negative and cognitive symptoms would be the 
result of noradrenergic hypoactivity. In this sense, positive symptoms could be associated with 
hypervigilant states of consciousness, while conversely negative symptoms could be linked to 
hypovigilant states. In an extremely alert state, as stress sensitivity is increased, even slight 
stimuli often provoke disproportionate fear and aggressiveness, which may develop into 
persecutory ideas or delusions. In contrast, an extremely hypovigilant state often results in 
blunted affect and cognitive impairment (Yamamoto & Hornykiewicz, 2004).  
 
It has been described that the blockade of catecholaminergic activity improves positive 
symptoms, whereas drugs that facilitates catecholaminergic transmission would worsen these 
psychotic states. On the other hand, catecholaminergic agonists ameliorate negative and 
cognitive symptoms, whilst antagonists would worsen them (Yamamoto & Hornykiewicz, 
2004). 
 
Animal models subjected to acute injection of NMDAR antagonist drugs have been shown to 
increase NE outflow in rat FC (Kubota et al., 1999; Quarta & Large, 2011). Likewise, the 
recreational drug amphetamine enhances DA release in the FC following systemic and cortical 
administration (Géranton et al., 2003). Antipsychotic drugs such as risperidone (Kaminska et 
al., 2013) and clozapine (Devoto et al., 2003b) also induces NE release in the FC. 
I. Mollinedo Gajate 
32 
 
 
NE also plays an important role in brain development and neuronal differentiation, potentially 
linked to the developmental process of the pathology of schizophrenia (Lechin & van der Dijs, 
2005). Noradrenergic system also controls cerebral blood flow and metabolic rate, suggesting 
that long-term NE dysfunction could take part in the altered blood flow and metabolic rate in 
the cortex, and the abnormalities seen in the ventricles and grey matter of schizophrenic 
patients, which may lead to brain atrophy (Yamamoto & Hornykiewicz, 2004). 
 
 
1.3.2.3. Serotonergic system in schizophrenia 
 
Serotonin (5-HT) is synthesized both in peripheral tissues and in the CNS. Enterochromaffin 
cells in the gastrointestinal tract are the major producers of this monoamine. However, 5-HT 
cannot cross the BBB. Therefore, 5-HT is also synthesized in the brain, in serotonergic neurons, 
where acts as a neurotransmitter. L-Tryptophan is the AA precursor of 5-HT. It is provided with 
the dietary intake and can cross the BBB, entering into the serotonergic neurons. Tryptophan 
is catalysed to 5-hydroxytryptophan (5-HTP) by the isoform 2 of tryptophan hydroxylase 
(TPH2), which is a rate-limiting step of the synthesis of 5-HT (Walther et al., 2003). The enzyme 
L-aromatic amino acid decarboxylase (DDC) then convert 5-HTP to 5-HT. Once synthesized, 
5-HT is taken from cytoplasm and transported into synaptic vesicles by VMATs, where they 
remain stored until exocytosis. 5-HT is released in synapses through a Ca2+-dependent 
mechanism, and can then be reuptake from the synaptic cleft by the serotonin transporter 
(SERT) (Yun & Rhim, 2011). 
 
The hypothesis regarding the involvement of 5-HT in schizophrenia emerged after the 
observation of the psychotic states that LSD and other indolamine compounds produced in 
healthy humans (Wooley & Shaw, 1954; Pletscher et al., 1955; Iqbal & van Praag, 1995). 
Natural hallucinogens, such as mescaline of psilocybin, and synthetic hallucinogens, such as 
LSD and diethylamine, cause their neuropsychological effects by activating 5-HT2AR 
(Vollenweider et al., 1998; Sealfon & González-Maeso, 2008). This hypothesis was further 
supported when observed that atypical antipsychotics such as clozapine, risperidone and 
olanzapine, show roughly 20-fold higher affinity for 5-HT2AR than for D2 receptors (Arnt & 
Skarsfeldt, 1998). 
 
Introduction 
33 
 
Studies on human postmortem brains from schizophrenia patients show some inconsistencies 
in the variation of 5-HT and 5-HT2AR levels, so it is not clear enough so far whether an increase 
or a decrease in those levels occurs in the disease (Lovett Doust et al., 1975; Crow et al., 1979; 
Bleich et al., 1988; Iqbal et al., 1991; Ohuoha et al., 1993; Muguruza et al., 2014). 
 
The connection between dreams and endogenous psychosis could be explained by a 
serotonergic hypothesis. 5-HT structure-related hallucinogens (LSD, mescaline) trigger mainly 
visual hallucinations. On the other hand, chronic schizophrenic states show primarily auditory 
perceptions, whereas acute schizophrenic states can entail visual hallucinations, as LSD does. 
Such visual perceptions resemble states shown while dreaming. Neurotransmission system 
activities, especially 5-HT, NE and D, also show some homologies between dreams and 
hallucinations (Fischman, 1983). 
 
Psychedelic drugs such as PCP or ketamine, substantially increase 5-HT release in rat FC 
(Quarta & Large, 2011). Likewise, cocaine, amphetamine, and amphetamine-related 
compounds, with the exception of (±)-DOI, increase 5-HT output in rat FC (Matsumoto et al., 
2014). Martin-Ruiz and co-workers (2001) observed decreased 5-HT release following acute 
administration of (±)-DOI (1 mg/kg i.p.) in rat FC. 
 
Antipsychotics can also modulate 5-HT output in animal models. Thus, risperidone induces 5-
HT release in rat FC (Ichikawa et al., 1998; Huang et al., 2006), whereas clozapine, olanzapine, 
and haloperidol are able to diminish 5-HT release in rat FC (Amargós-Bosch et al., 2006), and 
co-administration with PCP and ketamine blunt the high 5-HT release evoke by the latter 
recreational drugs (Amargós-Bosch et al., 2006). However, discrepancies have been found 
since Ichikawa and co-workers (1998) observed that clozapine augments 5-HT ouput in the FC, 
while olanzapine, sulpiride, haloperidol and M100907 have no effect on extracellular 5-HT 
concentrations in that region. 
 
1.3.2.4. Glutamatergic and GABAergic systems in schizophrenia 
 
Glutamate is the principal EAA neurotransmitter in the brain. Apart from its role in 
neurotransmission, glutamate fulfills a broad array of functions in the CNS. It serves as a 
precursor for peptide and protein synthesis, is involved in fatty acids synthesis, contributes to 
the regulation of ammonia levels, serves as a precursor for GABA, and is involved in 
carbohydrate metabolism (Westerink et al., 2007). There is considerable body of evidence 
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indicating that dysfunction of the glutamate system may contribute to the pathophysiology of 
schizophrenia (Fusar-Poli et al., 2011). It is well-established that administration of NMDAR 
antagonists, such as PCP or ketamine, can induce psychosis-like states in healthy humans, 
resembling positive, negative and cognitive symptoms seen in schizophrenic patients (Insel, 
2010; Faludi et al., 2011). Even subanesthetic doses of ketamine can exacerbate these 
symptoms when administered to schizophrenic patients (Krystal et al., 1994). Psychoactive 
drugs modulate glutamatergic systems in the brain. NMDA receptor blockade, 5-HT2A 
agonism, THC and amphetamine administration, have all been reported to increase synaptic 
glutamate concentrations in PFC (Moghaddam et al., 1997; Pistis et al., 2002; Scruggs et al., 
2003; Muschamp et al., 2004; Rowland et al., 2005; Stone et al., 2012). Although it has not 
been established whether the increased glutamate concentrations are associated with the 
psychosis-like effects of these drugs, it is interesting to note that glutamine, a marker of 
increased prefrontal glutamate release, has been reported in patients in the early phase of 
psychosis (Marsman et al., 2013) and, moreover, that prefrontal glutamate concentrations 
appear to be associated with failure to achieve remission following dopaminergic antipsychotic 
drug treatment (Egerton et al., 2012; Szulc et al., 2013; Demjaha et al., 2014). 
 
Acute and chronic administration of PCP has been posited as an experimental animal model of 
schizophrenia, which evokes hyperlocomotion and stereotyped behaviors in rodents 
(Steinpreis, 1996). Furthermore, increased glutamate release in the PFC seems to be a 
common feature shared by non-competitive NMDAR antagonists and hallucinogenic drugs, 
both of which mimic some of the symptoms of acute psychosis (Aghajanian & Marek, 1999). 
NMDAR antagonists increase prefrontal glutamate concentrations, demonstrated both in 
animal microdialysis studies and in human proton magnetic resonance spectroscopy studies 
(Moghaddam et al., 1997; Rowland et al., 2005; Stone et al., 2012). Moreover, it has been 
shown that NMDA receptor antagonism leads to a reduction in GABAergic interneuron 
function, possibly through the blockade of NMDAR expressed on GABAergic cells (Homayoun & 
Moghaddam, 2007).   
 
On the other hand, antipsychotic drugs as clozapine, whereas at a dose of 15 mg/kg s.c. do not 
exert any response on extracellular glutamate concentrations, at 25 mg/kg s.c. dose 
significantly increase its release in rat FC (Daly & Moghaddam, 1993). Quetiapine activates 
glutamatergic projections from the mediodorsal thalamic nucleus and enhances glutamate 
release in the FC (Yamamura et al., 2009). The typical antipsychotic haloperidol does not exert 
any change (Daly & Moghaddam, 1993).  
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Substantial evidence suggests that cortical GABAergic neurotransmission is altered in 
schizophrenia, especially including alterations of parvalbumin (PV)-positive cells (Lewis, 2011). 
Alterations in PV neuron-mediated inhibition could cause an impairment of gamma band 
synchrony - known to play a crucial role in cognitive functions - and contribute to cognitive 
deficits in schizophrenia (Gonzalez-Burgos et al., 2010; Lewis, 2011). It has been suggested that 
NMDAR hypofunction is an upstream cause of alterations of PV neurons in schizophrenia 
(Coyle, 2006). NMDAR hypofunction could lead to PV neuron abnormalities through various 
direct and indirect mechanisms (Lewis & Gonzalez-Burgos, 2008). Systemic NMDA receptor 
antagonists increase pyramidal cell firing, apparently by producing disinhibition, and repeated 
exposure to NMDA antagonists leads to changes in the GABAergic markers that mimic the 
impairments found in schizophrenia (Olney & Farber, 1995; Rotaru et al., 2012). Some 
researchers assert that PV neuron deficits in schizophrenia are secondary to NMDAR 
hypofunction at glutamatergic synapses onto these cells (Seamans, 2008). However, Rotaru 
and co-workers (2012) demonstrated that cortical disihibition and GABAergic impairment 
produced by NMDAR antagonists are unlikely to be mediated via NMDARs at glutamatergic 
synapses onto mature cortical PV neurons (Rotaru et al., 2012).  
 
It has been demonstrated that NMDA antagonists, while acting ubiquitously, seem to only 
evoke morphological changes to interneurons. Particularly, NMDA antagonist treatment 
diminished the expression of PV, a key calcium-binding protein in some GABAergic 
interneurons, and GAD67, a main synthesizing enzyme for GABA. Schizophrenics display a 
similar decrease in GAD67, in particular in the subgroup of PV-containing fast-spiking 
interneurons (Seamans, 2008).  
 
As mentioned above, the onset of schizophrenia usually occurs during adolesce or early 
adulthood. It is thought that disturbed maturation of the adolescent brain is highly involved in 
the pathophysiology of the disease. Significant developmental changes during adolescence 
occur in cortical GABAergic neurotransmission (Hoftman & Lewis, 2011). Development of 
innervations by PV neurons is dependent on GAD67 levels. Thus, environmemtal insults 
affecting GAD67 expression may lead to abnormal formation of synaptic contact by these 
interneurons (Rotaru et al., 2012). 
 
Moreover, previous studies have found an important relationship between glutamate and 
5-HT receptors. In that sense, indoleamine and phenethylamine hallucinogens which activate 
5-HT2AR, rather than 5-HT2CR, can increase the frequency of “spontaneous” (non-electrically 
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evoked) glutamatergic excitatory postsynaptic currents (EPSCs) in apical dendrites of layer V 
cortical pyramidal cells (Aghajanian & Marek, 1997; Aghajanian & Marek, 1999; Marek & 
Aghajanian, 1999), as well as glutamate release in the FC (Scruggs et al., 2003; Muschamp et 
al., 2004). Such EPSCs increase was fully blocked by the AMPA/kainate antagonist LY293558 
(Aghajanian & Marek, 1997). 
 
Vast preclinical data have led to the hypothesis that NMDA receptor hypofunction can play a 
role in the pathophysiology of schizophrenia (Coyle, 2006; Javitt, 2010; Rubeša et al., 2011). 
Decreasing tone at this receptor, moreover, may ultimately cause a dysregulation of 
thalamocortical circuitry by altering the balance of excitation and inhibition (Walker & Conn, 
2015). Research has suggested that hypofunction of NMDA receptors may potentially account 
for the hyper- and hypoactivity of DA pathways in regions highly implicated in limbic and 
cortical areas, respectively. That could explain positive, negative and cognitive symptoms of 
schizophrenia. Cortical areas are connected with mesolimbic dopaminergic pathways through 
GABA interneurons in the VTA. Stimulation of NMDA receptors, located on such interneurons, 
triggers the release of the inhibitory amino acid GABA, which evokes diminished activity of DA 
release in mesolimbic pathways. Therefore, hypoactivity of NMDA receptors on GABAergic 
cells would impair the inhibitory tonic state, resulting in a hyperactivity of dopaminergic 
pathways that could enhance DA release in mesolimbic areas, which in turn might evoke 
positive symptoms of psychosis. The cortex-brainstem projection communicates directly with 
mesocortical dopaminergic pathway in VTA (no GABAergic interneurons present) and causes 
tonic excitation in basal conditions. The hypofunctionality of NMDA receptors in the cortex-
brainstem projection could make mesocortical dopaminergic pathways hypoactive, potentially 
producing cognitive and negative symptoms of schizophrenia (Pralong et al., 2002; Rubeša et 
al., 2011; Marsman et al., 2014). 
 
Many aspects of synaptic development, plasticity, and neurotransmission are critically 
influenced by NMDARs. Dysfunction of NMDARs has been implicated not only in schizophrenia, 
but in a broad array of neurological disorders (e.g. stroke, epilepsy and neuropathic pain). 
Classically, NMDARs were thought to be exclusively postsynaptic. However, substantial 
evidence in the last 10 years demonstrates that NMDARs also exist presynaptically, and that 
presynaptic NMDA receptors modulate synapse function and have critical roles in plasticity at 
many synapses (Corlew et al., 2008). 
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Furthermore, mGluR2/3 receptors have been shown to influence a variety of glutamatergic 
dependent processes by either suppressing postsynaptic neuronal activity or inhibiting 
presynaptic release of glutamate (Vandergriff & Rasmussen, 1999). Preclinical findings in 
rodents have demonstrated that mGluR2/3 agonists block both the locomotor hyperactivity 
induced by PCP-like drugs (Moghaddam & Adams, 1998), and the HTR induced by LSD-like 
drugs (Gewirtz & Marek, 2000). 
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1.4. G PROTEIN-COUPLED RECEPTORS (GPCRs) 
1.4.1. GPCR: Overview 
G protein-coupled receptors are one of the largest super families of cell-surface protein 
receptors in vertebrate animals, which mediate important physiological functions and are 
target for myriad of modern drugs (González-Maeso & Sealfon, 2009a; Salon et al., 2011; 
Munk et al., 2016). These receptors are ubiquitously expressed and respond to a diverse range 
of physical and chemical compounds that include photons, enzymatic processes, soluble small 
molecules such as neurotransmitters and ions, peptides, and large proteins outside the cell, 
activating internal signaling pathways and subsequent cellular responses (Palczewski & Orban, 
2013). These receptors and their signaling have been studied extensively and breakthroughs in 
how they work have received various Noble prizes (Lin, 2013). GPCRs have been clustered in 
the following classes based on structural homology of amino acid sequence, location of the 
orthosteric binding site, and functional similarities: class A (rhodopsin-like), class B (secretin-
receptor), class C (metabotropic glutamate), class D (fungal mating pheromone receptors), 
class E (cyclic AMP receptors) and class F (frizzled/smoothened) (Figure 6). Classes D and E are 
not found in vertebrates (Schiöth & Fredriksson, 2005; Alexander et al., 2015). 
 
All GPCRs converge on a common structure, consisting of a single polypeptide with an 
extracellular amino terminus, an intracellular carboxy terminus, and seven hydrophobic 
transmembrane domains (TM1-TM7) linked by three extracellular loops (ECL1-ECL3) and three 
intracellular loops (ICL1-ICL3). Approximately 800 GPCRs have been described in the human 
genome, roughly half of which have been posited to mediate olfactory, tasty or visual 
functions, whereas the other half mediate intersignaling by ligands that differ in size, from 
small molecules to large peptides and serve as targets for the majority of drugs (Alexander et 
al., 2015). Studies on crystal structures have revealed highly conserved characteristics of the 
orthosteric ligand-binding sites across members of GPCRs, which sometimes make it difficult to 
achieve high selectivity for different GPCR subtypes. Alternatively, allosteric modulators have 
been proven highly successful for ligand-gated ions channels, and interest is growing for the 
development of selective allosteric modulators of specific receptor subtypes. These small 
molecules do not bind to the orthosteric ligand binding site but instead act at an alternatively 
located binding site (allosteric site), which is distinct from the orthosteric site, to either 
potentiate or inhibit activation of the receptor by an orthosteric agonist (Conn et al., 2009).  
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Fig. 6- Tree from the structure statistics page depicting crystallized receptors with a red circle. The tree can be navigated from its 
centre on the levels of class (endogenous) ligand type, receptor family and receptor. The receptor families are listed as defined by 
the nomenclature committee of the International Union of Pharmacology (from Munk et al., 2016). 
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In recent years, increasing efforts have being made to discover new positive allosteric 
modulators (PAMs), which increase the response of the receptor of study; or negative 
allosteric modulators (NAMs), which reduce receptor responsiveness, and neutral allosteric 
ligands, which bind to the allosteric site but display no effects on the responses to the 
orthosteric ligand.  
 
In class A GPCRs, the orthosteric binding site is present within the cavity formed by the 
transmembrane segments, able to bind small molecules as neurotransmitters, peptides and 
hormones. However, in class B GPCRs the orthosteric binding site is present on the 
extracellular loops and can bind large peptide ligands. Interestingly, class C GPCRs presents a 
large bi-lobed N-terminal “Venus fly trap” domain within the orthosteric binding site for 
neurotransmitters binding (Kolakowski, 1994; Chun et al., 2012; Munk et al., 2016) (Figure 7). 
 
 
 
Fig. 7- Structural topology of typical orthosteric and allosteric binding sites of families A, B and C of GPCRs (from 
Conn et al., 2009). 
 
Although this kind of proteins is often described as “bimodal switches with inactive and active 
states”, in reality there are more than those two conformational states, even a ligand for a 
specific GPCR can display diverse effects by stabilization of specific conformations of the 
extracellular part that lead to activation of distinct G-protein signaling pathways downstream 
(Kenakin, 2003; González-Maeso & Sealfon, 2009a). Thus, the term “agonist” is defined as a 
ligand that can fully activate the receptor; “partial agonist” is the one that induce a 
submaximal activation of the G protein, even at saturating concentrations; “inverse agonist” 
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inhibits basal activity; and “antagonist” while having no effect on basal activity, competitively 
block the access of other ligands. Allosteric modulator drugs can target a GPCR with a specific 
conformation (Kobilka & Deupi, 2007; Bokoch et al., 2010). 
 
1.4.2. Heterotrimeric guanine nucleotide-binding proteins 
Heterotrimeric guanine nucleotide-binding proteins (G-proteins) represent an ancient protein 
family that has been highly conserved over evolution. GPCRs associate with heterotrimeric G 
proteins to transduce ligand binding of the receptor to downstream effectors. Bacterial 
exotoxins (e.g. cholera toxin or pertussis toxin) were observed to modify the α-subunit of 
many heterotrimeric G-proteins and subsequently alter their function. Those toxins were key 
tools in the discovery, understanding and classification of the G-proteins. These cytosolic 
proteins bind guanine nucleotides and are coupled to transmembrane receptors  and mediate 
a wide variety of cellular functions, including synthesis of second messengers such as cAMP, 
mobilize internal calcium stores, modulate ion channel function, control neurotransmitter 
release and influence gene expression (Milligan & Kostenis, 2006; Johnson & Lovinger, 2016). 
G-proteins are composed of a nucleotide-binding α subunit (Gα), of 39-52 kDa, and a dimer 
consisting of the β-subunit, of 35-36 kDa, and γ-subunit, of 8-10 kDa (Gβγ) (Vuoristo et al., 
2000). Twenty different Gα, five different Gβ, and twelve different Gγ isoforms associate in 
distinct combinations with GPCRs (Milligan & Kostenis, 2006). 
 
 In their inactive state, Gα-subunits are bound to GDP and tightly associated with Gβγ. When a 
ligand binds to and activates the receptor, a conformational change in the receptor is 
produced, which in turn triggers a dramatic conformational change in the G-protein α subunit. 
Upon activation of a GPCR, the affinity of the receptor for the agonist is enhanced and the 
specificity of the G protein for guanine nucleotides changes in favor of GTP over GDP. Agonist 
binding to the receptor promotes its interaction with the GDP-bound Gαβα heterotrimer, 
leading to the exchange of GDP for GTP and the heterotrimeric G protein dissociates into Gα-
GTP and Gβγ subunits, both of which are biologically active and can regulate the functional 
activity of a diverse array of effector proteins to simultaneously influence many cellular 
functions. The system returns to its resting state when the ligand is released from the receptor 
and the GTPase activity that resides in the α-subunit hydrolyzes GTP to GDP. The latter action 
leads to re-association of the free α subunit with the βγ subunit complex to restore the original 
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heterodimers (Gilman, 1995; Nestler & Duman, 1999; Latek et al., 2012; Johnson & Lovinger, 
2016) (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
Gα proteins are divided into four families (Gs, Gi/o, Gq/11 and G12/13) based on the structural 
properties and function of α subunits, and each family is further subdivided into several 
subtypes (González-Maeso & Meana, 2006). The Gs class is involved in activating adenylyl 
cyclase (AC), the Gi/o in inhibiting AC and regulating ion channels, the Gq/11 in activating 
phospholipase C (PLC) and G12/13 in activating the Na
+/H+ exchanger pathway (Nestler & 
Duman, 1999).  
 
Stimulatory Gα (Gs) protein family couples the receptor activation with the stimulation of all 
isoforms of transmembrane AC activity, leading to cAMP formation. All Gαs isoforms can be 
Fig. 8- Functional cycle of heterotrimeric G proteins. A: basal conditions, G proteins exist in cell membranes as 
heterotrimers composed of α, β, and γ subunits, loosely associated with the receptor. GDP is bound to the α subunit. B: 
upon activation of the receptor by its agonist, such as a neurotransmitter, the receptor associates with the α subunit, 
which leads to the dissociation of GDP from the subunit and the binding of GTP instead. C: GTP binding induces the 
generation of free α subunit by causing the dissociation of the α subunit from β and γ subunits and the receptor. Free α 
subunits (bound to GTP) and free βγ subunit dimers are functionally active and directly regulate a number of effector 
proteins, which, depending on the type of subunit and cell involved, can include ion channels, adenylyl cyclase, 
phospholipase C, phospholipase A2 and phosphodiesterase. D: GTPase activity intrinsic to the α subunit degrades GTP to 
GDP. This leads to the reassociation of the α and βγ subunits, which, along with the dissociation of ligand from receptor, 
leads to restoration of the basal state (from Nestler & Duman, 1999). 
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activated by cholera toxin through the ADP-ribosylation on an arginine residue, leading to a 
constitutive activation of the Gα subunit. 
 
Conversely, inhibitory Gα (Gi/o) proteins receive its name due to its ability for inhibiting AC 
activity and consequently diminish the cAMP accumulation. All members of this family - with 
the exception of Gz - contain a conserved cysteine residue on its carboxy-terminus susceptible 
of being ADP-ribosylated by pertussis toxin (PTX) from Bordetella pertussis. In fact, Gαi proteins 
are also called PTX-sensitive G proteins; whereas the rest of Gα proteins are called 
PTX-insensitive G proteins (Merritt & Hol, 1995; Nestler & Duman, 1999; González-Maeso & 
Meana, 2006; Milligan & Kostenis, 2006). 
 
Finally, the activation of Gq/11 protein family members stimulates the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol-1,4,5-
trisphosphate (IP3) via PLC. The catalytic action of PLC leads to an IP3-induced release of 
calcium ions from intracellular stores and because of it, to a calcium-mediated downstream 
signaling. Moreover, calcium ions and diacylglycerol activate some isoforms of protein kinase C 
(PKC). 
 
Less is known about the non-dissociated Gβγ protein heterodimer. There are eight Gβ and 
twelve Gγ subunits and despite the initial thoughts, the Gβγ dimer also mediates signalling 
through GPCRs activation, including G protein-gated potassium channels, N-type calcium 
channels and also phospholipase Cβ (PLC-β) (Nestler & Duman, 1999; Chen & Lambert, 2000; 
González-Maeso & Meana, 2006; Milligan & Kostenis, 2006). 
 
Regulators of G protein signaling (RGS) are a family of proteins that has been found to play a 
role in desensitization of Gq and Gi/o proteins, by accelerating the rate of GTP hydrolysis 
(Diversé-Pierluissi et al., 1999). 
 
It has also been found that certain GPCR, besides activation of their canonical pathways, are 
able to activate other signal transduction cascades in a ligand-dependent manner. In this 
sense, ligands induce unique, ligand-specific receptor conformations that eventually can 
trigger differential activation of signal transduction pathways associated with that particular 
receptor. This ligand-induced distinct activation of downstream signaling pathways is termed 
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“functional selectivity”, “biased agonism”, “agonist-directed trafficking of receptor stimulus” 
(to name just a few). Functional selectivity allows some GPCRs to preferentially signal through 
a signaling pathway over another when they interact with certain ligands, namely biased 
agonists (Berg et al., 1998; Kenakin, 2007; Urban et al., 2007; Diez-Alarcia et al., 2016).  
1.4.2.1. Influence of pertussis toxin on Gαi/o proteins 
 
PTX is an exotoxin secreted by the Gram-negative, 
aerobic coccobacillus Bordetella pertussis, a pathogen 
that causes pertussis disease, also known as whooping 
cough. It comprises respiratory tract infections that 
most commonly affect immunocompromised patients 
(Zlamy, 2016). 
 
The crystal structure of PTX was solved for the first 
time by Stein and co-workers (1994). PTX belongs to the AB5 toxin family, a hexameric 
assembling comprising a single catalytic active A-subunit and a pentamer of B-subunits. 
A-fragment is responsible for the catalytic activity, whereas B-fragment has the function of 
binding and delivery of the toxin to the target cells (Figure 9). PTX modifies cell responses by 
two different mechanisms. 
 
• A-promoter: once the catalytic A-subunit of PTX is released from B-oligomer into the 
cytoplasm, it can irreversibly ribosylate cysteine residues of the Gα subunit of Gαi/o 
proteins, through its ADP-ribosyltransferase activity, locking the α subunit into a 
GDP-bound inactivate state. The inhibitory effect of Gαi/o protein on AC activity is then 
halted, accumulating cAMP levels intracellularly (Figure 10). Such accumulation of cAMP 
results in pathological effects where the second messenger takes part in, including insulin 
increase secretion by pancreatic cells, hypoglycemia, lipid degradation in adipocytes, 
lymphocitosis, neutrophil migration and vascular permeability. In fact, PTX-induced lipolysis 
has been used as a sensitive assay for the action of PTX. Restoration of Gαi/o function in cells 
is dependent on the synthesis of new Gαi/o proteins (Merritt & Hol, 1995; Mangmool & 
Kurose, 2011). 
 
Fig. 9- Schematic perpendicular view picture of 
PTX. A-helix is shown as a spiral (green). 
Β-strands are shown as arrows (Modified from 
Stein et al., 1994). 
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• B-oligomer: its effects mediate Gαi/o protein-independent actions. Most of the biological 
effects are related to an enhancement of immune responses through several receptors 
such as toll-like receptor 4 (TLR4), human platelet glycoprotein Ib (GPIb) and T-cell receptor 
complex (TCR). TLR4 activation generates a Rac-mediated signaling cascade that ends with 
the activation of NF-κB and the increase of interleukin IL-1β, whereas GPIb-PTX interaction 
leads to a downstream activation of platelet aggregation. Other effects ascribed to the 
B-oligomer of PTX are an induction of dendritic cell maturation, inhibition of growth cone 
guidance, induction of myelomonocytic cell adhesion, induction of ERK1/2 activation in 
endothelial cells, activation of T lymphocytes, induction of Th1/Th17 immune response 
through MAPK and IL-10 activation (Carbonetti, 2010). 
 
Gαi/o protein-dependent effects of PTX display a slow onset (at least 1-2 h) and require low 
concentrations of the toxin. Conversely, Gαi/o protein-independent responses of PTX have a 
rapid onset but demand higher concentrations of the toxin to induce the effects described 
above (Mangmool & Kurose, 2011). 
 
 
 
 
 
 
Fig. 10- Schematic picture of Gαi/o protein-dependent and -independent effects of A-promoter and B-oligomer 
subunits of PTX. 
I. Mollinedo Gajate 
46 
 
1.4.3. Serotonin 2 receptors: focus on 5-HT2AR and 5-HT2CR 
5-HT mediates its effects through the activation of 14 different receptors, grouped in seven 
families; each family being further subdivided into distinct subclasses, namely: 5-HT1 (5-HT1A, 
5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F), 5-HT2 (5-HT2A, 5-HT2B, and 5-HT2C), 5-HT3, 5-HT4, 
5-HT5 (5-HT5A, 5-HT5B), 5-HT6, and 5-HT7. The complexity of the 5-HT system is further 
increased by alternative splicing and mRNA editing of several 5-HT receptors. All these 
receptors are GPCRs, except for 5-HT3 that is a ligand-gated ion channel receptor (LGICR). So 
far, a vast number of studies have recognized the fundamental role of these receptors in 
behavior, mood control, anxiety disorders, cognitive impairment, circadian rhythm, 
reproductive behaviors, thermoregulation, food intake, reward processes, suicide, 
schizophrenia, depression, autism, and other psychiatric disorders (Tseng & Atzori, 2007; 
Millan et al., 2008; Yun & Rhim, 2011). 
 
 Overall, these receptors are widely distributed in the CNS, (except 5-HT2B, which is mainly 
expressed in peripheral tissues), displaying diverse densities and frequently overlapping 
expressions in some areas, such as cortex, hippocampus, hypothalamus, amygdala, thalamus 
or basal ganglia (Kumar & Mann, 2014).  
 
5-HT1 receptors negatively couple to AC via Gi/o proteins, whereas 5-HT4, 5-HT6 and 5-HT7 
receptors stimulate AC through Gs proteins, and 5-HT2 receptors share recruitment of PLC via 
Gq/11 proteins as their canonical signaling pathway. No cardinal pathway is recognized for 
5-HT5A receptors so far, but it seems that they primarily couple to Gi/o proteins (Millan et al., 
2008) (Figure 11; Table 1). 
Fig. 11- An integrated view of signaling at serotonergic neurons. 5-HT is derived from tryptophan by an action 
of tryptophan hydroxylase 2 (TPH2), and it is deactivated by MAOA after release and reuptake via 5-HT 
transporters (SERT). 5-HT receptors are localized both pre- and post-synaptically to serotonergic neurons, but 
all subtypes are not necessarily co-localized at the same postsynaptic location. 5-HT1A and 5-HT1B inhibitory 
autoreceptors are localized on cell bodies and terminals, respectively, and 5-HT5A autoreceptors might also be 
present on the former. Characterization of non-neuronal 5-HT receptors is far from complete. Note that ligand-
gated ion-channel 5-HT3 receptors, not considered herein, are present postsynaptically both on neurons and on 
non-neuronal cells. The major modes of signal transduction are shown at the postsynaptic level and many 
receptors converge on specific signaling pathways. Moreover, individual subtypes recruit multiple cascades, for 
example 5-HT2A receptors couple to Ca
2+
 channels, PLC and PLA2. Ion currents are an important mode for 
autoreceptor-feedback inhibition of serotonergic transmission. Abbreviations: 5-HIAA, 5-hydroxyindole amino 
acid; DAG, diacylglycerol; Gly, glycine; GlyT1, glycine transporter; IP, inositol phosphate; PIP2, phosphoinositol 
bisphosphate; D-Ser, D-serine; VMAT, vesicular monoamine transporter (from Millan et al., 2008). 
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PET studies have revealed an overactivity of the FC in acute states of psychosis as well as in 
drug-induced hallucinations, potentially mediated by hyperactivation of 5-HT2 receptors 
(Vollenweider et al., 1997). The binding rate of the endogenous neurotransmitter ligand 
serotonin varies across 5-HTR subtypes, for example, 5-HT1ARs (Ki= 0.2-400 nM), 5-HT1BR 
(Ki= 1-40 nM), 5-HT7R (Ki= 0.3-8 nM) and 5-HT2AR (Ki= 4-1000 nM). 
 
The 5-HT2Rs family comprises 5-HT2AR, 5-HT2BR and 5-HT2CRs, all of them are coupled 
preferentially to Gq/11 proteins, thus leading to a hydrolysis of PIP2 that increase levels of IP3, 
and elevate cytosolic Ca2+ that eventually modulate excitatory neurotransmission. 5-HT2R 
family members display a high degree of structural homology between them. Thus, 5-HT2BR 
has approximately a 70% homology to 5-HT2AR and 5-HT2CR, while 5-HT2AR and 5-HT2CR 
subtypes share 80% amino acid sequence homology (Hartig et al., 1990; Baez et al., 1995). 
While, as already mentioned, the main signal transduction mechanism for both receptors is 
the same, they can have opposite effects downstream. For instance, 5-HT has higher affinity 
(Kd=10 nM) for the low affinity state of the 5-HT2CR than for the low affinity state of the 5-
HT2AR (Kd=100-1000 nM) (Zifa & Fillion, 1992). 
 
At present, it is no easy matter to pharmacologically discriminate between the 5-HT2R family 
members, due to the lack of truly selective 5-HT2AR or 5-HT2CR ligands. There are a number of 
5-HT2 agonists and antagonists on the market, however all of them display at most about two 
orders of magnitude more affinity for one subtype rather than for others. (±)-DOI, and the 
Table 1- 5-HT receptor classification, signaling pathways, agonist and antagonist drugs. (+): stimulation; NT: not 
tested; PLC: phospholipase C; PKC: protein kinase C. (from Yun & Rhim, 2011). 
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analogues DOM and DOB, are psychedelic drugs with amphetamine-related structure, which 
display preferential affinity for 5-HT2ARs, but at higher doses can also bind at 5-HT2B and 
5-HT2CRs (May et al., 2003; Pigott et al., 2012). Ro 60-0175 has been raised as preferential 
5-HT2CR agonist (Porter et al., 1999; Higgins et al., 2001), whereas M100907 has been posited 
as a potent and selective antagonist of the 5-HT2ARs with much lower affinity for the 5-HT2CR 
or other receptors (Schreiber et al., 1994; Kehne et al., 1996; Pehek et al., 2006). Likewise, SB 
242084 is a 5-HT2CR antagonist with 100-fold higher affinity for 5-HT2C than for the other two 
receptors of the family (Bromidge et al., 1997; Kennett et al., 1997).  
 
1.4.3.1. 5-HT2ARs: localization, triggering effects, and signaling pathways  
 
Localization 
 
5-HT2AR belongs to the class A of GPCRs. This receptor is coupled to Gq/11 protein subtypes, 
which mediate excitatory neurotransmission (Millan et al., 2008). It has been located on 
human chromosome 13q14-q21 and comprises 471 amino acids in humans, mice and rats.   
 
It is widely distributed in peripheral and central tissues. Autoradiographic approaches as well 
as in situ hybridization and histochemistry studies in rats have revealed a high presence of 
5-HT2AR mRNA coding as well as receptor itself in FC, piriform cortex, CA3 subfield of the 
hippocampus, medial mammilary nucleus, the pontine nuclei, the motor cranial nerve nuclei in 
the brainstem, and the ventral horn of the spinal cord. Mild presence was also found in some 
areas of the basal ganglia, such as caudate-putamen, NAcc, SN, and amygdala; some areas in 
the thamalus, such as the reticular nucleus, lateral geniculate nucleus and zona incerta; some 
regions in the hypothalamus; some areas in the brainstem, such as raphe nuclei, subcoeruleus 
nucleus, vestibuar nuclei and PrH; and some regions of the reticular formation, such as PGi and 
lateral reticular nucleus (Pazos et al., 1985; Appel et al., 1990; Pompeiano et al., 1994; Willins 
et al., 1997; Jakab & Goldman-Rakic, 1998; Fay & Kubin, 2000; Miner et al., 2003; Weber & 
Andrade, 2010). It should be noted that a negligible presence of 5-HT2AR mRNA was found in 
LC (Pompeiano et al., 1994). Although previous studies did not observe the presence of 
5-HT2ARs in VTA, subsequent immunohistochemical studies indicated its existence (Doherty & 
Pickel, 2000; Nocjar et al., 2002). 
 
Within the FC there is expression of 5-HT2AR in layers II, III, V and VI (Willins et al., 1997; Puig, 
2011). Strikingly, layer V is the layer which shows the highest density of this receptor, as 
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assessed by using autoradiography with [3H]M100907 and FISH approaches in rodents (López-
Giménez et al., 1997; González-Maeso et al., 2007).  
 
The two major cell types in the FC are glutamate-containing pyramidal neurons and GABAergic 
interneurons. Pyramidal neurons represent approximately 70-80% of the neurons in the 
cortex, while the remaining 20-30% are mostly inhibitory interneurons (Markram et al., 2004; 
Espuny-Camacho et al., 2013). While both 5-HT2AR and 5-HT2CR are widely expressed 
throughout the mFC, the overall density of 5-HT2ARs seems to be higher (Pompeiano et al., 
1994; Clemett et al., 2000). Immunohistochemical and electrophysiological approaches using 
genetically modified mice revealed that the vast majority of 5-HT2ARs corresponds to layer V 
pyramidal cells, concretely on apical dendrites of pyramidal cells of the anterior cortex, and to 
a lesser extent, on parvalbumin expressing fast-spiking GABAergic interneurons of the middle 
layers (Willins et al., 1997; Jakab & Goldman-Rakic, 1998; Hamada et al., 1998; Cornea-Hebert 
et al., 1999; Miner et al., 2003; Weber & Andrade, 2010; Puig & Gulledge, 2011). In fact, both 
5-HT2AR and 5-HT2CR expression has been found on both GABAergic and pyramidal cells 
within the prelimbic FC (Willins et al., 1997; Jakab & Goldman-Rakic, 2000; Carr et al., 2002; 
Santana et al., 2004; Liu et al., 2007; Puig & Gulledge, 2011). A small percentage of 5-HT2CRs 
are co-localizing with 5-HT2AR on pyramidal cells, being the latter receptor highly expressed 
on these cells (Nocjar et al., 2015). This co-localization in pyramidal neurons is further 
supported by the finding that nearly all 5-HT2CR-expressing pyramidal shaped cells 
co-expressed 5-HT2AR mRNA, though only 28%-53% of 5-HT2AR-expressing pyramidal cells 
co-express 5-HT2CR mRNA (Vysokanov et al., 1998; Carr et al., 2002). Recently, a heterodimer 
formation between 5-HT2AR and 5-HT2CR has been reported (Moutkine et al., 2017). 
 
Inside the neurons, 5-HT2ARs are located both intracellularly and on the plasma membranes of 
nerve cell bodies and axons, albeit there is a predominant somatodendritic presence (López-
Giménez et al., 1997; Fiorica-Howells et al., 2002). Such a synaptic localization is consistent 
with previous findings reporting that 5-HT2A receptor expression is reduced in PSD-95 
knockout mice (Abbas et al., 2009). Moreover, it is suggested that 5-HT2ARs are also located 
on cortical axon terminals of projecting neurons (Marek et al., 2001; Scruggs et al., 2003), and 
in astrocytes (Barnes & Sharp, 1999). Light microscopic studies in the rat frontal cortex have 
localized 73% of 5-HT2ARs on postsynaptic dendritic shafts, or dendritic spine heads and 
necks; 24% on presynaptic axons and varicosities, most of these with morphological features 
characteristic of monoamine axons, and the remaining 4% on glial cells (Miner et al., 2003). 
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Regarding the potential presence of 5-HT2AR presynaptically located on monoaminergic axons 
in the FC reported by Miner and co-workers (2003), it is unlikely that the 5-HT2AR-labeled 
monoaminergic profiles are noradrenergic, as it has been reported that the LC is devoid of 
mRNA for 5-HT2AR (Pompeiano et al., 1994, López-Giménez et al., 2001a). On the contrary, it 
is plausible that such terminal axons belong to dopaminergic neurons. Moderate mRNA 
expression for the 5-HT2AR has been shown in DA-rich areas of the rat midbrain (Pompeiano 
et al., 1994) that include cells with projections to the FC (Berger et al., 1976). Supporting 
findings reveal, using dual immunocytochemical localization, that midbrain dopamine cell 
bodies express 5-HT2ARs (Nocjar et al., 2002). Pehek and co-workers (2001) also stand up for a 
presynaptic presence of 5-HT2ARs on dopamine axon terminals that modulate the functioning 
of DA pathways. Microdialysis studies have suggested the potential presence of 5-HT2ARs 
presynaptically on glutamatergic terminals in the FC arising from the mediodorsal thalamus 
(Martin-Ruiz et al., 2001), although no substantial number of 5-HT2AR immunoreactive axon 
terminals whose features are characteristic of glutamate profiles were observed in the study 
performed by Miner and co-workers (2003).   
 
5-HT2AR is not merely co-expressed with 5-HT2CR within cells in the mFC. It has been revealed 
that 5-HT2AR is also co-expressed with 5-HT1AR on the majority of pyramidal neurons, both 
receptors triggering opposing crosstalk (Celada et al., 2004, 2013). 
 
5-HT2AR-dependent effects 
 
5-HT2AR is coupled to Gq/11 proteins, activates downstream PLC isoforms that leads to the 
production of IP3, enhances intracellular Ca
2+ release and activates PKC (Carr et al., 2002; Yun 
& Rhim, 2011). 
In vitro slice recordings have reported that 5-HT2ARs activation increases the excitability of 
neurons in the FC (Araneda & Andrade, 1991). Moreover, 5-HT2ARs stimulation enhances 
spontaneous glutamatergic EPSCs in layer V, a layer enriched with pyramidal neurons 
(Aghajanian & Marek, 1997). That effect was partially attributed to a boost in voltage-
dependent Na+ currents, likely as a consequence of 5-HT2 receptor-mediated activation of 
PKC, which finally increases dendritic excitability and thereby reverses the activity-dependent 
reduction in dendritic action-potential propagation (Astman et al., 1998; Franceschetti et al., 
2000). 
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Intracortical administration of 5-HT2AR agonists enhances local pyramidal cell excitation in a 
dose-dependent manner (Ashby et al., 1990; Arvanov et al., 1999; Nocjar et al., 2015), while 
local 5-HT2CR agonism triggers GABAergic excitation and transmitter release that are thought 
to conversely inhibit cortical pyramidal activity (Abi-Saab et al., 1999; Leggio et al., 2009; Zhang 
et al., 2010; Nocjar et al., 2015). GABAergic stimulation elicited by (±)-DOI is partially blocked 
by 5-HT2CR antagonists, yet fully blocked by dual 5-HT2A/2C receptor antagonism (Zhang et 
al., 2010).  
 
Other responses likely mediated by the 5-HT2AR include hyperthermia, hyperlocomotion, drug 
discrimination, and neuroendocrine responses such as increased secretion of cortisol, ACTH, 
rennin and prolactin (Barnes & Sharp, 1999). Even activation of 5-HT2AR in cortical areas has 
been linked with DA release induced by mild stress, as that produced by gentle handling 
(Pehek et al., 2006). A variety of biological functions such as mood, cognition, sleep, pain, 
motor function and endocrine secretion are under control of 5-HT2ARs. Correspondingly, 
disruptions of serotonergic transmission are implicated in the pathogenesis of depression, 
anxiety, schizophrenia and chronic pain, among others (Millan et al., 2008). Particularly, 
several lines of evidence underscore the crucial role of 5-HT2AR in the pathophysiology and 
therapeutics of neuropsychiatric disorders, including schizophrenia (Gray & Roth, 2007). 
 
 
Hallucinations: molecular and behavioral effects 
 
Despite behavioral animal models of acute hallucinations cannot mimic perturbations of 
perception, cognition, and mood evoked by hallucinogens in humans, head twitch response in 
rodents and wet-dog shakes in rats have emerged as a robust and reliable proxy of human 
hallucinogenic effects.   
 
Certain behavioral responses have been attributed to activation of 5-HT2A receptors. Head 
twitches in mice and wet dog shakes in rats induced by drugs such as (±)-DOI and structural 
analogues, as well as 5-HT releasing agents and precursors like 5-HTP, have been largely 
proven to be 5-HT2AR-mediated. The potency which 5-HT2R antagonists inhibit agonist-
induced head shakes closely correlates with their affinity for the 5-HT2A binding site rather 
than the 5-HT2C binding site. Furthermore, 5-HT2AR antagonists such as ketanserine and 
M100907 inhibit the head shake response (Hoyer et al., 2002), while 5-HT2B/2C receptor 
selective antagonists do not (Barnes & Sharp, 1999). Furthermore, genetically modified mice 
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lacking 5-HT2AR do not display such HTR (González-Maeso et al., 2003). Genetic restoration of 
5-HT2AR signaling in cortical neurons of htr2A-/- mice is sufficient to rescue hallucinogenic-
specific signaling signature and behavioral response. The sole expression of 5-HT2AR in cortex 
is sufficient to mediate the signaling pattern and behavioral response to hallucinogens. 
Subcortical populations of 5-HT2AR appear not to be required for hallucinogenic actions 
(González-Maeso et al., 2007). 
 
Mescaline (found in peyote cactus), psilocybin (found in magic mushrooms) and LSD are all 
hallucinogenic drugs which act via agonism at 5-HT2AR. However, not all 5-HT2ARs agonists 
trigger hallucinations. The closely related 5-HT2AR agonists lisuride or ergotamine lack 
comparable psychoactive properties, although their agonist activity at 5-HT2AR is similar 
(González-Maeso et al., 2007). Moreover, pharmacological or genetic inactivation of 5-HT2AR 
signaling blocks the behavioral effects of hallucinogens (González-Maeso et al., 2007).  
 
While all the 5-HT2AR agonists induce c-fos expression, the induction of egr-2 and egr-1 most 
robustly predict behavioral activity. c-Fos and egr are transcription factors that control the 
expression of genes, being in this way master regulators of every cell’s development and 
functioning (Herdegen & Leah, 1998). In primary cultures of cortical neurons from htr2A+/+ and 
htr2A
-/- mouse embryos, using fluorescent in situ hybridization (FISH) approaches, both LSD 
and lisuride were found to induce c-fos expression in neurons expressing 5-HT2AR mRNA, 
while only LSD induced egr-2 expression in 5-HT2AR-expressing neurons. FISH studies of 
primary cultures from htr2A-/- mice showed no induction of these transcripts. The presence of 
TTX, which suppresses action potentials propagations, does not affect the induction of gene 
transcripts in cortical primary culture, thus indicating that neuronal circuitry is unlikely 
involved in the induction of egr-1 and egr-2 mRNAs. LSD-mediated activation of egr-1 and egr-
2 is suggested to be intrinsic to neurons with 5-HT2AR signaling capacity (González-Maeso et 
al., 2007). 
 
5-HT2AR antagonists have been demonstrated to induce the internalization of 5-HT2ARs in 
vitro and a redistribution of 5-HT2ARs in vivo in apical dendrites of rat cortical pyramidal 
neurons. Chronic treatment with the atypical antipsychotics clozapine and olanzapine 
enhances intracellular 5-HT2AR-like immunoreactivity, while causing a decrease in labeling of 
apical dendrites in the mFC. On the contrary, the typical antipsychotic drug haloperidol did not 
induce the latter effect. It is plausible that the loss of 5-HT2ARs from the apical dendrites of 
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pyramidal neurons is important for the beneficial effects of atypical antipsychotic drugs in 
schizophrenia (Willins et al., 1999). 
 
 
Functional selectivity of 5-HT2AR 
 
Evidence in cellular recombinant systems as well as in human brain tissue has reported the 
existence of multiple conformations/states of the 5-HT2AR (López-Giménez et al., 2001b). The 
5-HT2ARs are primarily coupled to Gq/11 subtype proteins. The activation of Gq/11 proteins 
stimulates PLC-β, which catalyzes the cleavage of membrane-bound PIP2 into the second 
messengers IP3 and DAG (Raote et al., 2007). IP3 elicits Ca
2+ release from intracellular stores, 
while DAG diffuses along the plasma membrane and mediates protein kinase C (PKC) 
activation (Berridge et al., 2003; Becker & Hannun, 2005). Elevated intracellular Ca2+ binds and 
allosterically activates calmodulins proteins, which in turn go on to activate enzymes such as 
Ca2+/calmodulin-dependent kinases (CAMKs). 
 
It is well-established that drugs with affinity at 5-HT2ARs (both agonists and antagonists) can 
stabilize distinct receptor conformations leading to biased interactions or functional selectivity 
with various downstream effectors, which can include the canonical Gq/11 protein and different 
non-canonical signaling (Roth, 2011; Martí-Solano et al., 2015). The agonist functional 
selectivity has been proposed to explain the mechanism of action of hallucinogens, an 
explanation that posits that different receptor agonists stabilize distinct conformations of the 
receptor that preferentially recruit and activate specific signaling pathways, leading to distinct 
behavioral responses (Kenakin, 2003; Urban et al., 2007).  
 
One of the first evidence of functional selectivity of 5-HT2AR arose from the findings of Berg 
and co-workers, regarding the ability of this receptor to signal not only via PLC bus also via 
phospholipase A2 (PLA2), mediating arachidonic acid (AA) release (Berg et al., 1998) 
 
Hallucinogenic and non-hallucinogenic 5-HT2AR agonists also differentially influence FC 
patterns of gene expression (González-Maeso et al., 2007). The relationship of multiple 
signaling pathways to function at 5-HT2AR is complex, but these observations help explain the 
paradox of why some 5-HT2AR agonists elicit hallucinations whereas structurally related 
compounds do not (Millan et al., 2008). While the signaling pathways activated by both the 
non-hallucinogenic 5-HT2AR agonist lisuride, and the hallucinogenic agonist LSD, involve Gq/11 
and phospholipase C, only LSD effects involve PTX-sensitive Gi/o proteins (González-Maeso et 
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al., 2007). The hallucinogenic-type transcriptome response to LSD depends on its specific 
regulation of Gi/o proteins (González-Maeso et al., 2007). 
 
Additionally, 5-HT2AR activates other signal transduction cascades, besides G protein 
mediated PLC-β pathway, in a ligand-dependent manner. β-Arrestins are ubiquitous 
intracellular scaffolding proteins that can diminish or facilitate GPCR signaling and may 
represent a key point at which receptor signaling may diverge in response to particular ligands 
(Gurevich & Gurevich, 2006). 5-HT and (±)-DOI can differentially activate the 5-HT2AR in 
cellular models and in vivo. The precursor of 5-HT, 5-HTP, requires β-arrestin2-mediated 
signaling cascade for inducing HTR, whereas (±)-DOI does not (Schmid et al., 2008). In this way, 
β-arrestin2-KO mice display HTR following 5-HT2AR activation by (±)-DOI and 
N-methyltryptamines - psychoactive metabolites of 5-HT -, but not in response to 5-HT. Using 
mice and cortical neuron cultures from these animals, 5-HT was shown to stimulate Akt 
phosphorylation through the activation of a β-Arrestin2, Src and Akt complex. Moreover, the 
signaling through this complex was demonstrated to be necessary to evoke 5-HT-induced HTR 
(Schmid & Bohn, 2010). Conversely, endogenous N-methyltryptamines, produced by 
tryptamines and 5-HT degradation by N-methyltransferases, evoked HTR in the absence of β-
arrestin2 and thus, in the absence of recruitment of the β-arrestin2-Scr-Akt complex (Schmid & 
Bohn, 2010).  
 
5-HT, the cognate neurotransmitter at the 5-HT2AR, is able to induce 5-HT2AR internalization 
dependently of β-arrestin2 (Schmid et al., 2014). On the other hand, the atypical antipsychotic 
clozapine inhibits 5-HT2AR signaling through G protein-dependen mechanisms, induces 
5-HT2AR internalization and Akt phosphorylation independently of receptor interactions with 
β-arrestin2 (Schmid et al., 2014). Thus, the pharmacologically oppositional ligands 5-HT and 
clozapine use distinct molecular mechanisms to achieve the same 5-HT2AR-mediated 
downstream events: Akt phosphorylation and receptor internalization. Albeit β-arrestin2 has 
no effect on clozapine’s actions in vivo, Akt phosphorylation is required for clozapine’s efficacy 
in suppressing schizophrenic behaviors in mice induced by MK-801 and PCP administration 
(Schmid et al., 2014). 
 
This functional selectivity arises independently of differences in efficacy and/or potency at the 
different signaling pathways (Urban et al., 2007; Martí-Solano et al., 2015). Moreover, 
5-HT2AR activation could also lead to phospholipase A-2 activation and to subsequent release 
of arachidonic acid (Berg et al., 1998).  
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1.4.3.2. 5-HT2CRs: localization, triggering effects, and signaling pathways 
 
Localization 
The 5-HT2CR has been mapped to human chromosome Xq24 (Hoyer et al., 2002). In situ 
hybridization histochemistry studies in rats have revealed 5-HT2CR presence in choroid plexus, 
the FC, anterior olfactory nucleus, lateral septal nucleus, subthalamic nucleus, amygdala, 
substantia nigra pars compacta, several nuclei in the brainstem, PGi, DR, and the whole gray 
matter of the spinal cord. Moderate presence of 5-HT2CR mRNA was found in many nuclei of 
the basal ganglia, thalamus, VTA, and LC (Molineaux et al., 1989; Pompeiano et al., 1994; 
Clemett et al., 2000; López-Giménez et al., 2001a). Within the cortex, moderate presence was 
found in neocortex - restricted to layer V - and cingulate cortex (Pompeiano et al., 1994; López-
Giménez et al., 2001a).  
 
At a cellular level, receptor autoradiography and in situ hybridization histochemistry studies 
suggest a predominantly somatodendritic presence of 5-HT2CR, according to the high levels of 
mRNA for 5-HT2CRs and the high density of binding sites. However, 5-HT2CRs are also 
suggested to be presynaptically located in axon terminals of some brain areas, since receptor 
labeling has been found with no presence of 5-HT2CR mRNA, suggesting its synthesis in septal 
and diagonal band cell bodies and its subsequent transport to axon terminals (López-Giménez 
et al., 2001a). Supporting these findings, a study carried out in humans showed a predominant 
presence of 5-HT2CRs in layer V of cortical areas (Pasqualetti et al., 1999), contrarily to the 
final disposition in layer III where these receptors are commonly found employing radioligand 
binding techniques. This could indicate that 5-HT2CRs are present either in dendrite or axon 
terminals of the same cells located in layer V (Pazos et al., 1987). 
 
Many neuronal populations have been shown to express 5-HT2CR mRNA and/or protein, 
including serotonergic, cholinergic, GABAergic, neuropeptidergic, glutamatergic and 
dopaminergic neurons (Mengod, 2011). In that sense, 5-HT2CRs can be key players on 
modulating the activity of other neurotransmission systems. 
 
As mentioned above, 5-HT2CR co-expresses with  5-HT2AR on both GABAergic and pyramidal 
cells within the prelimbic FC (Willins et al., 1997; Jakab & Goldman-Rakic, 2000; Carr et al., 
2002; Santana et al., 2004; Liu et al., 2007; Puig & Gulledge, 2011). However, there is a larger 
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presence of 5-HT2AR than 5-HT2CR on pyramidal cells (Vysokanov et al., 1998; Carr et al., 
2002; Nocjar et al., 2015).  Studies employing immunofluorescence with confocal microscopy 
in rat prelimbic mFC have revealed that the majority of neurons expressing 5-HT2CR 
immunoreactivity in layers V-VI also co-express the 5-HT2AR. These cells are likely GABAergic 
for the most part, since 73% of the 5-HT2CR-IR cells in this region co-express the GABA cell 
marker GAD-67, suggesting that a cellular subpopulation within the deep layers of the FC could 
be directly co-regulated by 5-HT2CR and 5-HT2AR. Thus, both receptors could be mediating 
the inhibitory control over efferent pyramidal projections from the FC (Nocjar et al., 2015). 
 
 
5-HT2CR-dependent effects 
 
5-HT2CRs are coupled to Gq/11 proteins, activate downstream PLC isoforms, leading to the IP3, 
enhance intracellular Ca2+ release and activate PKC (Carr et al., 2002; Yun & Rhim, 2011). 
 
5-HT2CR has long been associated with the regulation of food seeking behavior (Aulakh et al., 
1992; Higgins et al., 2016) and addictive disorders including drug reward (Higgins & Fletcher, 
2003; Filip et al., 2012; Higgins & Fletcher, 2015). Characteristic behavioural responses evoked 
by 5-HT2CRs agonist agents, such as meta-chlorophenylpiperazine (mCPP)  and Ro 60-0175, 
attribute to central 5-HT2CR activation an important role in hypoactivity, hypophagia, 
increased penile grooming/erections, and oral dyskinesia (Hoyer et al., 2002). 5-HT2CR 
stimulation has been shown to exert a tonic inhibitory influence upon frontocortical 
dopaminergic and adrenergic, but not serotonergic, transmission (Millan et al., 2003) and, in 
part, to play a role in the neuroendocrine function. Consistent with its action as a 5-HT2CR 
antagonist, RS 102221 increased food intake and weight gain in rats, yet it failed to reverse the 
hypolocomotion induced by mCPP, possibly due to restricted brain penetration. Moreover, the 
5-HT2CR KO mouse suffers from spontaneous convulsions, cognitive impairment, increased 
food intake and obesity, although similar effects are not reproduced by selective antagonists, 
suggesting that these changes may result from neuroadaptation (Hoyer et al., 2002).  
 
5-HT2CRs have received growing attention as a target for the treatment of depressive and 
anxious states (Greenwood et al., 2012; Chagraoui et al., 2016), even for depressive episodes 
in schizophrenia (Englisch et al., 2016). 
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1.4.4. Metabotropic glutamate receptors 
Glutamate receptors are divided into two main families: voltage-gated ion channels, 
commonly referred as ionotropic glutamate receptors (iGluRs), and G protein-coupled 
glutamate receptors, also termed metabotropic glutamate receptors (mGluRs) (Traynelis et al., 
2010; Julio-Pieper et al., 2011). The ionotropic receptor family includes NMDA, AMPA, and 
kainate receptor subfamilies, so-called due to the chemical agonist that selectively binds to 
each subfamily. While iGluRs regulate rapid responses upon activation, mGluRs modulate 
signal transduction cascades.  
 
mGluRs belong to the C family of GPCRs. On the basis of their intracellular signal transduction 
mechanisms, pharmacological characteristics, and structural homology, mGluRs are split into 
three families (Figure 12): group I (comprising mGluR1 and mGluR5), group II (comprising 
mGluR2 and mGluR3), and group III (comprising mGluR4, mGluR6, mGluR7, and mGluR8) 
(Cryan & Dev, 2008; Willard & Koochekpour, 2013). Receptors belonging to the same group 
exhibit roughly 70% sequence homology, whereas the homology between receptors from 
different groups is about 45% (Pin & Duvoisin, 1995). Alternatively, spliced receptor variants 
have been reported and confirmed for mGluR1, mGluR3, mGluR5, mGluR6, mGluR7, and 
mGluR8 (Pin & Duvoisin, 1995; Flor et al., 1997; Corti et al., 1998; Zhu et al., 1999; Valerio et 
al., 2001; Malherbe et al., 2002; Sartorius et al., 2006) 
 
Group I mGluR are coupled to Gq proteins, thus 
its activation leads to stimulation of PLC and 
PKC, stimulates phosphoinositide hydrolysis 
with subsequent formation of IP3 and DAG, and 
causes the release of Ca2+ from intracellular 
stores. Group II and group III in contrast are 
coupled to Gi proteins, and inhibit AC activity, 
decreasing levels of cAMP formation (Julio-
Pieper et al., 2011) (Figure 13), and are thought 
to function as inhibitory presynaptic 
autoreceptors that may play a role in synaptic 
plasticity (Conn & Pin, 1997). 
 
Fig. 12- mGlu receptor families and signaling pathways 
(from Julio-Pieper et al., 2011). 
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mGluRs are expressed in the CNS, 
mainly located on neurons and glial 
cells, adjacent to the synaptic cleft. They 
can regulate not only the effect of 
glutamate in postsynaptic neurons, but 
also the release of glutamate and other 
neurotransmitters in presynaptic 
locations. These receptors are widely 
distributed in the brain and are 
implicated in a number of diseases, 
such as Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease and 
schizophrenia, among others (Ribeiro et 
al., 2017). They are also expressed in 
peripheral tissues where they play a role in a variety of physiological and pathological 
processes, including hormone production in the adrenal gland and pancreas, regulation of 
mineralization in the developing cartilage, modulation of lymphocyte cytokine production, 
direction of the state of differentiation in embryonic stem cells, and modulation of 
gastrointestinal secretory function (Julio-Pieper et al., 2011). 
 
1.4.4.1. Metabotropic glutamate II receptors: localization and functioning 
 
Localization 
The gene encoding the human mGluR2 has been mapped to chromosome 3p21.1-p21.2, and 
no splicing variants have been reported so far (Muguruza et al., 2016). mGluR2/3 receptors are 
presynaptically and postsynaptically located in the neurons, primarily away from the site of 
release in various regions of the brain, such as cortex, mainly in FC, amygdala, basal ganglia, 
thalamus, hypothalamus, and LC, among other many regions (Petralia et al., 1996; Ohishi et al., 
1998; Cartmell & Shoepp, 2000; Wright et al., 2001; Gu et al., 2008). While mGluR2 expression 
is restricted to neurons, mGluR3 has been found on glial cells throughout brain regions 
(Tamaru et al., 2001). In mouse FC, the largest density of mGluR2/3 binding has been shown in 
layers I and Va (Marek et al., 2000), and both pre- and post-synaptically located (Venkatadri & 
Lee, 2014). Thus, glutamate can act potentially as an inhibitory neurotransmitter, by binding to 
Fig. 13- Schematic representation of group I, group II, and 
group III mGluRs pre- and post-synaptically located (from 
Benarroch, 2008). 
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postsynaptic group II mGluRs. mGluR2s are known to function as autoreceptors on terminal 
thalamorcortical neurons (Marek et al., 2001). 
 
Group II mGluRs functioning and schizophrenia 
Psychomimetic agents increase activity of glutamatergic synapses (Aghajanian & Marek, 1999; 
Anneken et al., 2013) in the FC, a feature that has been postulated to be critical in the 
pathophysiology of schizophrenia. Effects of psychomimetic agents on glutamatergic 
transmission in the FC are blocked by group II mGluR agonists (Conn & Jones, 2009). 
 
Intense efforts in targeting mGluR2/3 to treat psychosis in schizophrenia have been made for 
decades. In fact, preclinical data demonstrated promising antipsychotic potential of orthosteric 
mGluR2/3 agonists (such as LY354740, LY404039, LY2140023 and related compounds) by 
blocking the hyperlocomotive, glutamate release in FC and NAcc, and stereotypy inducing 
effects of the NMDA receptor antagonist PCP in rats (Moghaddam & Adams, 1998). 
Subsequent studies confirmed the latter results and also demonstrated that these compounds 
additionally block excessive release of DA, glutamate, and NE, triggered by NMDA antagonists 
by in vivo microdialysis (Cartmell et al., 1999; Lorrain et al., 2003a; Lorrain et al., 2003b; Winter 
et al., 2004; Swanson et al., 2004). Despite the promising therapeutic benefits in preclinical 
studies (Patil et al., 2007), clinical trials were eventually not successful (Delille et al., 2012; Li et 
al., 2015; Walker & Conn, 2015).  
 
Development of highly selective agonists and antagonists that act at the orthosteric binding 
site of mGluR2 is difficult, inasmuch as the glutamate binding site is highly conserved across 
mGluR subtypes. Recently, tremendous advances have been made in the creation of new 
drugs that interact with allosteric sites on the receptors, which is a region less highly 
conserved. This novel class of compounds, known as positive allosteric modulators (PAMs), 
that are selective for mGluR2 have shown exciting potential as an alternative approach to 
mGluR2/3 agonists. mGluR2-selective PAMs, possessing distinct structural properties, have 
displayed efficacy in animal models of psychosis and anxiety disorders (Conn & Jones, 2009). 
These compounds do not activate mGluR2 directly but bind to a site distinct from the 
glutamate-binding site to enhance responses of mGluR2 to glutamate. Various mGluR2 PAMs 
have been identified, all of which are structurally related to two prototypical mGluR2 PAMs, 
termed LY487379, and BINA (Conn & Jones, 2009). Furthermore, some PAMs, frequently 
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named “ago-PAMs” can also produce allosteric agonist activity by generating receptor 
signaling in the absence of glutamate besides potentiating glutamate response (Walker & 
Conn, 2015). 
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1.5. GPCRs HETEROMERS 
 
There is an increasing body of evidence suggesting that GPCRs exist and function as 
monomeric entities and coupled with others to create dimers or even higher-order oligomers. 
These heterocomplexes can display alternative ligand-binding properties and signaling 
pathways compared to the individual monomeric units (George et al., 2000; Gomes et al., 
2000; Angers et al., 2002; Milligan, 2007; Moreno et al., 2013). 
 
Experimental evidence indicates that family C GPCRs, including GABAB and mGlu receptors, 
exist and function as constitutive dimers. For instance, GABAB receptors need the assembly of 
GABAB-R1 and GABAB-R2 to function properly. mGluRs are thought to be present at the plasma 
membrane as strict dimers, and not higher-order oligomers, that are covalently linked through 
a disulfide bond (Maurel et al., 2008). Class A GPCRs likely exist as homomers, dimers and 
potentially as higher-order oligomers.  
 
 
GPCR heteromer formation can affect functional outcomes such as ligand binding profiles, 
patterns of G-protein coupling, and subcellular location (Figure 14). They have gained 
importance inasmuch as they can modulate mechanisms underlying physiological and 
behavioral responses induced by signaling pathways downstream GPCRs. As various DA, 5-HT, 
glutamate, NE, and adenosine receptors have been shown to form GPCR heteromers in vitro, 
in tissue culture and in vivo, in animal models, a better understanding of their structure, 
neuroanatomical location, and physiological function may represent a new target for the 
design of new drugs for the treatment of neuropsychiatric disorders (Moreno et al., 2013). 
 
Co-immunoprecipitation, bioluminescence resonance energy transfer (BRET), and fluorescence 
resonance energy transfer (FRET) assays have enabled the identification of a wide range of 
GPCR heteromers potentially implicated in neuropsychiatric disorders, all of them in cell lines, 
and others in further tissues: 5-HT2A-D2 in striatum, A1-A2A in striatum, A1-D1 in striatum, A1-
mGluR1 still only in cell lines, A1-5-HT2A in cortex, A2A-D2 in striatum, A2A-mGluR5 in striatum, 
A2A-D2-mGluR5 in striatum, A2A-CB1 in striatum, A2A-CB1-D2 still only in cell lines, α2A-MOR in 
striatum, CB1-D2 in striatum, CB1-5-HT2A in cortex, striatum and hippoccampus, D1-D2 in 
striatum, D1-D3 in cell lines, D2-D3 in striatum, D2-H3 in striatum, D4-MOR in striatum, GHS-R1a-
D2 hypothalamus, GHS-R1a-5-HT2CR in cell lines, mGluR2-5-HT2AR in cortex, mGluR2-5-HT2B 
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in cells, and mGluR2-mGluR5 in cells (Albizu et al., 2011; Delille et al., 2012; Moreno et al., 
2013; Schellekens et al., 2013; González-Maeso, 2014; Viñals et al., 2015). 
 
The present work focuses on 5-HT2AR/mGluR2 heteromer or heteroxomplex, its formation, 
signaling pathways and functionality. 
 
 
 
 
1.5.1. 5-HT2AR/mGluR2heterocomplex formation 
Marek and co-workers (2000) were the first to describe a functional interaction between 
mGluR2/3 and 5-HT2AR in the medial FC (mFC). They previously reported stimulated 
glutamatergic activity in the FC, subsequent to the activation of 5-HT2ARs in such area 
(Aghajanian & Marek, 1997; Aghajanian & Marek, 1999; Marek & Aghajanian, 1999). Shortly 
after, it was discovered that the selective mGluR2/mGluR3 agonist LY354740 attenuated the 
5-HT2AR agonism-induced EPSCs and glutamate release recorded in layer V pyramidal cells of 
the mFC. In fact, (±)-DOI binding was enhanced by thalamic lesions (Marek et al., 2001). 
Moreover, autoradiography studies show a laminar overlapping for 5-HT2AR and mGluR2/3 
receptor binding in the mFC, compared to other cortical regions (Marek et al., 2000). Thus, 
Marek and co-workers state that mGluR2/3 function as inhibitory autoreceptors in cortical 
glutamatergic terminals whose transmitter release is positively regulated by 5-HT2AR 
activation. Further studies have shown that pharmacological activation of mGluR2/3 can 
Fig. 14- Schematic model of functional responses induced by GPCR homomers compared to GPCR heteromers. 
Combinations of drugs modulate different signaling pathways, as well as a cross-talk between the components of 
the GPCR heteromeric complex leads to unique signaling properties (Moreno et al., 2013). 
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inhibit behavioral and electrophysiological effects derived from hallucinogenic drugs (Zhai et 
al., 2003; Benneyworth et al., 2007), and prevent the down-regulation of 5-HT2ARs in FC 
induced by repeated administration of (±)-DOI (Marek et al., 2006). 
 
González-Maeso and co-workers (2008) demonstrated for the first time that the Gq/11-coupled 
5-HT2AR and the Gi/o-coupled mGluR2, but not the closely related Gi/o-coupled mGluR3, form a 
GPCR heteromer in mouse and human FC (Snyder, 2008). Studies using mGluR2 and mGluR3 
chimeric constructs enable to discern the ability of mGluR2 and not mGluR3 to co-express in 
close proximity with 5-HT2ARs. The three amino acid residues Ala-6774.40, Ala-6814.44, and Ala-
6854.48 located at the intracellular end of TM4 of mGluR2 seem to be necessary to form a GPCR 
heteromer with 5-HT2AR in HEK293 cells. Supporting evidence was found when performed 
immunoprecipitation assays using mGluR3 chimeras containing TM4 and TM5 of mGluR2 
receptor (mGluR3∆TM4,5) showed the formation of a heterodimer with the 5-HT2AR (Moreno 
et al., 2012). A recent report performing immunoprecipitation assays with chimeras of 
5-HT2AR and 5-HT2CR demonstrated that TM4 of the 5-HT2AR was the key domain to form 
heterocomplex with mGluR2 (Moreno et al., 2016). Assays with subcellular purified fractions 
enriched in presynaptic active zone (PAZ) and postsynaptic density (PSD) proteins have 
revealed that the exact localization of this heterocomplex in mouse is in postsynaptic cortical 
neurons (Moreno et al., 2016).  
 
It has been shown, in postmortem brains of antipsychotic-free schizophrenic subjects, 
increased 5-HT2AR and decreased mGluR2 densities, and such increase in 5-HT2AR negatively 
correlated with aging (González-Maeso et al., 2008). However, there are some discrepancies in 
this field, since some studies have shown decrease or unchanged 5-HT2AR densities in 
schizophrenia patients (Dean, 2003). On the other hand, atypical antipsychotic drugs have 
been shown to decrease the density of 5-HT2AR and mGluR2 (Dean, 2003; González-Maeso et 
al., 2008). Later, it was discovered that the allosteric binding crosstalk between 5-HT2AR and 
mGluR2 as a GPCR heterocomplex is upregulated in postmortem prefrontal cortex of 
schizophrenia brains (Moreno et al., 2012; Muguruza et al., 2013). In contrast, no changes in 
expression and density of both 5-HT2AR and mGluR2/3 in the postmortem prefrontal cortex of 
subjects with major depressive disorder under basal conditions have been reported, 
reinforcing the assumption that the latter imbalances are characteristic of schizophrenia 
(Muguruza et al., 2014).  
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The same profile showed in postmortem brains of schizophrenic subjects was shown in the 
offspring of pregnant mice infected with influenza virus during pregnancy. Cortical 5-HT2AR 
was up-regulated, as well as c-fos, egr-1 and egr-2, whereas mGluR2 was down-regulated 
(Moreno et al., 2011b). Likewise, prenatal stress leads to a similar pattern of receptor 
expression, increased 5-HT2AR and decreased mGluR2 densities in FC, as well as to a higher 
sensitivity to evoke HTR induced by (±)-DOI (Holloway et al., 2013). 
 
1.5.2. Signaling pathways of 5-HT2AR/mGluR2 heterocomplex and its involvement in 
behavioral responses 
To determine whether the formation of the 5-HT2AR/mGluR2 heterocomplex has functional 
consequences, the effects of an mGluR2/3 agonist on the competition binding of several 
hallucinogenic 5-HT2AR agonists, and vice versa, were examined in mouse cortex (González-
Maeso et al., 2008). Radioligand binding assays showed that activation of mGluR2 increased 
the affinity of hallucinogenic drugs for the 5-HT2AR, whereas conversely activation of 5-HT2AR 
decreased the affinity of agonists for the mGluR2 (González-Maeso et al., 2008). 
Hallucinogenic and non-hallucinogenic drugs activate the same population of 5-HT2ARs in 
cortical pyramidal neurons, but differ in the 5-HT2AR-dependent pattern of G protein 
regulation and gene expression that they elicit (González-Maeso et al., 2003; González-Maeso 
et al., 2007). In brain cortical neurons, the signaling elicited by hallucinogenic and non-
hallucinogenic drugs causes the induction of c-fos and requires Gq/11-dependent activation of 
PLC. However, the signaling of hallucinogens such as (±)-DOI and LSD acting at the 5-HT2AR 
also induces egr-2 expression, which is Gi/o-dependent (González-Maeso et al., 2008). Studies 
of ion channels in Xenopus oocytes as markers of Gq/11-dependent and Gi/o-dependent G 
proteins signaling demonstrate that both serotonergic and glutamatergic ligands balance the 
pattern of G protein signaling downstream of the 5-HT2AR/mGluR2 heteromer in a way that 
predicts their pro- or anti-psychotic potential (Fribourg et al., 2011). Supporting this theory, 
Molinaro and co-workers (2009) reported that in the FC mGluR2/3 receptors negatively 
regulate the canonical Gq and PLC pathway activated by 5-HT2ARs, unless PLC is activated by 
Gi/o proteins in response to (±)-DOI. 
 
The implication of 5-HT2AR/mGluR2 heterocomplex in behavioral effects has been 
demonstrated using hallucinogenic 5-HT2AR agonists as a mouse model of psychosis. As 
mentioned above, hallucinogenic 5-HT2AR agonists, such as LSD, mescaline or (±)-DOI, induce 
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head twitch behavior in mice, and this behavior is absent in 5-HT2AR knockout mice (González-
Maeso et al., 2003; González-Maeso et al., 2007). Moreover, head twitch response is reduced 
in mGluR2 knockout mice, as is the high-affinity binding site of (±)-DOI at 5-HT2AR in mouse FC 
membranes, despite the 5-HT2AR level of expression is unaffected (Moreno et al., 2011a) 
(Figure 15). Remarkably, viral-mediated overexpression of mGluR2 in FC rescues the effects of 
LSD-like hallucinogenic drugs in mGluR2-null mice (Moreno et al., 2011a; Moreno et al., 2012). 
Importantly, overexpression of mGluR2∆TM4N, a construct lacking TM4 of the mGluR2 which 
therefore cannot form heterocomplex with 5-HT2AR, does not rescue the LSD-like-mediated 
HTR (Moreno et al., 2012). Taken together, these data suggest that the 5-HT2AR/mGluR2 
heterocomplex, and not 5-HT2AR alone, is the molecular target responsible for the psychosis-
like behavioral effects of LSD-like hallucinogenic drugs (Fribourg et al., 2011; Moreno et al., 
2011a; Moreno et al., 2012). 
 
The most recent findings in this field show that activation of the mGluR2 (with the mGluR2/3 
agonist LY379268) activates Gq/11-dependent signaling leading to stimulation of PLC and 
increased Ca2+ intracellularly through a molecular mechanism that requires the functional 
Fig. 15- G protein-dependent signaling and behavioral responses that require a GPCR heterocomplex. When 
5-HT2AR and mGluR2 are prevented from forming a receptor heterocomplex, activation of 5-HT2AR by LSD-like 
compounds elicits signaling characteristic of Gq/11 protein subtypes. In contrast, LSD-like compounds acting at the 
5-HT2AR/mGluR2 receptor heterocomplex activate both Gq/11- and Gi/o-dependent signaling. Head twitch behavior 
is reliably and robustly elicited by hallucinogenic 5-HT2AR agonists, and is absent in mGluR2 knockout mice (from 
González-Maeso, 2011). 
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presence of both 5-HT2AR and mGluR2 forming a heterocomplex. mGluR2 coupled to an 
activation of Gi/o proteins is necessary for the 5-HT2AR/mGluR2 heterocomplex-dependent 
effects of LY379268, since this drug failed to increase intracellular Ca2+ after pre-treatment 
with PTX. [35S]GTPγS binding assays followed by immunoprecipitation with antibodies against 
Gαi1,2,3 proteins or Gαq/11 proteins in plasma membrane preparations from the mouse FC 
suggest that the canonical coupling of mGluR2 receptors is activation of Gαi1,2,3 proteins, and 
such activation is unaffected by the loss of 5-HT2AR. However, the existence of 5-HT2AR is an 
essential condition for mGluR2 to couple to Gq/11 proteins (Moreno et al., 2016).  
 
As mentioned above, postmortem frontal cortex of schizophrenic subjects have higher density 
of 5-HT2AR. The extent of activation of Gq/11 proteins by LY379268 in such frontal cortices is 
markedly reduced compared to controls, whereas the ability of LY379268 to activate Gi1,2,3 
proteins was unaffected (Moreno et al., 2016). Moreover, an apparent supersensitivity to 
activate inhibitory G proteins (Gαi1,3 and Gαz) has been observed in postmortem drug-naïve 
human brains of schizophrenic patients (unpublished data). 
 
Therefore, it is possible that 5-HT2AR/mGluR2 heteromer-dependent signaling effects may 
involve 5-HT and glutamate signaling, thus contributing to the abnormalities of thought and 
behavior observed in schizophrenic patients. 
 
 
  
  
2. AIMS
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Schizophrenia is a severe and complex brain disorder that is the result of multiple interactions 
between genetic, environmental, and social risk factors. Despite great efforts have been made 
so far, the basic understanding of the etiopathogenesis of schizophrenia, in which multiple and 
insufficiently known molecular pathways are likely to be involved, is still incomplete. In this 
sense, the tools for treatment or prevention of this disease are urgently needed. Currently, 
antipsychotic treatment focuses primarily on the antagonism of the dopaminergic D2 receptors 
and serotonergic 5-HT2A receptors. However, these treatments do not work effectively in a 
substantial number of patients, and lead to serious side effects. A deeper understanding of 
schizophrenia at a neurobiological level would enable the identification of new molecular 
targets which could act as therapeutic targets for new drugs. In this context, the generation of 
animal models would be a useful tool to gain insight into the neurobiological and molecular 
aspects related to the disease, allowing more effective treatments to be designed.   
 
There is extensive evidence to support the involvement of the glutamatergic system with the 
pathophysiology of schizophrenia, linking the dysfunction of the ionotropic glutamate 
receptors with the disease.  Moreover, drugs acting through the mGluR2 are emerging as new 
possible therapeutic approaches due to their regulatory capacity over the glutamatergic 
system.  Noradrenergic and dopaminergic systems are also altered in this disease. The 
existence of the 5-HT2AR/mGluR2 complex in cellular and animal models, as well as in human 
brain is convincingly demonstrated from a structural, molecular, biochemical, and cellular 
point of view, but only partially from a neurochemical, pharmacological and behavioral 
outlook. It is suggested that the 5-HT2AR/mGluR2 complex must be intact to allow the proper 
cortical modulation of NE and DA release. A heterocomplex dysfunction (knockout mice for 
each receptor), or the use of selective drugs acting specifically through each receptor result in 
a neurochemical and behavioral dysbalance that alters the effects mediated by the other 
receptor that comprises the complex. In schizophrenic patients and animal models of this 
disease, the functional activity of the heterocomplex is dysbalanced, likely toward a 
hyperactivation of the 5-HT2AR and a hypoactivation of mGluR2. The mechanism of action of 
antipsychotic drugs requires the 5-HT2AR/mGluR2 heterocomplex integrity and would act 
toward the 5-HT2AR hyperactivation blockade (atypical antipsychotics) or restoring the 
hypoactivation of mGluR2.  
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In this framework, the specific goals of this research work were to study: 
 
1. The in vivo evaluation of the effect induced by the 5-HT2AR/2CR agonist (±)-DOI on 
cortical DA and NE release. 
 
2. The comparison of the (±)-DOI-induced effect on cortical DA and NE release between 
intra-cortical and systemic administration.  
 
3. The in vivo neurochemical characterization of the influence of the mGluR2/5-HT2AR 
heterocomplex on cortical DA and NE release evoked by (±)-DOI administration.  
 
4. The influence of iGluRs located on the LC and/or the FC in the (±)-DOI-induced effect 
on NE release.  
 
5. The influence of α2-adrenoceptors located in the LC on the modulation of cortical NE 
release induced by (±)-DOI.  
 
6. The in vivo characterization of the influence of the mGluR2/5-HT2AR heterocomplex 
on head-twitch responses to (±)-DOI administration.  
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3. 1. ANIMALS 
3.1.1. Genetically modified mice 
Wild-type and genetically modified mice weighting between 25-40 g were housed 5-10 per 
cage, until the beginning of the experiment, on a 12/12-h light/dark cycle at 22±2°C and 
65-70% humidity. Food and water was provided ad libitum.  
 
Animal husbandry, housing as well as experimental procedures were carried out at the 
University of the Basque Country, Leioa, Spain. Animal care and experimental protocols were 
executed in accordance with the principles of animal care established by the European 
Directive for the Protection of Vertebrate Animals used for experimental and other scientific 
purposes (European Union Directive 2010/63/UE), as well as in agreement with the Spanish 
legislation which regulates the welfare of animals used in experimentation and other scientific 
purposes (Royal Decree 53/2013). Procedures were approved by the Ethics Committee for 
Animal Welfare (CEBA) of the University of the Basque Country (UPV/EHU) 
(CEBA/107/2010/MEANA MARTINEZ, CEBA/181/2011/MEANA MARTINEZ, 
CEBA/182/2011/MEANA MARTINEZ, CEBA/203/2011/MEANA MARTINEZ, 
CEEA/345/2013/MEANA MARTINEZ). 
 
3.1.1.1. Metabotropic glutamate 2 receptor knock-out mice (mGluR2
-/-
, mGluR2-KO) 
 
mGluR2-KO animals were kindly donated by Dr. Javier González-Maeso (Department of 
Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Virginia, 
USA). 
 
This animal model corresponds to a mouse (Mus Musculus) generated in a 129/Sv strain 
background by directed mutagenesis of embryonic stem cells. The 15.3-kb DNA fragment 
containing exon 2 of the gene encoding mGluR2 was isolated from a 129/Sv mouse genomic 
library. For gene targeting, the translation initiation site and its downstream sequence in exon 
2 were disrupted by replacement of this exon with the neomycin resistance gene (NEO) (Masu 
et al., 1995).  
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The lack of mGluR2 expression has been largely verified by DNA, RNA assays and protein 
expression in southern, northern and western blot experiments. These mGluR2-deficient mice 
showed neither behavioral abnormalities nor any gross anatomical changes in the brain 
compared to the wild-type littermates (Yokoi et al., 1996). 
Knockout (mGluR2-/-) and wild-type (mGluR2+/+) mice were regularly genotyped by using 
conventional PCR coupled to an electrophoresis procedure (data not shown) to verify the lack 
or presence of mGlu2 receptor.  
 
3.1.1.2. Serotonin 2A receptor knock-out mice (5-HT2AR
-/-
, 5-HT2AR-KO) 
 
These animals were kindly donated by Dr. Rafael Maldonado (Department of Experimental and 
Health Sciences, Pompeu Fabra University, Barcelona, Spain). 
 
The 5-HT2AR-/- mice were originally generated at Columbia University (USA) in a 129S6/SvEv 
background mice.  A transcriptional termination sequence (NEO-STOP) was placed between 
the promoter and the coding sequence blocking transcription and translation of the htr2a gene 
(Figure 16). Subsequently, animals were backcrossed over at least ten generations onto the 
inbred C57BL/6 line (González-Maeso et al., 2003; Weisstaub et al., 2006; González-Maeso et 
al., 2007; Orejarena et al., 2011). 5-HT2AR-KO and WT mice were further genotyped by 
conventional PCR analyses of tissue samples from the tails of the animals (data not shown), as 
described by Fiorica-Howells and co-workers (2002) to verify the lack or presence of 5-HT2AR.   
 
5-HT2AR-/- mice had no detectable changes in brain development or cytoarchitecture 
(González-Maeso et al., 2003). 
Fig. 16- Schematic representation of the generation of the genetically modified mice with global 
disruption of 5-HT2AR signaling capacity (5-HT2AR
-/-
). Filled blue boxes represent exons of htr2a gene. The 
narrow box labeled with phtr2a represents the endogenous promoter for the gene. Serpentine symbol 
indicates the htr2a gene product. Left panel: Schematic of the wild-type htr2a locus. Right panel: Lox-p 
(triangles)-flanked cassette (red box) inserted upstream from the first initiation codon of the htr2a gene 
blocks transcription and translation. Modified from Weisstaub et al., (2006). 
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3.1.1.3. Metabotropic glutamate 3 receptor knock-out mice (mGluR3
-/-
, mGluR3-KO) 
 
These animals were kindly donated by Dr. Pedro Grandes (Neuroscience Department, 
University of the Basque Country UPV/EHU, Leioa, Spain). 
 
These mGlu3 receptor knock-out mice (mGluR3-/-) were generated in a C57BL/6J X 129/Sv 
background. Similarly as for breeding mGlu2R KO animals, mGluR3 mice were generated by 
directed mutagenesis using embryonic stem cells. Briefly, targeted disruption of exon 2 of the 
Grm3 gene and further cloning into different vectors were performed. Then, the final Grm3 
targeting construct was injected into a line of mouse embryonic stem cells, and isolated 
recombinant cells were injected into murine C57BL/6J blastocysts (Masu et al., 1995) (Figure 
17). 
 
 
 
 
 
 
3.1.2. Sprague-Dawley rats 
Male Sprague-Drawley rats weighting 245-300 g at the time of surgery were used. Rats were 
housed 5 per cage in a controlled temperature room with free access to food and water, on a 
12/12-h light/dark schedule and 60% humidity. Animals were obtained from the Animal Facility 
of the University of the Basque Country (SGIKER), Leioa, Spain.  
 
Animal care and all experimental protocols were performed in agreement with European 
Union Regulations for the protection of animals used for scientific purposes, housing, caring 
and good laboratory practice (European Union Directive 2010/63/UE) and National Regulations 
Fig. 17- Schematic representation of a targeted disruption of the mGluR3 gene. Homologous 
recombination resulted in replacement of a fragment encoding a part of the mGluR3
transmembrane TM region with the neomycin resistance gene (NEO). The herpes simplex virus 
thymidine kinase gene (TK) was attached to the 5’end of the targeting vector for negative 
selection. Modified from Masu et al., (1995). 
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for animals welfare, transportation, experimentation, slaughter, as well as basic safety 
standards for the protection of animals used for scientific purposes (Royal Decree 53/2013).  
All protocols were approved by the Ethics Committee for Animal Welfare (CEBA) of the 
University of the Basque Country (CEBA/90/2010/MEANA MARTINEZ, CEBA/106/2010/MEANA 
MARTINEZ).  
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3.2. MATERIALS 
3.2.1. Drugs 
- Desipramine  (Desmethylimipramine hydrochloride): Tricyclic antidepressant inhibitor 
of the norepinephrine transporter (NET) (Sigma Aldrich®, St. Louis, MO, USA. Batch: 
86H0942). 
 
- Chloral hydrate  (Trichloroacetaldehyde hydrate): general anesthetic (Sigma Aldrich®, 
St. Louis, MO, USA. Batch: 1173065). 
 
- (±)-DOI  ((±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride; (±)-2,5-
Dimethoxy-4-iodoamphetamine hydrochloride): potent 5-HT2 receptor agonist with 
higher affinity for 5-HT2A than for 5-HT2C receptors (Sigma Aldrich®, St. Louis, MO, 
USA. Batches: 078K4625, 012M4612V). 
 
- Dopamine (2-(3,4-Dihydroxyphenyl)ethylamine hydrochloride): neurotransmitter 
(Sigma Aldrich®, St. Louis, MO, USA. Batch: 83H2512). 
 
- Isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether): general inhaled 
anesthetic drug. Two-pore potassium channel activator. It is also a very widely used 
anesthetic for in vivo animal research and for in vitro studies on anesthesia 
mechanisms. (IsoFlo®, ESTEVE VETERINARIA, Barcelona, Spain. Batches: 50003XN, 
50016XN). 
 
- Kynurenic acid  (4-Hydroxyquinoline-2-carboxylic acid): non-selective antagonist 
NMDA and AMPA/kainate receptors and nicotinic acetylcholine receptors (Tocris®, 
Ellisville, MO, USA. Batch: 40A/50307). 
 
- M100907 ((R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-
yl]methanol; Volinanserin): selective 5-HT2AR antagonist (Sigma Aldrich®, St. Louis, 
MO, USA. Batch: 082M4604V). 
 
I. Mollinedo Gajate 
 
78 
 
- Norepinephrine (L-(−)-Noradrenaline (+)-bitartrate salt monohydrate): 
neurotransmitter (Sigma Aldrich®, St. Louis, MO, USA. Batches: 035K0960, 
SLBC1882V). 
 
- Pertussis Toxin  (PTX): Toxin from Bordetella Pertussis bacteria (Merck Millipore®, 
Darmstadt, Germany. Batch: D00079735). 
 
- Ro 60-0175  ((aS)-6-Chloro-5-fluoro-a-methyl-1H-indole-1-ethanamine monofumarate): 
5-HT2C receptor agonist (Sigma Aldrich®, St. Louis, MO, USA. Batch: 030M4621V). 
 
- RX821002    (2-[2-(2-Methoxy-1,4-benzodioxanyl)]imidazoline hydrochloride): Selective 
α2-adrenoceptor antagonist (LASA Laboratory, Barcelona, Spain). 
 
- Serotonin (3-(2-Aminoethyl)-5-hydroxyindole hydrochloride; 5-HT; 5-Hydroxy-
tryptamine hydrochloride): neurotransmitter (Sigma Aldrich®, St. Louis, MO, USA. 
Batch: 061M5178). 
 
- SB 242084  (6-Chloro-5-methyl-1-[[2-(2-methylpyrid-3-yloxy)pyrid-5-yl]carbamoyl]in-
doline dihydrochloride hydrate): selective 5-HT2C receptor antagonist (Sigma Aldrich®, 
St. Louis, MO, USA. Batch: 3A/130042) 
 
3.2.2. Antibodies 
Antibodies used for immunohistochemical assays were: 
 
- Primary polyclonal antibody: Rabbit policlonal antibody anti-GFP (Santa Cruz 
Biotechnology, Dallas, TX, USA. Batch: C2614). 
 
-  Fluorescent secondary antibody: Alexa 488 fluor donkey anti-rabbit (Invitrogen, 
Waltham, MA, USA. Batch: 51811A). 
 
3.2.3. Gases 
- Oxygen: (Carburos Metálicos, Barcelona, Spain). 
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3.2.4. Reagents 
 
 
 
  
Supply company Reagent 
Carlo Erba Reagents (Val de Reouil, France) Methanol 
Thermo Fisher Scientific (Waltham, MA, USA) 
Citric acid monohydrate, 99.5% 
Ethylenediaminetetraacetic acid, disodium salt 
dihydrate, +99% 
1-Octanesulfonic acid, sodium salt, HPLC 
grade 
Merck (Darmstadt, Germany) 
Calcium chloride dihydrate 
Ethylenediaminetetraacetic acid disodium salt  
(EDTA) 
Magnesium chloride hexahydrate 
Paraformaldehyde 
Potassium chloride 
Sodium dihydrogen phosphate monohydrate 
Sodium chloride 
Sodium hydroxide 
Sodium hydroxide solution 
Panreac Química S.A.U. (Barcelona, Spain) 
Acetonitrile 
Glacial Acetic acid (HPLC) 
Hydroxypropyl-beta-cyclodextrin 
Ortho-Phosphoric acid 85% 
D(+)-Sucrose 
Probus S.A. (Badalona, Spain) Perchloric acid 60% 
Sigma Aldrich® (St. Louis, MO, USA) 
Bovine Serum Albumin (BSA) 
Sodium azide 
Sodium octyl sulfate 
Triton® x-100 
Tween® 20 
Table 2- Summary table of the reagents employed for the development of the procedures and providers. 
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3.3. DRUG ADMINISTRATION 
3.3.1. Systemic administration 
Acute systemic administrations containing the drug of interest dissolved were injected 
intraperitoneally. Injections volumes were between 0.15-0.20 ml for mice and 0.25-0.30 ml for 
rats. Dissolution procedures were as follows: 
 
- (±)-DOI  was dissolved in saline solution (0.9% NaCl).  
 
- M100907 was dissolved in acidified saline (0.9% NaCl) - with HCl, pH 0.6 approx. -, by 
steady heating and swirling until the solid compound had dissolved completely. 
Solution was neutralized with NaOH up to pH 6.25-7. Aliquots of 600 µl were made 
and stored at -80 °C until used. M100907 was injected 35 minutes before (±)-DOI. 
 
- Ro 60-0175 was dissolved in saline solution (0.9% NaCl). 
 
- SB 242084 was dissolved as previously described (Deurwaerdère et al., 2004) in a 
mixture of physiological saline (0.9% NaCl) containing hydroxypropyl-beta-cyclodextrin 
(8% by weight) plus citric acid (25 mM), constantly swirling until dissolution was 
complete. Solution was neutralized with HCl and NaOH up to pH 6.25-7. SB 242084 
was injected 35 minutes before (±)-DOI. 
 
 
3.3.2. Local administration 
One of the main advantages of brain microdialysis is the ability to administer a drug through a 
probe accurately in a specific cerebral nucleus, allowing getting insight into the effects 
triggered by a drug in that nucleus. Drugs were dissolved to a desired concentration in CSF and 
pH was neutralized to physiological pH of 7.2-7.4. CSF comprised: 148 mM NaCl, 2.7 mM KCl, 
1.2 mM CaCl2 and 0.85 mM MgCl2, pH 7.4 - neutralized with 1 mM K2HPO4 -. 
 
Dissolved drugs can easily flow through the dialysis probe to the tip, where osmotic exchange 
makes the drug pass through the pores of the membrane (6-kDa size) to the brain. Likewise, 
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neurotransmitters pass from the brain to the membrane and finally are collected in the 
dialysates. 
 
Basal neurotransmitter concentration values in mouse brain dialysates were under the 
detection limits of our high-performance liquid chromatography (HPLC) equipment. Due to the 
inability to detect basal levels of DA and NE, desipramine was dissolved in the CSF (1.5 µM) of 
all the experiments carried out in mice. However, the presence of this drug was no longer 
necessary in experiments performed in rats, since basal concentrations of these 
neurotransmitters were higher than threshold values. 
 
Drugs, except for M100907, were prepared immediately before perfusion: 
 
(±)-DOI was dissolved in CSF pH 7.4 and vortexed until the solution was homogeneous and 
transparent. Concentrations of 100 µM and 300 µM were prepared. 
 
Kynurenic acid  was suspended at 1 mM concentration in CSF and sonicated for 7 min. Solution 
with small particles suspended turned transparent after alkalizing with NaOH up to pH 7.2-7.4 
and continuous agitation (Legault et al., 2000).  
 
M100907 was dissolved in 5 µl of glacial acetic acid and CSF. The pH was controlled and 
neutralized with NaOH up to 7.4. In co-perfusion experiments combining M100907 + (±)-DOI, 
M100907 solution was prepared and subsequently (±)-DOI was added. Final solution was 
aliquoted and stored at -80ºC. 
 
RX821002 was dissolved in CSF as a stock solution (1 mM) and then the solution was further 
diluted with CSF (pH 7.4) to reach a final concentration of 1 µM. 
 
3.3.3. I.c.v. administration of Pertussis Toxin 
Lyophilized pertussis toxin was reconstituted with Milli-Q® water to a final concentration of 0.1 
µg/µl and distributed in aliquots of 25 µl. Accordingly, vehicle was prepared (50 mM NaCl, 10 
mM sodium phosphate buffer, pH 7.0) and also distributed in aliquots of 25 µl. Both vehicle 
and pertussis toxin were kept refrigerated at 4°C until administration. 
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3.4. INTRACEREBRAL MICRODIALYSIS IN FREELY MOVING ANIMALS 
 
The principle of microdialysis technique is based on the balance between the release of 
neurotransmitters and its re-uptake. To study neurotransmitter levels more directly related to 
synaptic transmission, it is necessary to sample specifically the content of the extracellular 
space, which is the site of exchanges between neurons, glial cells and blood vessels (Chefer et 
al., 2009; Gardier, 2014).  
 
Brain microdialysis requires the insertion of a small dialysis catheter, termed microdialysis 
probe, into a specific brain region. Through that probe, CSF is perfused. This technique is based 
on the law of passive diffusion of low molecular weight compounds (neurotransmitters in this 
case) through a porous membrane from the compartment with the highest concentration (the 
synaptic extracellular space) to the less concentrated compartment (the dialysis probe 
perfused with a buffer solution at physiological pH that does not contain neurotransmitters). 
The dialysate samples, obtained from the probe outlet, can be analyzed using HPLC with 
electrochemical detection for the quantification of oxidizable molecules recovered from the 
extracellular space. DA and NE neurotransmitters were analyzed in this project. 
 
 
3.4.1. Microdialysis probes manufacture 
Handmade probes used for microdialysis experiments comprised the following materials:  
 
- One 25-G steel tube (0.3 mm internal diameter x 0.5 mm external diameter) 2 cm 
length (CIBERTEC S.A., Madrid, Spain). 
- Two 27-G steel tubes (0.2 mm internal diameter x 0.4 mm external diameter) 0.7 cm 
length (CIBERTEC S.A., Madrid, Spain). 
- One 2.5 cm length and one 4.5 cm length silica tube (Composite Metal Services Ltd, 
Southampton, United Kingdom). 
- Two polyethylene tubes (0.28 mm internal diameter x 0.61 external diameter) (BD 
Intramedics, New Jersey, USA). 
- 6-kDa cut off cuprophan membrane 0.25 mm diameter (Enka AG, Wuppertal, 
Germany). 
- Araldit adhesive® (Huntsman Advanced Materials, The Woodlands, TX, USA). 
- Loctite® gel (Loctite Spain S.A., Madrid, Spain). 
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- TAB 2000 Dental cement (Kerr®, Orange, CA, USA). 
- Low melting point thermoplastic adhesive. 
 
Probes consisted of the assembly of silica piping systems covered by steel tubes, which provide 
the formers with robustness and resistance (Figure 18). This “Y” shape system was fixed with 
Araldit adhesive and TAB 2000 dental cement at the insertion point. 
 
Two- or four-mm length of silica tube leaned out from the bottom of the probe, depending on 
animal species and implantation area. A dialysis membrane surrounded the external silica and 
was assembled to the bottom of the probe using Loctite gel. The other end of the membrane 
was sealed with Loctite gel, leaving a space of 1 mm from the silica tube. Input and output 
steel tubes were connected to a polyethylene cable in each side and glued with a 
thermoplastic low melting point adhesive (Figure 18). 
 
The 6-kDa pore size membrane enables the exchange of small molecules substances, excluding 
proteins and big compounds. Therefore, sample purification was not necessary before 
chromatographic analysis. 
 
 
 
 
 
 
 
Fig. 18- Representative image of a microdialysis probe (Modified from M. Victoria Puig Velasco, 
2004, Doctoral Thesis, University of Barcelona, IDIBAPS). 
Polyethylene tube 
27-G steel tube 
TAB 2000 Dental 
Silica tubes 
6-kDa cut off membrane Loctite® gel 
25-G steel tube 
Araldit adhesive® 
Thermoplastic adhesive 
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3.4.2. Stereotaxic surgery 
3.4.2.1. Anesthesia  
 
The general advantages to the use of inhalation agents are that the procedure is precise, 
rapidly adjustable, safe and effective. Moreover, postoperative recovery is rapid and less 
complicated than with injectable anesthetics.  
 
Animals were anesthetized using a CA-ECA20 Anesthesia Trolley System (CIBERTEC, Madrid, 
Spain) equipment (Figure 19), composed of: 
 
- Flowmeter: to adjust medical oxygen flow rate. 
- Vaporizer: chamber where volatile liquid anesthetic is deposited. Gas flux coming from 
the flowmeter flows through the vaporizer and anesthetic is added to this flux in the 
desired proportion. 
- Emergency valve of O2: after pressing allows oxygen to flow directly without 
anesthetic agent. 
- Safety pressure valve: does not allow exceeding the maximum system working 
pressure. 
- Manifold: it has three individual connection valves in order to provide up to three 
accessories which can be connected simultaneously (induction boxes, anesthetic 
masks, etc). 
- Manometer: it displays the gas pressure rate into the system.  
- Evacuation system with fluosorber canister: Active vacuum to eliminate excesses of 
anesthetic gas. 
 
Animals were anesthetized with isoflurane. This volatile drug possesses general anesthetic 
properties and was delivered to animals via inhalation. Animals were placed in an induction 
chamber until they were completely anesthetized. For induction, a 4% concentration of gas 
was supplied. Afterwards, animals were moved to a stereotaxic frame and coupled to a mouse 
or rat mask where anesthesia maintenance was provided (1.5-2% concentration of isoflurane). 
Breathing rate was visually controlled by the researcher during the entire procedure. 
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3.4.2.2. Stereotaxic surgery equipment 
 
Surgery was performed using a Kopf™ stereotaxic frame (David Kopf Instruments, Tujunga, CA, 
USA). The system possesses two arms to allow accurate probe positioning in specific brain 
areas by following three coordinates: anteroposterior (AP), lateral (L) - both relative to 
bregma -, and dorsoventral (DV) - relative to skull surface -. Head immobilization was assured 
by adjustment of the skull inserting two earbars in both ears, model 957 18º (David Kopf 
Instruments, Tujunga, CA, USA). The stereotaxic frame is connected to the anesthesia system 
- for anesthesia maintenance - by a mask where snout is adapted (Figures 19 and 20).  
 
 
 
 
 
 
 
 
 
 
Fig. 19- Left panel: inhalation anesthesia system. Right panel: mouse mask for anesthesia 
maintenance coupled to the inhalation anesthesia system shown on the left. 
Fig. 20- Surgery equipment. 
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3.4.2.3. Microdialysis probes implantation 
 
Mice 
 
Animals were anesthetized in an induction chamber breathing isoflurane (4%) for 1-2 min, until 
they were utterly anesthetized. Unconscious mice were placed on the stereotaxic frame under 
constant flow of isoflurane (1.5%) for anesthesia maintenance. To avoid hypothermia, animals 
laid over a heating pad during surgery. 
 
Once the head was horizontally immobilized - bregma and lambda in the same plane -, a 
sagittal 1 cm length incision was performed to expose the skull surface. A surgical microscope 
(OPMI 99, Carl Zeiss, Oberkochen, Germany) was necessary to gain precision in the 
implantation. Firstly, skull was drilled twice, one hole - 1 mm approx. - was for the probe 
implantation and the other one - 0.5 up to 1 mm - was for the anchor screw placement, to aid 
fixation to the skull with the help of dental cement. These orifices were milled using a steel 
burr connected to an electric turbine (Elco 5118, Leobersdorf, Austria). Prior to probe 
implantation, meninges were carefully removed to allow vertical insertion of the probe. 
 
Intra-cerebral probes, with 3-mm membrane length, were stereotaxically implanted into the 
brain (comprising cingulate, prelimbic and infralimbic cortex). Implantation coordinates were 
selected following the guidelines set by Franklin and Paxinos atlas (2008) and 
strain-comparative atlas by Hof and co-workers (2000). Insertion coordinates were as follows 
(Figure 21): 
 
 
      
 
 
 
 
 
Bregma was the benchmark to obtain AP and L 
coordinates, meanwhile skull surface was for 
DV coordinate. Artificial cerebrospinal fluid 
solution was steadily perfused through the 
probe during the insertion time to gain 
strength and firmness, avoiding breakage of 
 129/Sv strain FC 
C57BL/6 strain FC  
Fig. 21- Representative picture of microdialysis 
probe location in the frontal cortex of mice.  
AP: +1.6 mm 
L: +0.3 mm 
DV: -3.3 mm 
AP: +2.0 mm 
L: +0.3 mm 
DV: -3.3 mm 
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the dialysis membrane and facilitating a vertical inlet to ensure an accurate implantation. 
Probes were fixed in place with an anchor screw, a plastic housing as reinforcement and dental 
cement (Figure 22). Once the surgery was completed, the proper functioning of the probes 
was checked out and the ends of the polyethylene tubes were sealed. 
 
After surgery, animals were left to recover for at least 18 hours, housed in single cages 
provided with free access to water and food. A major concern with intra-cerebral microdialysis 
is that the implantation of the probe could evoke inflammation and subsequent healing which 
could affect the results of the experiments. Benveniste and co-workers (1987) investigated 
local cerebral blood flow (LCBF) and local cerebral glucose metabolism (LCGM), being sensitive 
indicators of regional damage, following implantation of a microdialysis probe into the 
hippocampus. During the first 2 hours after implantation, rats showed disturbances in LCGM 
and LCBF, accompanied by a general decrease in blood flow. Around the probe small spots 
with increased glucose phosphorylation and decreased blood flow were detected. These 
disturbances, as well as damages to neuronal morphology in the vicinity of the dialysis tube, 
and BBB integrity, become normal when allowing animals to recover between 10 and 24 hours 
post-implantation (Imperato & Di Chiara, 1984; De Lange et al., 1997). The extension of the 
recovery period beyond 3 days may give interpretation problems due to the developing gliosis 
in the surroundings of the probe, increasing the risk of reducing dialysis and subsequently 
neurotransmitters detection. 
Fig. 22- Left image: skull fixation by earbars inside both ears prior to mouse surgery. Right image: 
intra-cortical implantation of a dialysis probe and anchor screw. 
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Correct placement of the probes was histologically verified at the end of the experiments by 
staining the membrane with Fast Green solution (Figure 23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rats 
 
Rats were anesthetized in an induction chamber breathing isoflurane (4%) for 1-2 min, until 
they were utterly anesthetized. Unconscious animals were placed on the stereotaxic frame 
under constant flow of isoflurane for anesthesia maintenance (2%). To avoid hypothermia, 
animals laid over a heating pad during surgery. The general procedure was the same as 
mentioned for mouse surgery with some differences explained below. 
 
Once the head was immobilized, a sagittal incision was performed to expose the skull surface. 
The head was oriented downward at an angle of 10° - bregma 2 mm below lambda -. The skull 
was drilled four times: two holes - 3 mm approx. - were for probes implantation in the FC and 
LC, whereas the other two - around 0.5-1 mm diameter - were for the anchor screws 
placement. Prior to probe implantation, meninges were carefully removed to allow vertical 
insertion of the probe. 
 
Intra-cerebral probes were stereotaxically implanted into the brain to allow positioning of 
dialysis probe tip in the FC and LC (Figure 24). Implantation coordinates were selected 
following the guidelines set by Paxinos & Watson atlas (1986).  
 
A 2-mm membrane length was implanted into the LC vicinity. Lambda suture was the 
benchmark to obtain AP and L coordinates. Brain surface was the reference point to calculate 
DV coordinate. 
Fig. 23- Representative photograph of microdialysis probe location in mouse FC.  
Microdialysis probe 
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AP: -3.7 mm 
L: -1.3 mm 
DV: -8.2 mm 
A 4-mm membrane length was implanted into the FC. Bregma suture was the reference point 
to obtain AP and L coordinates, whereas brain surface was for DV coordinate. 
 
Insertion coordinates were as follows: 
 
 
   
    
     
 
 
  
 
 
 
CSF was steadily perfused through the 
probe during the insertion process to gain 
strength and firmness, avoiding breakage 
of the dialysis membranes and facilitating 
a vertical inlet to ensure an accurate 
implantation. Probes were fixed in place 
with two anchor screws (Figure 25), plastic 
housing as reinforcement, and dental 
cement. Once the surgery was completed, 
the proper functioning of the probes was 
checked out, and the ends of the 
polyethylene tubes were sealed. 
 
 
FC LC 
AP: -3.7 mm 
L: -1.3 mm 
DV: -8.2 mm  
 
 
Fig. 24- Representative picture of microdialysis probes location in the frontal cortex (left) and 
locus coeruleus (right) of rats.  
AP: +2.8 mm 
L: +1.0 mm  
DV: -5.0 mm 
 
 
Fig. 25- Picture of a rat subjected to cerebral surgery, where 
microdialysis probes are being implanted into the FC and LC.  
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After surgery, animals were left to recover for at least 18 hours, housed in single cages 
provided with free access to water and food. Microdialysis procedures were performed the 
following two days after recovery. Probes placement was histologically verified at the end of 
the experiments by staining the membrane with Fast Green solution.  
 
3.4.3. Collecting dialysate samples 
3.4.3.1. Microdialysis equipment for awake mice 
 
Sampling was carried out using a BASi equipment (BASi, West Lafayette, IN, USA), which 
allowed a constant flow rate throughout the probes (Figure 26). The equipment comprised the 
following components:  
 
- Methacrylate cage covered by sawdust, where animal remained from the inception to 
the end of the experiment (MD-1570, BASi, West Lafayette, IN, USA). 
 
- Precision pump (MD-1001, BASi, West Lafayette, IN, USA) which allowed to work at 
constant flow rates from 0.1 to 100 µl/min with two separate syringes. 
 
- Liquid switch (MD-1508, BASi, West Lafayette, IN, USA) allows manual switching 
between up to three perfusion syringes and a microdialysis probe. This makes it 
possible to change different solutions instantaneously without any risk of introducing 
air bubbles into the microdialysis probe. 
 
- Refrigerated microvolume fraction collector (MD-1201, BASi, West Lafayette, IN, USA) 
kept the samples refrigerated at 4°C from the sample collection until their transfer to 
the analytical equipment. 
 
All these components were interconnected by a red tubing system (PEEK-tubing, BASi, West 
Lafayette, IN, USA) to protect monoamines from light deterioration, as well as by adaptors 
(Microdialysis Tubing Connectors BASi, West Lafayette, IN, USA). Raturn Microdialysis 
Stand-Alone System for use with mice (MD-1409 BASi, West Lafayette, IN, USA) allowed 
animals to freely move in the cage, as well as to record the frequency and duration of 
rotational movements and elevations. 
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3.4.3.2. Microdialysis equipment for awake rats 
 
Sampling was carried out using a CMA/Microdialysis AB equipment (Stockholm, Sweden), 
which allowed a constant flow rate through the probes (Figure 27). The equipment is 
composed of the appliances below:  
 
- Methacrylate cage covered by sawdust, where animal remained from inception to the 
end of the experiment. 
 
- Precision pump (CMA/102, CMA/Microdialysis AB, Stockholm, Sweden) which 
guarantees working at constant flow rates from 0.1 to 20 µl/min with two separate 
syringes. 
 
- Liquid switch (CMA/110, CMA/Microdialysis AB, Stockholm, Sweden) permits manual 
switching between up to three perfusion syringes and a microdialysis probe. This 
Fig. 26- Left photograph: BASi equipment used for microdialysis experiments in mice. Right 
photograph: 129/Sv strain mouse during microdialysis experiment. 
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makes it possible to change different solutions instantaneously without any risk of 
introducing air bubbles into the microdialysis probe. 
 
- Swivel (CMA/120, CMA/Microdialysis AB, Stockholm, Sweden) enables free movement 
of the animal. The swivel brace holds a wire with a collar connector and two holders to 
place plastic vials for sampling. The wire attached to the animal collar, turns the swivel 
and supports the tubing. 
 
- Tubing system interconnecting all the components of the microdialysis equipment 
with the implanted probes in the experimental animals (FEP-tubing, Metalant AB, 
Stockholm, Sweden). Tubes have a dead volume of 1.2 µl/10 cm and opaque red color 
to protect neurotransmitters from light degradation. Special adaptors enable tubing 
interconnection (Tubing Adapters Metalant AB, Stockholm, Sweden). 
 
 
 
 
 
 
3.4.3.3. Conventional microdialysis 
 
After the recovery period, probes were connected to the system and CSF solution was 
perfused at a rate of 1 μl/min through the microdialysis probes incessantly during the entire 
trial. CSF driven by the precision pump flowed through the system from the inlet tube until 
Fig. 27- Equipment used for microdialysis experiments in rats.  
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reaching the dialysis membrane, where osmotic balance is produced. Dialysate fluid was 
pushed into the outlet tube and collected into a microvial. 
 
Mice 
 
Cortical administration 
 
Following 1 hour of acclimatization, 35-min samples were collected into a fraction collector. 
Time points were corrected for lag time of the perfusate from the microdialysis site to the 
probe outlet. The first six 35-min fractions - CSF alone or in combination with M100907 -, were 
used to establish monoamine baseline concentrations. The mean of the basal values was 
considered 100%, and the pharmacological effect was analyzed using that basal value as 
reference. Subsequently, the drug of interest was administered for 175 minutes (5 samples), 
after which CSF alone or combined with M100907 was perfused again (Figure 28). As 
previously mentioned, switching between syringes with no risk of air entrance or changes in 
pressure was possible by a Liquid switch (CMA/110, CMA/Microdialysis AB, Stockholm, 
Sweden). 
 
 
 
 
A key factor able to modulate the amount of drug that can reach the tissue is the flow rate at 
which CSF is being flushed. The lower the flow-rate, the higher the recovery is (De Lange et al., 
1997; Stahle et al., 2000). The dead volume is the time spent since the drug is flushed from the 
inlet tube, until it reaches the microvial at the outlet tube. Thirty-five µl were calculated to be 
the dead volume of the BASi equipment. As the flow rate was 1 µl/min, eventually the dead 
volume corresponded to 35 minutes. In order to cover the time corresponding to that dead 
volume, an extra basal sample was collected in experiments using the BASi equipment. 
 
 
Fig. 28- Representative time-course scheme of intra-cortical administration of drugs in mice. 
Purple Drug 1: M100907 (300 µM); Green Drug 1: (±)-DOI (300 µM); Green Drug 2: M100907 
(300 µM) + (±)-DOI (300 µM).  
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Systemic administration 
 
Following 1 hour of acclimatization, 35-min samples were collected into a fraction collector. 
The first five 35-min fractions with CSF were used to establish monoamine baseline 
concentrations. Subsequently, the drug of interest was intraperitoneally injected and 7 
additional fractions were collected the following 245 minutes (Figure 29). In double-injection 
experiments, the first four fractions were collected to calculate basal concentrations. 
Afterwards, the first drug was injected and 35 min later the second one. As above, 7 additional 
35-min samples were collected the following 245 minutes (Figure 30). 
 
 
 
 
Rats 
 
After 1 hour of acclimatization, and collection of three 35-min fractions to determine basal 
values of monoamines, drugs were delivered systemically or locally into the FC or LC. The 
mean of the basal values was considered 100% and the pharmacological effect was analyzed 
using that basal value as reference. To minimize inter-experimental error, pharmacological 
treatments were crossed, administering the same day control solution to some of the animals 
and drugs to others. Each animal was its own control, receiving one day vehicle or treatment 
and the second day the opposite.  
 
Fig. 29- Representative time-course scheme of a single systemic administration of drug or saline 
in mice. Drug: (±)-DOI (0.5-5 mg/kg) or Ro 60-0175 (3 mg/kg). 
Fig. 30- Representative time-course scheme of a double systemic administration of drugs in 
mice. Drug 1: saline, M100907 (0.5 mg/kg) or SB242084 (1 mg/kg); Drug 2:  (±)-DOI (1 mg/kg). 
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Dead volumes were calculated in the equipment allocated for experiments in rats. In this case, 
a 10-minutes waiting time between drugs administration was enough to get rid of such dead 
volume. 
 
Experimental designs of local administrations of drugs into the FC (Figure 31) or LC (Figure 32), 
as well as systemic administrations (Figure 33) are explained below: 
 
 
Local administration in frontal cortex and simultaneous drug perfusion in the locus coeruleus  
 
 
 
 
 
 
 
 
 
 
 
Local administration in locus coeruleus 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31- Representative time-course scheme of cortical administration of drugs in rats. Purple
Drug 1: KYN (1 mM); Green Drug 1: (±)-DOI (300 µM); Green Drug 2: KYN (1 mM) + (±)-DOI (300 
µM). 
Fig. 32– Representative time-course scheme of intra-locus coeruleus administration of (±)-DOI 
(100 and 300 µM) in rats.  
Probe in FC 
Probe in LC 
Probe in FC 
Probe in LC 
I. Mollinedo Gajate 
 
96 
 
Systemic administration 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fractions were stored at 0-10°C until their chromatographic analysis. To prevent NE and DA 
degradation from dialysate samples when using HPLC equipment, 5 µl of 0.6% HClO4 were 
added to each vial. When using Alexys UHPLC equipment to quantify NE, DA and 5-HT, 5 µl of 
0.1 M acetic acid were added to the vials instead of HClO4 to prevent neurotransmitters from 
degradation.  
 
Substances diffusion was carried out by concentration gradient. Substances transport is a slow 
process, and the concentration reaches in the dialysate does not correspond to the 
concentration that exists in the extracellular matrix. To get an approximation of the real 
extracellular concentrations is necessary to calculate the percentage of probe recovery of 
neurotransmitter of interest by in vitro assays. This parameter depends on the flow-rate, the 
pore size of the membrane and the molecular weight of the substance of interest. In vitro 
studies carried out in our own laboratory determined that this percentage is about 15-20% of 
the real concentration in the case of the neurotransmitters of interest, using a 2-mm length 
membrane (data not shown). Results displayed in this study are not corrected for probe 
recovery. 
 
 
 
 
 
Fig. 33- Representative time-course scheme of systemic administration of drugs alone or in 
co-administration with other drugs locally into the rat FC or LC. Purple Drug 1: KYN (1 mM), 
RX821002 (1µM); Green Drug 1: (±)-DOI (1 mg/kg). 
Probe in FC 
Probe in LC 
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3.4.3.4. Histological verification of probe placement 
 
At the end of the experiments, mice were slaughtered by cervical dislocation. Rats were culled 
by overdose of chloral hydrate solution. A dye solution was perfused through the probe for a 
few seconds to color the adjacent area where the probe was set. After removing the probe, 
brain was extracted and kept frozen at -20°C or -80°C. Coronal brain sections were obtained 
and checked to ensure correct location of the probe (see Figure 23). 
 
 
3.4.4. Chromatographic analysis of the samples 
3.4.4.1. Fundamentals of the HPLC technique 
 
Chromatography is a technique commonly used for separating mixtures of substances into 
their individual components on the basis of their molecular structure and molecular 
composition. This involves a stationary phase (a solid, or a liquid supported on a solid) and a 
mobile phase (a liquid or a gas). The mobile phase flows through the stationary phase and 
carries the components of the mixture with it. Sample components that display stronger 
interactions with the stationary phase will move more slowly through the column than 
components with weaker interactions. This difference in relative affinities of the molecules for 
the mobile and the stationary phase, therefore the difference in rates, causes the separation 
of various components. The retention time (RT) is a measure of the time taken for a solute to 
pass through the chromatography column. It is calculated as the time from injection to 
detection and it is specific for a substance under the same environmental conditions. 
 
HPLC is basically a highly improved form of column liquid chromatography. Instead of a solvent 
being allowed to drip through a column under gravity, it is forced through under high 
pressures of up to 400 atmospheres. That makes it much faster.  
 
The sort of chromatography carries out in this study was reversed phase HPLC. In this case, the 
column is filled with long hydrocarbon chains (C1-C18) attached to the surface of silica particles, 
which makes the stationary phase non-polar. A polar solvent is used, combining a specific 
range of salts to create the appropriate electrochemical conditions to detect the substances of 
interest, passing through the column. There is a strong attraction between the polar solvent 
and polar molecules in the mixture being passed through the column. However, there is not as 
much attraction between the hydrocarbon chains in the stationary phase and the polar 
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molecules in the solution. Polar molecules in the mixture therefore spend most of their time 
moving with the solvent. Non-polar compounds in the mixture tend to form attractions with 
the hydrocarbon groups because of the van der Waals dispersion forces.  
 
The detection system coupled to the chromatographic equipment depends on the 
characteristics of the analytes of study. Electrochemical detection is based on potential 
difference resulting from the oxidation-reduction reaction of the analytes induced by the 
electrodes adjusted to a specific electrochemical potential. The difference in potentials is 
directly proportional to the concentration of the analyte. Subsequently, a chromatogram was 
obtained, which is the record of the chromatographic separation, where each peak 
corresponds to a specific redox component in the sample. 
 
 
3.4.4.2. Chromatographic equipments 
 
Two different HPLC equipments were used. The first one was used to carry out experiments in 
mice and, as Figure 34 shows, it consists of: 
- Degasser system for the mobile phase that avoids air entrance (Agilent HP 1100 Series, 
Santa Clara, CA, USA). 
- A quaternary pump to push mobile phase at a constant rate through the system 
(Agilent HP 1100 Series, Santa Clara, CA, USA). 
- Refrigerated autosampler (Agilent HP 1100 Series, Santa Clara, CA, USA). 
- A chromatographic column, which contains stationary phase (Antec Scientific, 
Zoeterwoude, The Netherlands). 
- Thermostat that allows to keep column temperature constant (Agilent HP 1100 Series, 
Santa Clara, CA, USA). 
- Electrochemical detector Decade II (Antec Scientific, Zoeterwoude, The Netherlands). 
- Control station to obtain chromatograms (DELL Optiplex 760, Round Rock, TX, USA). 
 
 
The other chromatographic system used for experiments in rats, was an ALEXYS™ UHPLC 
Neurotransmitter Analyzer (Antec Scientific, Zoeterwoude, The Netherlands). It consists of 
(Figure 34): 
 
- Degasser (OR 110, Antec Scientific, Zoeterwoude, The Netherlands), double-channel 
degasser with an integrated pulse snubber.  
  
- 2 pumps (LC 110s, Antec
to 700 bars of pressure.
- A double loop refrigerated 
Netherlands), able to 
simultaneously the same sample into two separate chromatographic columns.
- Electrochemical detector
Netherlands) with high sensitivity and integrated thermostat. It holds two 
electrochemical detection cells (SENCELL™, 
Netherlands). 
- Control station (Hewlett
(DataApex, Prague, The Czech Republic)
 
3.4.4.3. Monoamines detection
 
Samples from mice 
 
Samples with a final volume of
the Agilent HP 1100 Series autosampler. The injection volume for chromatographic analysis 
was 30 µl. The mobile phase used allowed the detection and measure of NE and DA and it 
comprised the following reagents: 50 mM phosphoric acid, 0.1 mM EDTA, 8 mM NaCl, 500 
mg/l sodium octyl sulfate and methanol (12
Fig. 34- Left panel: High-Performance Liquid Chromatography (HPLC) equipment coupled to an electrochemical detector.
High Performance Liquid Chromatography (UHPLC) equipment coupled to two electrochemical detectors. 1=degasser; 2=pump; 
3=autosampler; 4=chromatographic column; 5=electrochemical detector; 6=control station.
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autosampler (AS 110, Antec Scientific, Zoeterwoude
effectively inject low volumes. This injector is able to inject 
 (DECADE Elite, Antec Scientific, Zoeterwoude
Antec Scientific, Zoeterwoude
-Packard computer, Palo Alto, CA, USA) with CLARITY software
. 
 
 40 µl: 35 µl dialysate + 5 µl of HClO4 (0.1 M) were allocated in 
-20%). The pH 6.0 was adjusted with 85% H
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This mobile phase was filtered to avoid impurities, passing it through a filter - pore size of 0.45 
µm diameter (Millipore, Billerica, MA, USA) -, with the help of a vacuum pump.  
 
The mobile phase flowed through the system at a 0.2 ml/min rate. To detect and quantify DA 
and NE levels, a VT-03 (Antec Scientific, Zoeterwoude, The Netherlands) electrochemical cell 
was used (Figure 35). Redox potential was 0.300 mV, and ALF-215, 2.1 x 150 mm, C18 (Antec 
Scientific, Zoeterwoude, The Netherlands) chromatographic column was used. The oven 
temperature was 35°C.   
 
The peak areas of DA and NE were integrated by a Chemstation plus software (Hewlett 
Packard Ltd., Morain, OH, USA). A calibration line was calculated by the integration of peak 
areas from 6 standard concentration solutions of DA and NE in CSF (0.1, 0.5, 1, 3, 5, 10 nM). 
 
 
Samples from rats 
 
40 µl samples: 35 µl dilysate + 5 µl acetic acid (0.1 M) were placed in the AS 110, Antec 
autosampler. The injection volume in this UHPLC equipment was 10 µl. The mobile phase 
conditions used allowed the detection of DA, NE and 5-HT. However, only NE results obtained 
from these assays are discussed in the present study. DA and 5-HT levels were also measured 
and integrated for its use as internal controls. The mobile phase components were as follows: 
100 mM phosphoric acid, 100 mM citric acid, 0.1 mM EDTA, 950 mg/l 1-octanesulfonic acid 
(OSA), 5% v/v acetonitrile, and Milli-Q® water. The pH was adjusted up to 6.0 with 50% NaOH 
solution. The mobile phase was degassed for 10-15 minutes in a sonic bath. 
 
The mobile phase flowed through the system at a rate of 75 µl/min. The flow cell  SenCell 
(Antec Scientific, Zoeterwoude, The Netherlands), with a redox potential of 0.46 V, and an 
Acquity UPLC BEH C 18, 1.7 µm, 1 x 100 mm (Waters, Milford, MA, USA) chromatographic 
column were able to separate and detect NE, DA and 5-HT neurotransmitters (Figure 35). The 
oven temperature was 37°C.   
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DA, NE and 5-HT peaks were integrated by Clarity software (DataApex, Prague, Czech 
Republic). A calibration line was calculated by the integration of peak areas from 8 standard 
concentration solutions of DA, NE and 5-HT in CSF (0.01, 0.05, 0.1, 0.5, 1, 3, 5, 10 nM).
Fig. 35- Upper panel: Representative chromatogram of NE (RT: 5.776 min) and DA (RT: 13.241 
min) in a 3 nM standard sample from HPLC system. Lower panel: Representative chromatogram
of NE (RT: 1.66 min), DA (RT: 4.89 min) and 5-HT (RT: 11.61 min) in a 3 nM standard sample from 
UHPLC system. 
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3.5. VIRUS-MEDIATED GENE TRANSFER AND VIRAL DIFFUSION 
3.5.1. Virus administration 
The primers BamHI-hG2 (5’-TTTTGGATCCATGGTCCTTCTGTTGATCC-3’) were used to amplify 
the sequence using the pcDNA3.1-HA-mGlu2 as template. The PCR product (2658 bp) was 
digested using BamHI and subcloned into the same restriction sites of a published bicistronic 
p1005+ herpes simplex virus (HSV) plasmid (Barrot et al., 2002; Tsankova et al., 2006; Kurita et 
al., 2012; Moreno et al., 2012). Viral particles were then packaged (Clark et al., 2002). 
HSV-mGluR2 or control HSV-GFP virus were injected into the mice FC by stereotaxic surgery. 
Animals were anesthetized with isoflurane (4% for induction and 1.5% for maintenance). The 
virus was delivered unilaterally with a Hamilton syringe (65459-01 2 µl Neuros model 7002 KH, 
point style 3, Reno, NV, USA), coupled to a Kopf® microinjector unit (Model 500, David Kopf 
Instruments, Tujunga, CA, USA),  at a rate of 0.1 µl/min for a total volume of 0.5 µl. The 
following coordinates were used for virus delivery: AP= +1.6 mm; L= +0.3 mm; DV= -3.3 mm 
(AP and L relative to bregma and DV relative to the skull surface), with a 10° lateral angle.  
 
Immediately after viral injection, a cannula (MAB 4.15.IC, Microbiotech/se AB, Stockholm, 
Sweden) was implanted in the insertion point location and was fixed to the skull using dental 
cement (liquid and powder TAB 2000, Kerr, Orange, CA, USA). Animals were housed 2 per cage 
during the following days, until microdialysis experiments were performed, in which animals 
were single housed. Three days after virus delivery, a commercial probe was implanted into 
the cannula (MAB 4.15.2.Cu, Microbiotech/se AB, Stockholm, Sweeden). The day after, four 
days after viral injection, microdialysis experiments were carried out. It has been reported that 
transgene expression is maximal 3-4 days after virus injection (Barrot et al., 2002; Kurita et al., 
2012). Virus-mediated mGluR2 overexpression level in the FC was confirmed by Western 
blotting (Moreno et al., 2012). 
 
 
3.5.2. Immunohistochemistry 
Immunohistochemistry is a microscopy-based technique for visualizing cellular components, 
for instance proteins or other macromolecules in tissue samples. The strength of this 
technique is the intuitive visual output that reveals the presence and localization of the target-
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protein in the context of different cell types, biological states, and/or subcellular localization 
within complex tissues. 
 
This technique involves the detection of epitopes expressed by a single protein-target within a 
tissue sample using a "primary antibody" capable of binding those epitopes with high 
specificity. After the epitope-antibody binding event, a "secondary antibody" capable of 
binding the primary antibody with high specificity is added. The secondary antibody is coupled 
to a reporter molecule and after the antibody-antibody binding event, a chemical substrate is 
added which reacts with the reporter molecule to produce a colored precipitate at the site of 
the whole epitope-antibody complex.  
 
Immunofluorescence relies on the use of antibodies to label a specific target antigen with a 
fluorescent dye (also called fluorophores or fluorochromes) - such as fluorescein 
isothiocyanate (FITC) -. A fluorophore is a functional group in a molecule which absorbs energy 
of a particular wavelength and emits energy at a different but specific wavelength. Antibodies 
that are chemically conjugated to fluorophores are commonly used in immunofluorescence. 
The fluorophore allows visualization of the target distribution in the sample under a 
fluorescent microscope.  
 
The method used in this study was indirect immunofluorescence. Two antibodies were used. 
The primary antibody is unconjugated and a fluorophore-conjugated secondary antibody 
directed against the primary antibody is used for detection (Figure 36). 
 
 
 
 
 
 
Fig. 36- Schematic picture of indirect immunofluorescence. 
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3.5.2.1. Tissue fixation 
 
Preparation of the sample is important to preserve tissue morphology, architecture and 
antigenicity of target epitopes. The advantage of directly perfusing fixative through the 
circulatory system is that the chemical can quickly reach every corner of the organism using 
the natural vascular network. 
 
Prior to surgery, animals were deeply anesthetized via intraperitoneal injection of chloral 
hydrate (8%). A 4-5 cm lateral incision along the entire length of the rib cage was made to 
expose the pleural cavity. Carefully, any tissue connecting it to the heart was trimmed. The tip 
of the sternum was clamped with the hemostat and the hemostat was placed over the head. A 
perfusion needle was inserted through the left ventricle into the ascending aorta, without 
reaching the aortic arch. A hemostat was used to clamp the heart, this secured the needle and 
prevented leakage. After making an incision to the right atrium to create as large an outlet as 
possible without damaging descending aorta, animals were perfused for 30 minutes at a 
pressure of 35 mmHg with a saline solution - 0.9% NaCl - to remove all the blood in vascular 
system. Subsequently, the fixation was performed using a freshly prepared solution of 4% 
paraformaldehyde (PFA) in phosphate buffered saline (PBS) (42.58 g Na2HPO4 and 13.79 g 
NaH2PO4·H2O in 1 l of water). The pump’s pressure was also 35 mmHg and fixation lasted for 
30 minutes. 
 
Afterwards, the brain was removed from the skull and the fixation process was extended by 
incubation with 4 ml of 4% PFA for 24 additional hours in 10-ml tubes at 4°C. After this time, 
PFA was replaced by 4 ml of 30% sucrose solution (30 g sucrose, 5 µl sodium azide dissolved in 
100 ml PBS at pH 7.4) for 3-7 days at 4°C, until its precipitation. Once precipitated, the brain 
was stored at 4°C until sectioning. 
 
 
3.5.2.2. Brain sectioning 
 
Frozen brains were embedded in a cryogenic gel (Tissue-Tek, Radnor, PA, USA) on mounting 
plates for cryostat sectioning (Thermo Fisher Scientific, Waltham, MA, USA). 40 µm-thick 
coronal slices were sectioned and preserved in 1 ml PBS (1x) at 4°C to perform 
immunofluorescence assays in 12-well plates. 
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3.5.2.3. Immunofluorescence 
 
Immunofluorescence procedure was carried out following a modified method used by Fribourg 
and co-workers (2011). Cerebral sections were incubated for 2 hours at room temperature in 1 
ml/well blocking buffer (5% BSA, 0.2% Triton X-100 in 1x PBS) with agitation (75 rpm), to 
reduce nonspecific binding and to permeabilize the cell membrane to antibodies. 
Subsequently, the slices were incubated overnight at 4°C in PBS containing 2.5% BSA, 0.2% 
Triton X-100 and (1:100 dilution) rabbit anti-GFP primary antibody (sc-8334, Santa Cruz 
Biotechnology, Dallas, TX, USA) with agitation (75 rpm). 
 
The following day, after washing with blocking buffer (3 times x 1 ml, 3 minutes each), the 
slices were further incubated with the secondary antibody (1:500 dilution) Alexa 488-
conjugated donkey anti-rabbit (A21206, Invitrogen, Carlsbad, CA, USA) for 1 hour at room 
temperature in the dark, with agitation (110 rpm). After washing (PBS, 3 times x 1 ml), the 
slices were mounted onto a glass slide to dry at 4°C in the dark. Once dried, a few drops of DPX 
(Electron Microscopy Sciences, Hatfield, PA, USA) were added to the slices and a coverslip was 
attached. Fluorescence was measured using a Nikon DS-Ri1microscope (Nikon, Tokyo, Japan) 
equipped with a 488 nm laser to observe FITC (Figure 37). Photographs at 4, 10, 20 and 40 
times magnification were taken. 
 
Fig. 37- Immunofluorescence microscope used for immunofluorescence assays. 
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3.6. Gi PROTEINS INHIBITION THROUGH PTX INJECTION 
3.6.1. Intracerebroventricular administration of pertussis toxin 
Pre-treatment with pertussis toxin (1 µl/min) or vehicle was intracerebroventricularly 
administered in a final volume of 4 µl. Once animals were immobilized by the researcher, 
injections were made into the right lateral ventricle by a 10 µl Hamilton syringe with a 
26-gauge needle (Model 701 N SYR, 26 s gauge, point style 2, Hamilton, Reno, NV, USA), as 
previously described (Sánchez-Blázquez et al., 1995). 
 
 
3.6.2. Behavioral study: Head twitch response to (±)-DOI 
The head twitch response (HTR) is a rapid side-to-side rotational head movement that occurs 
in rats and mice after administration of serotonergic 5-HT2AR agonist hallucinogens. The HTR 
is widely used as a behavioral assay for 5-HT2AR activation and psychotic response (Moreno et 
al., 2012; Halberstadt & Geyer, 2013a). 
 
To carry out these assays, mice were transferred individually into plastic cages in the behavior 
room, at least one hour before testing. Twenty minutes after the intraperitoneal 
administration of (±)-DOI (0.5 mg/kg or 1.0 mg/kg) or saline, animals were recorded using 
SMART software (SMART v3.0, Panlab Harvard Apparatus, Barcelona, Spain) for 30 minutes. 
Afterwards, the recordings were examined for head twitch events quantification. 
 
 
3.6.3. Temperature variation induced by (±)-DOI 
Animals were transferred into the behavioral room at least one hour before the experiment 
performance. The room was pre-heated with a stove up to 26°C. Saline and (±)-DOI solution 
were heated up to body temperature to prevent hypothermia mediated by liquid injection. 
 
Rectal temperature was measured and monitored every 30 minutes using a digital 
thermometer with flexible probe (PiC solution, Artsana, Grandate, Italy) and Vaginesil gel 
(Combe International Ltd, Leatherhead, United Kingdom) to lubricate the rectal area. Three 
basal temperatures were taken, and the average of these values was considered the basal 
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temperature. Temperature was measured 4 times (120 min) after intraperitoneal injections of 
saline or (±)-DOI 0.5 mg/kg. Variations of temperature were represented as the difference in 
temperature over the basal value every 30 minutes. 
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3.7. DATA AND STATISTICAL ANALYSIS 
 
Graphs and statistical analysis were carried out using GraphPad Prism v5.01™ software 
(GraphPad Software, San Diego, CA, USA). In all cases, results were represented as mean 
values ± standard error of the mean (SEM) and the minimum statistical significance was set at 
p<0.05. 
 
 
3.7.1. Intracerebral microdialysis in freely moving animals 
In order to establish DA and NE basal concentrations, the first 5 or 6 sample fractions in mice, 
and 3 in rats, were collected. Mean basal values were considered 100%. The effect triggered by 
the administration of the drugs of interest was calculated and represented as the percentage 
of baseline. The statistical analysis undertook to measure differences between groups were as 
follows:  
 
- The analysis of basal levels between groups was performed by two-tailed unpaired 
Student’s t-test. 
 
- Two-way repeated measures ANOVAs, with drug or genotype groups as the 
independent variables, and time as the repeated-measure factor, were used to 
evaluate whether an interaction between these two variables on the dependent 
variable existed (e.g. % of neurotransmitter release, AUC). Bonferroni’s post hoc test 
was employed for individual sample comparison. F values are expressed as: Ftreatment 
expresses the ability of the treatment to exert an effect, Fgenotype expresses differences 
between genotypes, Finteraction (Fi) expresses the magnitude of difference in the 
response between the two independent variables on the dependent variable (e.g. 
genotype or treatment over time). 
 
- Areas under curve (AUC) were calculated from the drug administration time point until 
the end of the assay. Prior to calculate AUC values from each animal, every single 
percentage value was subtracted 100. Afterwards, net area AUCs were calculated and 
differences between treatment and genotype groups were assessed by two-way 
ANOVA followed by Least Significant Difference (LSD)’s post hoc test (InVivoStat 
software, Cambridge, United Kingdom).  
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- One-way ANOVA followed by Dunnett’s post hoc test was used to analyze the effect of 
a drug over time, from AUC data of specific drug treatment groups.  
 
 
3.7.2. Head-twitch response and Temperature variation 
Differences between two groups in HTR experiments were assessed using unpaired two-tailed 
Student’s t-test. Two-way ANOVA analyses followed by Bonferroni’s post hoc test were 
calculated to evaluate interactions between an independent variable (pre-treatment or 
genotype) on a dependent variable (treatment).  
  
Weight and temperature variation was evaluated using two-way ANOVA, regarding time as the 
dependent variable, and genotype or pre-treatment as the independent variable. In 
experiments undertaken to determine whether an interaction effect between three 
independent variables (e.g. genotype, treatment and time course) on a continuous dependent 
variable (temperature variation) exists, three-way ANOVA was performed. All data were 
represented as means ± SEM. These ANOVA analyses were followed by Bonferroni’s post hoc 
test. As above, the level of significance was chosen at p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS
 
 
  
 
 
 
 
 
 
 
Results 
 
113 
 
4.1. FUNCTIONAL EVALUATION OF THE 5-HT2AR/mGluR2 
HETEROCOMPLEX BY IN VIVO BRAIN MICRODIALYSIS IN AWAKE, FREELY 
MOVING MICE 
 
4.1.1. Influence of the 5-HT2AR/mGluR2 heterocomplex located in mice frontal 
cortex in the responses triggered by the cortical administration of the hallucinogenic 
5-HT2A/2C receptor agonist (±)-DOI 
4.1.1.1. Effect of the cortical infusion of (±)-DOI on DA and NE release in the frontal cortex of 
mGluR2
+/+
 and mGluR2
-/-
 mice 
 
At least 18 hours after the implantation of the probes, 1.5 µM desipramine dissolved in CSF 
was perfused into the FC during the entire procedure. Desipramine is a NET inhibitor that 
blocks NE reuptake into the nervous terminal, increasing the concentration of this 
neurotransmitter in the synaptic cleft. NET is also able to reuptake extracellular DA. According 
to a substantial number of studies, both acute and chronic desipramine administration 
increase cortical NE and DA concentrations (Carboni et al., 1990; Devoto et al., 2003a; Devoto 
et al., 2003b; Pan et al., 2004; Bongiovanni et al., 2005; Higashino et al., 2014). The presence 
of desipramine enabled to raise NE and DA basal extracellular concentrations, facilitating the 
detection of these monoamines in the HPLC. 
 
(±)-DOI is a 5-HT2A/2C receptor agonist showing nearly 10-fold higher affinity for 5-HT2AR 
than for 5-HT2CR (Hemrick-Luecke & Evans, 2002; May et al., 2003; Pigott et al., 2012). 
According to Bortolozzi and co-workers (2003), a concentration of 300 µM of (±)-DOI would be 
optimal to exert the maximum extracellular 5-HT release in mice FC after its cortical perfusion. 
Therefore, this concentration was selected to be infused into the FC in the following 
experiments. 
 
Dopamine 
After 1 hour period of stabilization, basal extracellular DA concentrations in dialysates were 
measured. DA basal dialysate concentrations were collected from five-six consecutive samples 
from the FC without considering probe recovery and pooling from all the experiments 
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undertook with these mice. Basal values did not differ across genotype:  1.637 ± 0.115 nM 
(n=99) in mGluR2+/+ mice and 1.799 ± 0.204 (n=71) in mGluR2-/- mice (t=0.738; p=0.461). 
 
Perfusion of (±)-DOI (300 µM) through FC microdialysis probes markedly increased DA output 
in control mGluR2+/+ animals, displaying a maximal effect (Emax) of 163 ± 16% of basal values 
(Figure 38).  Two-way repeated measures ANOVA revealed a significant (±)-DOI-induced effect 
over time, when compared to the group treated with vehicle (VEH) (Fi[13, 221]=5.397; 
p<0.0001). In mGluR2-/- mice, (±)-DOI triggered a lower DA stimulation (Figure 38), but still 
significant with respect to VEH (Emax = 134 ± 11%) (Fi[13, 234]=3.498; p<0.0001). The maximal 
concentration was yielded at the same time point as for its wild-type counterparts.  
 
Despite both genotypes displayed a rise in extracellular DA concentration after (±)-DOI 
administration, the magnitude of the effect was significantly higher in mGluR2+/+ mice. Thus, 
two-way repeated measures ANOVA revealed a significant genotype x time interaction (Fi[13, 
325]= 3.267; p<0.0001) (Figure 38). 
 
 
 
 
In order to evaluate the magnitude of the effects after local VEH or (±)-DOI administration, DA 
AUC values after drug infusion were analyzed (Figure 39). In both genotypes (±)-DOI evoked a 
rise of DA outflow comparing to the respective group where CSF was administered (Ftreatment[1, 
(±)-DOI
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Fig. 38- Effect of cortical administration of VEH or 300 µM (±)-DOI on extracellular 
concentrations of DA in the FC of mGluR2
+/+
 ( n=6,  n=13) and mGluR2
-/-
 mice ( n=6, 
 n=14). Data are means ± SEM of DA expressed as a percentage of basal values (100%). Line 
represents drug infusion time. *p<0.05, **p<0.01, ***p<0.001 versus (±)-DOI-treated mGluR2
+/+
mice (two-way repeated measures ANOVA followed by Bonferroni’s post hoc test). 
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35]=12.26; p<0.01). Wild-type animals displayed a higher stimulatory effect after (±)-DOI 
infusion when compared to their knock-out counterparts. Nonetheless, differences between 
genotypes did not but were close to reach significance (Fgenotype[1, 35]=3.60; p=0.066).  
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
Basal extracellular concentrations of NE in the FC were obtained  by pooling values from all the 
experiments regarding cortical infusion of CSF and without considering probe recovery. Basal 
values were significantly higher in mGluR2-/- mice when compared to mGluR2+/+ group: 1.690 ± 
0.106 nM (n=77), 1.420 ± 0.065 nM (n=125), respectively (t=2.302; p<0.05). Intra-cortical CSF 
infusion did not alter cortical extracellular NE concentrations in either genotype. 
 
As previously reported for DA, the intra-cortical administration of 300 µM (±)-DOI elicited a 
significant enhancement of NE outflow in the FC of mGluR2+/+ control animals, when compared 
to VEH-treated group (Fi[13, 260]=6.372; p<0.0001). The (±)-DOI-induced increase of 
extracellular NE concentrationss in mGluR2-/- mice was roughly half of the magnitude as 
produced by wild-type animals, but still significant with respect to the VEH-treated group 
(Fi[13, 234]=5.223; p<0.001). The maximal (±)-DOI-induced increase in extracellular NE 
concentrationss of mGluR2-/- animals was 128 ± 5%, whereas the hallucinogen increased 
extracellular NE concentrationss in mGluR2+/+ up to 156 ± 13% (Figure 40). Two-way repeated 
Fig. 39- Cortical DA AUC values 210 minutes after the beginning of the procedure to the end, 
where drug was perfused in the FC of mGluR2
+/+
 ( n=6,  n=13) and mGluR2
-/-
 mice ( n=6,      
 n=14).  All results are expressed as means ± SEM. *p<0.05, **p<0.01 (two-way ANOVA 
followed by LSD’s post hoc test). 
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measures ANOVA revealed a significant interaction based on the drug response yielded 
between genotypes over time (Fi[13, 351]=3.579; p<0.0001). 
 
In terms of the (±)-DOI-induced effect magnitude, the drug exerted an enhancement of NE 
release in both genotypes, compared to the respective VEH-treated groups (Ftreatment[1, 
38]=20.68; p<0.0001). Moreover, wild-type animals displayed a substantially higher 
stimulatory effect compared to their knock-out counterparts (Fgenotype[1, 38]=6.70; p<0.05), as 
shown in Figure 41.  
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Fig. 40- Effect of cortical administration of VEH or 300 µM (±)-DOI on extracellular 
concentrations of NE in the FC of mGluR2 
+/+
 ( n=6,  n=16) and mGluR2
-/-
 mice ( n=7, 
n=13). Data are means ± SEM of NE expressed as a percentage of basal values (100%). Line 
represents drug infusion time. **p<0.01 versus (±)-DOI-treated mGluR2
+/+
 mice (two-way 
repeated measures ANOVA followed by Bonferroni’s post hoc test). 
 
Fig. 41- Cortical NE AUC values 210 minutes after the beginning of the procedure to the end, 
where drug was perfused in the FC of mGluR2
+/+
 ( n=6,  n=16) and mGluR2
-/-
 mice ( n=7,      
 n=13).  All results are expressed as means ± SEM. *p<0.05, **p<0.01, ***p<0.001 (two-way 
ANOVA followed by LSD’s post hoc test). 
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4.1.1.2. Effect of intra-cortical co-perfusion of the 5-HT2AR antagonist M100907 on 
(±)-DOI-induced rise of extracellular DA and NE in the cortex of mGluR2
+/+
 and mGluR2
-/-
 mice 
 
M100907 is a potent and primarily 5-HT2AR antagonist that displays approximately 100-fold 
higher affinity for 5-HT2AR than for other receptors, including 5-HT2CR and sigma receptors 
(Sorensen et al., 1993; Schreiber et al., 1994; Kehne et al., 1996; Gobert et al., 2000; Knight et 
al., 2004; Kristiansen et al., 2005; Pehek et al., 2006). Substantial scientific evidence suggests 
that M100907 can abolish effects derived by (±)-DOI (Pehek et al., 2001; Szabo et al., 2001; 
Body et al., 2006; Pehek et al., 2006).  
 
Dopamine  
The sole administration of M100907 (300 µM) into the FC was able to significantly decrease 
cortical DA release in both mGluR2+/+ and mGluR2-/- genotype groups (Emax= -65 ± 2% and 
Emax= -66 ± 7%, respectively) (Figure 42). Two-way repeated measures ANOVA showed a strong 
effect of treatment over time, when compared to VEH-treated groups, in both genotypes 
(Fi[13, 117]=26.09; p<0.0001 in mGluR2
+/+ and Fi[13, 117]= 8.905; p<0.0001 in mGluR2
-/-). There 
was no significant differences between genotypes in the response triggered by the drug 
(Fgenotype[1, 104]=0.011; p=0.920), neither a significant interaction genotype x treatment over 
time (Fi[13, 104]=1.323; p=0.211).  
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Fig. 42- Effect of cortical administration of VEH or 300 µM M100907 on extracellular DA 
concentrations in the FC of mGluR2 
+/+
 ( n=6,  n=5) and mGluR2
-/-
 mice ( n=6,  n=5). Data 
are means ± SEM of DA expressed as a percentage of basal values (100%). Line represents drug 
infusion time.  
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Before M100907 administration, there was not significant differences in basal values 
compared to the control (VEH) group, neither in mGluR2+/+ nor in mGluR2-/- mice. mGluR2+/+ 
mice subjected to M100907 perfusion (n=5), displayed a basal values reduction of up to 57% 
with respect to VEH-treated group (n=24) (t=1.90; p=0.068). Likewise, in mGluR2-/- mice, basal 
concentrations also decreased when perfused with M100907 (n=5), showing a reduction of 
70% of basal values obtained with VEH perfusion (n=25) (t=1.96; p=0.06). Here again, no 
differences in DA basal values between genotypes were shown in VEH-treated (t=1.820; 
p=0.07) nor in M100907-treated groups (t=1.488; p=0.175). 
 
Perfusion of 300 µM M100907, administered since the beginning of the experiment, 
significantly attenuated the (±)-DOI-induced increase in extracellular DA concentrations in the 
FC of mGluR2+/+ mice (Figure 43). Statistical analysis using two-way repeated measures ANOVA 
showed a significant interaction between treatment and time (Fi[13, 208]=2.780; p<0.01). 
Conversely, M100907 did not block the (±)-DOI-induced rise of DA outflow in mGluR2-/- mice 
(Fi[13, 221]=0.866; p=0.589) (Figure 44). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 43- Influence of the presence or absence of the 5-HT2AR antagonist M100907 (300 µM) on 
the modulation by the 5-HT2A/2C receptor agonist (±)-DOI (300 µM) of extracellular 
concentrations of DA in the FC of mGluR2
+/+
 mice ( n=13,  n=5). Data are means ± SEM of DA 
levels expressed as a percentage of basal values (100%). M100907 perfusion was initiated since 
the beginning of the experiment. The line represents (±)-DOI infusion time. *p<0.05 (two-way 
repeated measures ANOVA followed by Bonferroni’s post hoc test). 
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As shown in Figure 45, CSF perfusion did not modify AUC of DA efflux either in mGluR2+/+, nor 
in mGluR2-/- mice. The figure also reports the magnitude of the overall increase in cortical DA 
efflux induced by 300 µM (±)-DOI (AUC mean=9271 ± 2132) in mGluR2+/+ mice. This response 
was prevented by the continuous infusion of the 5-HT2AR antagonist M100907 (300 µM) in 
mGluR2+/+ mice (AUC mean=3299 ± 1109). In contrast, the low DA stimulation generated by the 
hallucinogen in mGluR2-/- mice (AUC mean=4507 ± 1401) was not reverted by the presence of 
the antagonist (AUC mean=5520 ± 1413), showing a carry-over effect potentially unresponsive 
to 5-HT2AR antagonism. In that sense, two-way ANOVA analysis unmasked a significant effect 
of treatment (Ftreatment[2, 43]=7.07; p<0.01). 
 
 
 
 
 
 
Fig. 44- Influence of the presence or absence of the 5-HT2AR antagonist M100907 (300 µM) on 
the modulation by the 5-HT2A/2C receptor agonist (±)-DOI (300 µM) of extracellular 
concentrations of DA in the FC of mGluR2
-/-
 mice ( n=14,  n=5). Data are means ± SEM of DA 
concentrations expressed as a percentage of basal values (100%). M100907 perfusion was 
initiated since the beginning of the experiment. The line represents (±)-DOI infusion time. 
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Norepinephrine 
Local administration of the antagonist 5-HT2AR M100907 (300 µM) slightly but significantly 
declined extracellular NE outflow in mGluR2+/+ animals, compared to vehicle-treated group 
(Fi[13, 130]=3.332; p<0.001). The maximal inhibitory effect reached was Emax= -13 ± 8% (Figure 
46). Likewise, an inhibitory effect after intra-cortical M100907 administration was exhibited in 
their knock-out counterparts (Emax= -24 ± 9%) (Fi[13, 143]=5.067; p<0.0001) (Figure 46). 
Statistical analysis established no differences among genotypes in the inhibitory response 
triggered by the local administration of 300 µM M100907 over time (Fi[13, 130]=1.095; 
p=0.369). 
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Fig. 45- Cortical DA AUC values 210 minutes after the beginning of the procedure to the end. 
Effect of intra-cortical infusion of vehicle, (±)-DOI (300 µM) and M100907 (300 µM) + (±)-DOI 
(300 µM) in mGluR2
+/+
 ( n=6,  n=13,  n=5) and mGluR2
-/-
 mice ( n=6,  n=14,  n=5).  All 
results are expressed as means ± SEM. *p<0.05, **p<0.01 (two-way ANOVA followed by LSD’s 
post hoc test). 
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Despite the local administration of M100907 yielded a statistically significant inhibitory effect 
(Figure 46), in the following experiments pre-treatment with M100907 (300 µM) showed a 
downward trend in basal extracellular NE, but not sufficient to reach statistical significance in 
either mGluR2+/+ and mGluR2-/- groups, compared to groups pre-treated with vehicle. Basal 
values in mGluR2+/+ mice were 11% lower in M100907-treated group (n=5) than they were in 
vehicle-treated group (n=28) (t=0.441; p=0.662). mGluR2-/- mice undergone to M100907 
perfusion (n=6) displayed a reduction of 35% in basal concentrations, compared to the vehicle-
treated group (n=26) (t=1.738; p=0.092). No significant differences between genotypes were 
found in vehicle-treated groups (t=0.237; p=0.814), or in M100907-treated groups (t=1.568; 
p=0.151). 
 
Local administration of M100907 since the beginning of the experiment was able to fully block 
the NE stimulation induced by intra-cortical (±)-DOI in both mGluR2+/+ animals (Figure 47) 
(Fi[13, 247]=5.461; p<0.0001) as well as in mGluR2
-/- mice (Figure 48) (Fi[13, 221]=5.834; 
p<0.0001). 
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Fig. 46- Effect of cortical administration of VEH or M100907 (300 µM) on extracellular NE 
concentrations in the FC of mGluR2 
+/+
 ( n=6,  n=6) and mGluR2
-/-
 mice ( n=6,  n=6). Data 
are means ± SEM of NE expressed as a percentage of basal values (100%). M100907 perfusion 
was initiated after collecting the sixth sample. Line represents drug infusion time.  
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Fig. 47- Influence of the cortical presence or absence of the 5-HT2AR antagonist M100907 (300 
µM) on the modulation by the 5-HT2A/2C receptor agonist (±)-DOI (300 µM) of extracellular 
concentrations of NE in the FC of mGluR2
+/+
 mice ( n=16,  n=5). Data are means ± SEM of NE
levels expressed as a percentage of basal values (100%). M100907 perfusion was initiated since 
the beginning of the experiment. The line represents (±)-DOI infusion time. *p<0.05, ***p<0.001
(two-way repeated measures ANOVA followed by Bonferroni’s post hoc test). 
Fig. 48- Influence of the cortical presence or absence of the 5-HT2AR antagonist M100907 (300 
µM) on the modulation by the 5-HT2A/2C receptor agonist (±)-DOI (300 µM) of extracellular 
concentrations of NE in the FC of mGluR2
-/-
 mice ( n=13,  n=6). Data are means ± SEM of NE
levels expressed as a percentage of basal values (100%). M100907 perfusion was initiated since 
the beginning of the experiment. The line represents (±)-DOI infusion time. *p<0.05, ***p<0.001
(two-way repeated measures ANOVA followed by Bonferroni’s post hoc test).  
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In terms of AUCs magnitudes, Figure 49 reports that there were not alterations in NE 
concentrations consequently to CSF perfusion. However, as already described, extracellular NE 
release as a result of local (±)-DOI administration was significantly higher in wild-type animals 
(AUC mean=7980 ± 1391), compared to their knock-out littermates (AUC mean=3608 ± 633). 
Interestingly, continuous intra-cortical infusion of M100907 prior to (±)-DOI perfusion in the 
same brain region, was successfully able to block that stimulation in both mGluR2+/+ (AUC 
mean=66 ± 1374) and mGluR2-/- (AUC mean=-186 ±794) animal groups. Two-way ANOVA 
showed significant genotype-dependent response to drugs (Fgenotype[1, 47]=6.2; p<0.05) and 
that treatments were able to modulate NE release (Ftreatment[2, 47]=17.33; p<0.0001).  
 
 
 
 
 
 
 
 
 
 
 
4.1.1.3. Effect of cortical infusion of (±)-DOI on DA and NE release in the frontal cortex of 
5-HT2AR
+/+ 
and 5-HT2AR
-/-
 mice 
 
As mentioned above, (±)-DOI is not a selective 5-HT2AR agonist drug, but possesses to some 
extent higher affinity at 5-HT2AR than at 5-HT2CR (Hemrick-Luecke & Evans, 2002; May et al., 
2003; Pigott et al., 2012). To assess the influence of the existence of 5-HT2AR on the boost in 
cortical DA release after intra-cortical administration of (±)-DOI, the same procedure was 
carried out using 5-HT2AR+/+ and 5-HT2AR-/- mice.  
Fig. 49- Cortical NE AUC values 210 minutes after the beginning of the procedure to the end. 
Effect of intra-cortical infusion of vehicle, (±)-DOI (300 µM) and M100907 (300 µM) + (±)-DOI 
(300 µM) in mGluR2
+/+
 ( n=6,  n=16,  n=5) and mGluR2
-/-
 mice ( n=6,  n=13,  n=5).  All 
results are expressed as means ± SEM. *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA 
followed by LSD’s post hoc test). 
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Dopamine 
In 5-HT2AR+/+ control mice, absolute basal concentrations of dialysate DA content, without 
considering probe recovery, were significantly lower compared to their 5-HT2AR-/- 
counterparts: 1.499 ± 0.179 nM (n=30) in 5-HT2AR+/+ mice versus 2.022 ± 0.160 nM (n=28) in 
5-HT2AR-/- mice (t=2.167; p<0.05). 
 
Intra-cortical (±)-DOI (300 µM) infusion elicited a significant rise in extracellular DA in the FC of 
5-HT2AR+/+ mice when compared to VEH (Fi[13, 156]=25.38; p<0.0001) (Figure 50). 
Interestingly, the hallucinogenic drug elicited a more acute DA stimulation in C57BL/6 control 
mice (5-HT2AR+/+) (Emax= 225 ± 21%) than experienced in 129/Sv control mice (mGluR2
+/+) 
(Emax= 163±16%).  
 
In 5-HT2AR-/- mice there was a mild but significant increase of extracellular DA as a result of 
(±)-DOI infusion, when compared to VEH (Emax=155 ± 16%) (Fi[13, 156]=6.60; p<0.0001) (Figure 
50). As expected, the lack of 5-HT2AR significantly impaired the stimulatory effect elicited by 
300 µM (±)-DOI in the cortex, compared to wild-type animals (Fi[13, 169]=7.932; p<0.0001) 
(Figure 50). 
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Fig. 50- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular DA 
concentrations in the FC of 5-HT2AR
+/+
 ( n=8,  n=6) and 5-HT2AR
-/-
 mice ( n=5,  n=9). Data 
are means ± SEM of DA expressed as a percentage of basal values (100%). The line represents 
drug infusion time. **p<0.01, ***p<0.001 versus 5-HT2AR
-/-
 (±)-DOI-treated group (two-way 
repeated measures ANOVA followed by Bonferroni’s post hoc test). 
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Looking at the extent of the effect, AUC values show that 300 µM (±)-DOI triggered a DA 
release in the FC in both genotype groups.  However, in 5-HT2AR+/+ that response was 
substantially higher than in 5-HT2AR-/- animals, unmasking a significant interaction between 
genotypes. Therefore, there was a significant interaction genotype x treatment (Fi[1, 24]=8.41; 
p<0.01) (Figure 51).   
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
NE extracellular basal values, without considering probe recovery, did not differ between 
5-HT2AR+/+ and 5-HT2AR-/- mice: 1.454 ± 0.101 nM (n=31) versus 1.263 ± 0.122 nM (n=28), 
respectively (t=1.214; p=0.230). 
 
Local administration of 300 µM (±)-DOI remarkably increased extracellular NE outflow in the 
FC of 5-HT2AR+/+ (Emax= 171 ± 16%) (Fi[13, 195]=9.83; p<0.0001) (Figure 52). On the contrary, a 
small but significant stimulatory effect was elicited in 5-HT2AR-/- mice (Emax= 119 ± 7%) (Fi[13, 
143]=2.344; p<0.01) (Figure 52). Two-way repeated measures ANOVA revealed a significant 
interaction between (±)-DOI response over time, depending on genotype (Fi[13, 182]=6.159; 
p<0.0001). 
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Fig. 51- Cortical DA AUC values 210 minutes after the beginning of the procedure to the end. 
Effect of intra-cortical infusion of vehicle or (±)-DOI (300 µM) in 5-HT2AR
+/+
 ( n=8,  n=6) and 
5-HT2AR
-/-
 mice ( n=5,  n=9).  All results are expressed as means ± SEM. *p<0.05, ***p<0.001
(two-way ANOVA followed by LSD’s post hoc test). 
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Two-way ANOVA showed a statistically significant difference between AUC values derived 
from (±)-DOI-treatment and genotype, leading to a significant interaction among these two 
factors (Fi[1, 26]=15.48; p<0.001) (Figure 53).  
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Fig. 52- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular NE 
concentrations in the FC of 5-HT2AR 
+/+
 ( n=8,  n=9) and 5-HT2AR
-/-
 mice ( n=6,  n=7). Data 
are means ± SEM of NE expressed as a percentage of basal values (100%). The line represents 
drug infusion time. **p<0.01, ***p<0.001 versus 5-HT2AR
-/-
 (±)-DOI-treated group (two-way 
repeated measures ANOVA followed by Bonferroni’s post hoc test). 
Fig. 53- Cortical NE AUC values 210 minutes after the beginning of the procedure to the end. 
Effect of intra-cortical infusion of vehicle or (±)-DOI (300 µM) in 5-HT2AR
+/+
 ( n=8,  n=9) and
5-HT2AR
-/-
 mice ( n=6,  n=7).  All results are expressed as means ± SEM. ***p<0.001 (two-way 
ANOVA followed by LSD’s post hoc test). 
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4.1.1.4. Effect of cortical infusion of (±)-DOI on DA and NE release in the frontal cortex of 
mGluR3
+/+
 and mGluR3
-/-
 mice 
 
It has been demonstrated that 5-HT2AR forms a heterocomplex with mGluR2, and not with the 
closely structurally related mGluR3 (González-Maeso et al., 2008; Moreno et al., 2012). In 
order to further elucidate the functional implication of mGluR2 and not mGluR3 in the 
(±)-DOI-induced response, mGluR3 knock-out mice were used.  
 
Note that vehicle and (±)-DOI-treated wild-type groups (mGluR3+/+) comprised the same 
animals used as wild-type 5-HT2A+/+ mice, for both dopaminergic and noradrenergic 
assessments, as they share the same genetic background (C57BL/6). 
 
Dopamine 
No differences in extracellular DA basal concentrations were found between wild-type (1.499 ± 
0.179 nM, n=30) and mGluR3-/- mice (2.134 ± 0.27, n=10) (t=1.823; p=0.076). 
 
Intra-cortical perfusion of (±)-DOI (300 µM) increased extracellular concentrations of DA in 
control animals when compared to VEH (as seen in section 4.1.1.3) (Emax= 225 ± 21%) (Fi[13, 
156]=25.38; p<0.0001) (Figure 54). Similar response was yielded by their mGluR3-/- littermates 
(Emax= 219 ± 19%) (Fi[13, 104]=19.90; p<0.0001) (Figure 54). Two-way repeated measures 
ANOVA disclosed no differences between genotypes on extracellular DA outflow after 
treatment with intra-cortical (±)-DOI (300 µM) (Fi[13, 117]=0.84; p=0.62). 
 
 
 
 
 
 
 
Fig. 54- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular DA 
concentrations in the FC of mGluR3 
+/+
 ( n=8,  n=6) and mGluR3
-/-
 mice ( n=5,  n=5). Data 
are means ± SEM of DA expressed as a percentage of basal values (100%). The line represents 
drug infusion time. 
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Two-way ANOVA of AUC values revealed a significant response to (±)-DOI administration 
(Ftreatment[1, 20]=69.49; p<0.0001) independently of the presence or absence of mGlu3 receptor 
(Fgenotype[1, 20]=0.17; p=0.687) in these mice (Figure 55). 
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
No differences in extracellular NE basal concentrations were found between mGluR3+/+ (1.454 
± 0.101 nM, n=31) and mGluR3-/- mice (1.499 ± 0.15 nM, n=11) (t=0.233; p=0.817). 
 
In accordance with the effect evoked by the 5-HT2A/2C receptors agonist (±)-DOI on DA 
release, intra-cortical perfusion of (±)-DOI (300 µM) significantly increased extracellular 
concentrations of NE in control animals, compared to VEH group (as shown in section 4.1.1.3) 
(Emax= 171 ± 16%) (Fi[13, 195]=9.83; p<0.0001) (Figure 56). A similar effect was observed in 
animals lacking mGluR3 receptors (Emax= 219 ± 19%) (Fi[13, 117]=2.840; p<0.01) (Figure 56). 
Two-way repeated measures ANOVA revealed no differences between genotypes on 
extracellular DA outflow after intra-cortical treatment with (±)-DOI (300 µM) (Fi[13, 
169]=0.499; p=0.923). 
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Fig. 55- Cortical DA AUC values 210 minutes after the beginning of the procedure to the end. 
Effect of intra-cortical infusion of vehicle or (±)-DOI (300 µM) in the FC of mGluR3
+/+
 ( n=8, 
 n=6) and mGluR3
-/-
 mice ( n=5,  n=5). All results are expressed as means ± SEM. ***p<0.001
(two-way ANOVA followed by LSD’s post hoc test). 
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Two-way ANOVA of AUC values found no statistically significant differences between the 
responses to (±)-DOI-treatment carried out by the above different genotypes. This statement 
indicates that (±)-DOI induced a similar noradrenergic stimulation in both genotypes and the 
only significant difference was reached in terms of treatment (Ftreatment[1, 24]=21.65; p<0.001) 
(Figure 57). 
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Fig. 56- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular NE levels in 
the FC of mGluR3 
+/+
 ( n=8,  n=9) and mGluR3
-/-
 mice ( n=5,  n=5). Data are means ± SEM of 
NE expressed as a percentage of basal values (100%). The line represents drug infusion time. 
Fig. 57- Cortical NE AUC values 210 minutes after the beginning of the procedure to the end. 
Effect of intra-cortical infusion of vehicle or (±)-DOI (300 µM) in the FC of mGluR3
+/+
 ( n=8, 
n=9) and mGluR3
-/-
 mice ( n=5,  n=5).  All results are expressed as means ± SEM. **p<0.01
(two-way ANOVA followed by LSD’s post hoc test). 
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4.1.1.5. Effect of cortical infusion of (±)-DOI on DA and NE release in the frontal cortex, 
following virus-mediated overexpression of mGluR2 in  mGluR2
-/-
 mice  
 
The previous results suggest that the lack of the mGluR2 leads to an impairment of 
catecholamine release in FC evoked by cortical administration of the hallucinogen 5-HT2A/2C 
receptors agonist (±)-DOI. This is potentially due to the absence of 5-HT2AR/mGluR2 
heterocomplex. To fully establish the role of mGluR2 in (±)-DOI-mediated response, mGluR2 
was overexpressed in the FC of mGluR2-/- mice to assess if the rescue of this receptor could 
result in similar catecholamine release as produced by their wild-type counterparts (see in 
4.1.1.2 section). Mice received an intra-cortical injection of bicistronic herpes simplex 2 viral 
particles (HSV), expressing either green fluorescent protein (GFP) and mGluR2 (HSV-mGluR2) 
or GFP alone (HSV-GFP). 
 
4.1.1.5.1. Immunofluorescence assay to determine virus expression location 
 
Immunohistochemistry combines anatomical, immunological and biochemical techniques to 
identify tissue components by the interaction of target antigens with specific antibodies 
tagged with a visible label. This technique makes it possible to visualize the distribution and 
location of specific cellular components within cells and the proper tissue context.  
 
It has been previously reported that mGluR2 can be rescued through HSV-mediated transgene 
expression in mGluR2-KO mouse FC (Moreno et al., 2012). In order to rescue the mGluR2, it 
was firstly confirmed that the virus expressed GFP protein (assuming that mGluR2 would be 
also expressed) in the same location as the probe would be later introduced, in the dialysis 
surrounding area. Four days after viral injection, when the maximum viral expression is 
reached, immunofluorescence assays were performed using 40-micron thick brain slices. 
Selected slices were those located in the surroundings of the viral injection area. 
 
As shown in Figure 58, the maximal fluorescence intensity and subsequently the maximal viral 
expression, was obtained around the injection area.  
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4.1.1.5.2. Effect of cortical administration of (±)-DOI on DA and NE release in the frontal cortex 
of mGluR2-/- mice after rescuing mGluR2 in the FC 
 
Afterwards, the neurochemical effects induced by the hallucinogenic drug (±)-DOI in 
HSV-mGluR2 and their HSV-GFP counterparts were then investigated. Immediately after the 
viral injection, a cannula was implanted and fixed in the same location until the end of the 
dialysis procedures. Three days after viral injection, a dialysis probe was implanted through the 
cannula, and microdialysis assays were performed in the following two days.  
 
Dopamine 
There were no differences in extracellular DA concentrations between mGluR2-KO mice 
pre-injected with HSV-GFP (2.126 ± 0.234 nM, n=18) or HSV-mGluR2 (1.918 ± 0.220 nM, n=20) 
(t=0.648; p=0.521). 
Fig. 58- Representative image of HSV-mediated transgene expression in the frontal cortex. HSV-GFP and HSV-mGluR2, which also expresses GFP, were 
injected into frontal cortex and GFP expression was revealed by immunofluorescence. Left upper panel: representative image showing the viral injection 
location, where slices were cut. Right panel: brain slice of the surrounding viral injection area observed with a fluorescence microscope: 4x magnification. Left 
lower panel: cortical neurons observed with a fluorescence microscope: 10x magnification.  
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The stimulatory response induced by the hallucinogenic 5-HT2A/2C receptors agonist (±)-DOI 
experienced in wild-type animals (Emax=163 ± 16%) and impaired in mGluR2 knock-out mice 
(Emax=134 ± 11%) (see 4.1.1.1. section), was rescued in mGluR2
-/- mice overexpressing mGluR2 
in the FC (Emax=172 ± 18%) (Fi[13, 234]=7.322; p<0.0001), but not in those animals expressing 
only GFP (Emax=137 ± 10%) (Fi[13, 208]=4.166; p<0.0001) (Figure 59). Two-way repeated 
measures ANOVA revealed a statistically significant difference between HSV-GFP and 
HSV-mGluR2 (±)-DOI-treated groups (Fi[13, 260]=3.223; p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two-way ANOVA analysis of AUC values within groups pre-injected with the viral vector 
revealed that, despite (±)-DOI was able to induce DA release in GFP- and mGluR2-HSV pre-
injected mGluR2-/- mice (Ftreatment [1, 34]=15.03; p<0.001), that response had a higher extent in 
animals were mGluR2 was rescued (Fgenotype[1, 34]=5.03; p<0.05) (Figure 60).  
 
Figure 60 represents AUC values of vehicle-treated or (±)-DOI-treated wild-type and mGluR2 
knock-out mice (see 4.1.1.1. section), pre and post virus-mediated GFP or mGluR2 
overexpression. The hallucinogenic 5-HT2A/2C receptors agonist (±)-DOI was able to evoke a 
rise in extracellular DA outflow in mGluR2+/+ mice (AUC mean=9272 ± 2132). That stimulation 
appeared to be impaired in mGluR2-/- animals (AUC mean=4573 ± 1414). (±)-DOI induced a 
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Fig. 59- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular DA 
concentrations in the FC of mGluR2
-/-
 mice overexpressing GFP ( n=8,  n=10) and mGluR2 
( n=8,  n=12). Data are means ± SEM of DA expressed as a percentage of basal values (100%). 
The line represents drug infusion time. **p<0.01 versus HSV-GFP (±)-DOI-treated group 
(two-way repeated measures ANOVA followed by Bonferroni’s post hoc test). 
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similar slight stimulatory effect in those mGluR2-/- animals pre-injected with HSV-GFP (AUC 
mean=4764 ± 1557), compared to mGluR2-/- without any previous virus transduction. 
Interestingly, after rescuing in the FC the expression of mGluR2 in mGluR2-/- mice 
(HSV-mGluR2), the hallucinogenic drug induced a higher extracellular DA outflow (AUC 
mean=12474 ± 2880), similar to the one previously displayed in mGluR2+/+ mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
Absolute basal NE concentrations, without considering probe recovery, did not differ between 
mGluR2-KO mice pre-injected with HSV-GFP (1.619 ± 0.147 nM, n=17) or HSV-mGluR2 (1.487 ± 
0.113 nM, n=21) (t= 0.726; p=0.472). 
 
As previously shown on dopaminergic modulation, the impaired noradrenergic stimulatory 
response in mGluR2 knock-out mice elicited after intra-cortical administration of (±)-DOI, was 
rescued in mGluR2-/- mice overexpressing mGluR2 in the FC (Emax=148 ± 9%) (Fi[13, 247]=17.95; 
p<0.0001), compared to those overexpressing only GFP (Emax=122 ± 6%) (Fi[13, 195]=6.665; 
p<0.0001) (Figure 61). Two-way repeated measures ANOVA revealed statistically significant 
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Fig. 60- Cortical DA AUC values 210 minutes after the beginning of the procedure to the end. 
Effect of intra-cortical infusion of vehicle or (±)-DOI (300 µM) in the FC of mGluR2
+/+
 ( n=6, 
 n=13), mGluR2
-/-
  ( n=6,  n=14), mGluR2
-/-
 expressing GFP (HSV-GFP) ( n=8,  n=10) and 
mGluR2
-/-
 expressing mGluR2 (HSV-mGluR2 ( n=8,  n=12). All results are expressed as means ± 
SEM. *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA followed by LSD’s post hoc test). 
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differences between HSV-GFP and HSV-mGluR2 (±)-DOI treated groups (Fi[13, 260]=6.209; 
p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two-way ANOVA analysis of AUC values within groups pre-injected with the viral vector 
revealed a statistically significant difference in the (±)-DOI response between knock-out 
animals where mGluR2 was rescued in the FC (HSV-mGluR2) and those in which mGluR2 was 
not rescued (HSV-GFP) (Fi[1, 34]=5.63; p<0.05) (Figure 62). 
 
In line with the previous studies shown above (section 4.1.1.1.), intra-cortical (±)-DOI (300 µM) 
enhanced NE release in the FC of mGluR2+/+ mice (AUC mean=7980 ± 1391). That stimulation 
was much lower in mGluR2-/- mice (AUC mean=3608 ± 632). According to these results, that 
stimulation was likely 5-HT2AR-dependent (4.1.1.2 section), suggesting that the absence of 
mGluR2 forming a heterocomplex with 5-HT2AR could be responsible for the impairment of 
the (±)-DOI-induced effect displayed in mGluR2-/- mice. (±)-DOI induced a similar small increase 
in NE dialysate concentrations in mGluR2-/- animals overexpressing GFP (HSV-GFP) (AUC 
mean=2540 ± 894), as compared to mGluR2-/- without viral manipulation. Remarkably, in those 
mGluR2-/- animals where mGluR2 was rescued after viral transduction (HSV-mGluR2), the 
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Fig. 61- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular NE 
concentrations in the FC of mGluR2
-/-
 mice overexpressing GFP ( n=7,  n=10) and mGluR2 
( n=9,  n=12). The line represents drug infusion time. Data are means ± SEM of NE expressed 
as a percentage of basal values (100%). *p<0.05, ***p<0.001 versus HSV-GFP (±)-DOI-treated 
group (two-way repeated measures ANOVA followed by Bonferroni’s post hoc test). 
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(±)-DOI-induced extracellular NE outflow (AUC mean=7142 ± 1159) was similar to the effect 
seen in mGluR2+/+ mice (Figure 62). 
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Fig. 62- Cortical NE AUC values 210 minutes after the beginning of the procedure to the end. Effect of 
intra-cortical infusion of vehicle or (±)-DOI (300 µM) in the FC of mGluR2
+/+
 ( n=6,  n=16), mGluR2
-/-
( n=7,  n=13), mGluR2
-/-
 expressing GFP (HSV-GFP) ( n=7,  n=10) and mGluR2
-/-
 expressing mGluR2 
(HSV-mGluR2) ( n=9,  n=12).  All results are expressed as means ± SEM. *p<0.05, **p<0.01, ***p<0.001 
(two-way ANOVA followed by LSD’s post hoc test). 
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4.1.2. Modulation of DA and NE release by systemic administration of the 
hallucinogenic 5-HT2A/2C receptor agonist (±)-DOI in mice 
4.1.2.1. Effect of systemic administration of (±)-DOI on DA and NE release in the frontal cortex 
of wild-type C57BL/6 strain mice 
 
Various studies have suggested that acute systemic administration of the hallucinogenic 
5-HT2AR/2CR agonist drug (±)-DOI increases dialysate DA concentrations in rat FC, as well as in 
C57BL/6 mice (Gobert & Millan, 1999; Pehek et al., 2001; Bortolozzi et al., 2005), apparently 
through the activation of 5-HT2A receptors (Huang et al., 2012). By contrast, the dose of 
1mg/kg (±)-DOI is able to reduce extracellular 5-HT output in rat FC (Martín-Ruiz et al., 2001). 
However, little is known about the noradrenergic modulation triggered by this hallucinogenic 
drug. Firstly, we determined the dopaminergic and noradrenergic modulation elicited by 
(±)-DOI after acute intraperitoneal injection. 
 
Dopamine 
Vehicle treatment failed to modify extracellular DA concentrations. As shown in Figure 63, 
systemic administration of (±)-DOI (1 mg/kg i.p.) induced a significant increase in the cortical 
DA efflux in wild-type animals (Emax=150 ± 6%). Two-way repeated-measures ANOVA displayed 
a statistically significant difference in the dopaminergic response elicited by (±)-DOI, compared 
to vehicle treatment (Fi[11, 154]=5.543; p<0.0001). 
 
 
 
 
 
 
 
 
  
 
Fig. 63- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
concentrations of DA in C57BL/6 mice ( n=6,  n=10). The arrow indicates the time of drug 
injection. Data are means ± SEM of DA expressed as a percentage of basal values (100%). 
*p<0.05, **p<0.01, ***p<0.001 versus vehicle-treated group (two-way repeated measures 
ANOVA followed by Bonferroni’s post hoc test). 
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Norepinephrine 
Acute administration of (±)-DOI (1 mg/kg i.p.) did not alter extracellular NE efflux in the FC of 
wild-type C57BL/6 mice (Emax=119 ± 5%). Two-way repeated measures ANOVA revealed a 
non-significant effect induced by (±)-DOI, compared to vehicle-treated group (Fi[11, 
132]=0.989; p=0.460) (Figure 64). 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.2. Role of the presence of the 5-HT2A receptor in (±)-DOI-induced responses 
 
In order to evaluate the involvement of the 5-HT2A receptor on the dopaminergic stimulatory 
effect carried out by the systemic injection of (±)-DOI (1 mg/kg i.p.), we decided to repeat the 
same procedure using 5-HT2AR knock-out animals. 
 
Dopamine 
As previously mentioned in 4.1.1.3 section, absolute baseline DA concentrations, without 
considering probe recovery, were significantly lower in 5-HT2AR+/+ than in 5-HT2AR-/- mice: 
1.499 ± 0.179 nM (n=30) in 5-HT2AR+/+ mice; 2.022 ± 0.160 nM (n=28) in 5-HT2AR-/- mice 
(t=2.167; p<0.05). 
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Fig. 64- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
NE concentrations in C57BL/6 mice ( n=5,  n=9). The arrow indicates the time of drug 
injection. Data are means ± SEM of NE expressed as a percentage of basal values (100%).  
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Acute administration of (±)-DOI induced greater DA release in 5-HT2AR wild-type mice 
(Emax=150 ± 6%), compared to the 5-HT2AR knock-out group, who apparently did not respond 
to (±)-DOI-derived dopaminergic modulations, when compared to saline administration 
(Emax=124 ± 4%) (Fi[11, 132]=0.556; p=0.861). Statistical analysis with two-way repeated 
measures ANOVA showed a significant difference in the response to (±)-DOI depending on 
genotype (Fi[11, 176]=3.990; p<0.0001), suggesting that 5-HT2ARs are necessary to increase 
cortical extracellular DA outflow after the injection of 1 mg/kg (±)-DOI (Figure 65). 
 
 
 
 
 
 
 
 
 
 
 
 
In terms of magnitude of the effects, regarding AUC values after the injection of saline or      
(±)-DOI, saline injection did not alter extracellular DA release. In contrast, acute (±)-DOI 
injection was able to increase extracellular DA efflux in 5-HT2AR+/+ mice (AUC mean=6893 ± 
986), but no increase was detected in 5-HT2AR-/- mice (AUC mean=2573 ± 846) (Figure 66). 
Consequently, two-way ANOVA displayed a statistically significant interaction between 
genotype and treatment (Fi[1, 26]=9.64; p<0.01). 
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Fig. 65- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
DA concentrations in 5-HT2AR
+/+
 mice ( n=6,  n=10) and in 5-HT2AR
-/-
 mice ( n=6,  n=8). 
The arrow indicates the time of drug injection. Data are means ± SEM of DA expressed as a 
percentage of basal values (100%). *p<0.05, **p<0.01, ***p<0.001 versus 5-HT2AR
-/-
(±)-DOI-treated group (two-way repeated measures Bonferroni’s post hoc test). 
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Norepinephrine 
As stated above, the pre-drug extracellular basal concentrations of NE in the FC were not 
different between 5-HT2AR+/+ (1.454 ± 0.101 nM, n=31) and in 5-HT2AR-/- mice (1.263 ± 0.122 
nM, n=28) (t=1.214; p=0.230) (see section 4.1.1.3). 
 
Acute injection of (±)-DOI (1 mg/kg i.p.) did not modify extracellular concentrations of NE 
neither in 5-HT2AR+/+ (Emax=119 ± 5%) (Fi[11, 132]=0.989; p=0.460) nor in 5-HT2AR
-/- groups 
(Emax=116 ± 3%) (Fi[11, 143]=0.528; p=0.881) when compared to saline injection (Figure 67). 
Two-way repeated measures ANOVA revealed that there was no statistically significant 
difference attributable to genotypes on (±)-DOI-induced responses (Fi[11, 176]=1.671; 
p=0.083). 
 
 
 
 
 
 
Fig. 66- Cortical DA AUC values after drug injection. Effect of systemic administration of VEH or 
(±)-DOI (1 mg/kg i.p.) on cortical dopaminergic modulation in 5-HT2AR
+/+
 ( n=6,  n=10) and 
5-HT2AR
-/-
 mice ( n=6,  n=8).  All results are expressed as means ± SEM. ***p<0.001 (two-way 
ANOVA followed by LSD’s post hoc test). 
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As observed in Figure 68, AUC values did not differ significantly among treatments (Ftreatment [1, 
25]=0.30; p=0.588) or genotypes (Fgenotype [1, 25]=0.04; p=0.839). 
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Fig. 67- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
NE concentrations in 5-HT2AR
+/+
 mice ( n=5,  n=9) and in 5-HT2AR
-/-
 mice ( n=6,  n=9). The 
arrow indicates the time of drug injection. Data are means ± SEM of DA expressed as a 
percentage of basal values (100%).  
Fig. 68- NE AUC values after drug injection. Effect of systemic administration of vehicle or (±)-
DOI (1 mg/kg i.p.) on cortical dopaminergic modulation in 5-HT2AR
+/+
 ( n=6,  n=9) and            
5-HT2AR
-/-
 mice ( n=6,  n=9).  All results are expressed as means ± SEM.  
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4.1.2.3. Effects of systemic (±)-DOI administration on DA and NE release in the frontal cortex of 
129/Sv strain mice  
 
In an attempt to replicate the (±)-DOI-induced dopaminergic and noradrenergic responses 
seen in C57BL/6 mice, the same procedure using wild-type 129/Sv mice was undertaken. At a 
later time, the intention was to perform the experiments in mGluR2-/- mice (genetically 
modified in a 129/Sv strain background), in order to compare systemic and local (see 4.1.1.1. 
section) administration of (±)-DOI. 
 
Dopamine 
The dose of 1 mg/kg i.p. of (±)-DOI unexpectedly evoked a slight, but significant, inhibitory 
effect on cortical extracellular DA release over time (Emax=-26 ± 3%) (Figure 69). Two-way 
repeated measures ANOVA revealed a statistically significant inhibitory effect when compared 
to saline-treated group (Fi[11, 165]=4.753; p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
Acute administration of (±)-DOI (1mg/kg i.p.) yielded an inhibitory effect, reducing extracellular 
NE concentrations slightly but significantly (Emax=-26 ± 4%) (Figure 70). Two-way repeated 
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Fig. 69- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
DA concentrations in 129/Sv mice ( n=7,  n=10). The arrow indicates the time of drug 
injection. Data are means ± SEM of DA expressed as a percentage of basal values (100%). 
*p<0.05, ***p<0.001 versus vehicle-treated group (two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test). 
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measures ANOVA highlighted statistically significant differences in the (±)-DOI-induced 
response comparing to the one exerted by saline injection (Fi[11, 231]=4.466; p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.4. Strain differences in dopaminergic and noradrenergic responses after acute injection of 
the hallucinogenic 5-HT2A/2C receptors agonist (±)-DOI 
 
There is plenty of evidence suggesting that mice can display distinct behavioral, signaling and 
physiological effects depending on their background strain (Weizman et al., 1999; Ventura et 
al., 2001; Bouwknecht & Paylor, 2002; Dimou et al., 2006; Tsuda et al., 2006; Banks et al., 
2015; Moloney et al., 2015; Campus et al., 2016; Schwartzer et al., 2016). Calagno & Invernizzi 
(2010) also reported neurochemical strain-dependent differences in 5-HT2CR sensitivity by 
microdialysis experiments. 
 
Dopamine 
When represented the previous findings simultaneously, opposite strain-dependent effects 
induced by (±)-DOI were found. C57BL/6 experienced a strong stimulatory effect on DA release 
in the FC, whereas in 129/Sv mice (±)-DOI not only did not elicit a stimulatory effect, but 
induced an inhibitory effect (Figure 71). Repeated measures two-way ANOVA showed 
significant opposite responses elicited by (±)-DOI between both mouse strains 
(Fi[11,198]=24.29; p<0.0001). 
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Fig. 70- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on extracellular NE
concentrations in the FC of 129/Sv mice ( n=10,  n=13). The arrow indicates the time of drug 
injection. Data are means ± SEM of DA expressed as a percentage of basal values (100%). 
*p<0.05, **p<0.01, ***p<0.001 versus vehicle-treated group (two-way repeated measures 
ANOVA followed by Bonferroni’s post hoc test). 
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As shown in Figure 72, CSF did not alter DA concentrations neither in C57BL/6, nor in 129/Sv 
mice (AUC mean=535 ± 575, AUC=447 ± 603; respectively). The acute systemic administration 
of the 5-HT2A/2C receptor agonist (±)-DOI (1 mg/kg i.p.) was able to significantly increase AUC 
values (AUC mean= 6893 ± 986), compared to the corresponding vehicle-treated group of 
C57BL/6 mice. The same dose of (±)-DOI induced a significant inhibitory effect on DA 
concentrations in the FC of 129/Sv mice (AUC mean=-3043 ± 642). Two-way ANOVA revealed a 
statistically significant difference among strains in response to treatment (Fi[1, 29]=36.82; 
p<0.0001). 
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Fig. 71- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on extracellular 
concentrations of DA in the FC of C57BL/6 mice ( n=7,  n=10) and 129/Sv mice ( n=9, 
 n=10). The arrow indicates the time of drug injection. Data are means ± SEM of DA expressed 
as a percentage of basal values (100%). *p<0.05, ***p<0.001 versus 129/Sv (±)-DOI-treated 
group (two-way repeated measures ANOVA followed by Bonferroni’s post hoc test). 
Fig. 72- DA AUC values after drug injection. Effect of systemic administration of vehicle or 
(±)-DOI (1 mg/kg i.p.) on cortical dopaminergic modulation in C57BL/6 mice ( n=7,  n=10) and 
in 129/Sv mice ( n=9,  n=10). All results are expressed as means ± SEM. **p<0.01, ***p<0.001
(two-way ANOVA followed by LSD’s post hoc test). 
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Norepinephrine 
NE modulation seemed to follow a similar pattern as DA. Although systemic (±)-DOI failed to 
alter extracellular NE efflux in the FC of C57BL/6 mice (Emax=119 ± 5%), an inhibitory effect over 
time was displayed in 129/Sv mice (Emax=-26 ± 4%). Two-way repeated measures ANOVA 
displayed statistically significant differences between strains as a result of (±)-DOI injection 
(Fi[11, 176]=2.731; p<0.01) (Figure 73). 
 
 
 
 
 
 
 
 
 
                                         
 
 
AUC values analysis showed negligible effects after vehicle injection in both C57BL/6 and 
129/Sv mice (AUC mean=560 ± 477, AUC mean=746 ± 574; respectively). Non-significant 
effect, compared to its saline-treated group, was exerted after systemic (±)-DOI administration 
in C57BL/6 mice (AUC mean=1584 ± 932). In contrast, a decrease in extracellular NE efflux was 
promoted as a result of the hallucinogenic drug administration in 129/Sv mice (AUC 
mean=-2458 ± 638). Hence, there was a significant interaction between strains and treatment 
(Fi[1, 33]=7.54; p<0.01) (Figure 74). 
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Fig. 73- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on extracellular NE 
concentrations in C57BL/6 mice ( n=7,  n=10) and 129/Sv mice ( n=9,  n=10). The arrow 
indicates the time of drug injection. Data are means ± SEM of DA expressed as a percentage of 
basal values (100%). **p<0.01 versus 129/Sv (±)-DOI-treated group (two-way repeated measures 
ANOVA followed by Bonferroni’s post hoc test). 
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4.1.2.5. Dose-dependent effects of (±)-DOI on extracellular DA and NE output in 129/Sv mice 
 
Microdialysis experiments were performed using five increasing doses of systemic (±)-DOI 
(0.1-5 mg/kg i.p.) in order to evaluate whether these 129/Sv mice could mimic, at a lower or 
higher dose, the stimulatory effect observed in C57BL/6 mice. Differences in sensitivity to 
specific receptors have been reported between mouse strains (Calcagno & Invernizzi, 2010). 
Only one dose was administered per mouse in each experiment. 
 
The effects of the intraperitoneal administration of increasing doses of (±)-DOI (0.1-5 mg/kg) 
on DA and NE extracellular release is shown in Figures 75 and 76. (±)-DOI elicited a significant 
and dose-dependent decrease in DA efflux in the FC (F[5, 42]=9.836; p<0.0001, one-way 
ANOVA), reaching a maximal inhibitory effect at 2.5 mg/kg i.p (Figure 75). NE modulation 
experienced a significant inhibitory response (F[5, 54]=3.683; p<0.01, one-way ANOVA), with a 
maximal inhibitory effect at a dose of 0.5 mg/kg (Figure 76).  
 
Dunnett’s post-hoc test revealed that the unique dose which triggered a statistically significant 
inhibitory effect in both catecholamines was 1 mg/kg. For that reason, we decided to complete 
this study using this dose. 
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Fig. 74- Cortical NE AUC values after drug injection. Effect of systemic administration of vehicle 
or (±)-DOI (1 mg/kg i.p.) on cortical noradrenergic modulation in C57BL/6 mice ( n=7,  =10) 
and 129/Sv mice ( n=9,  n=10). All results are expressed as means ± SEM. **p<0.01,
***p<0.001 (two-way ANOVA followed by LSD’s post hoc test). 
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4.1.2.6 Effect of systemic administration of M100907 on (±)-DOI-induced attenuation of 
extracellular DA and NE release in frontal cortex of 129/Sv mice 
 
In order to discern whether the 5-HT2A or 5-HT2C receptors were implicated in the 
catecholaminergic inhibitory actions exerted by the systemic administration of the agonist 
5-HT2A/2C receptors (±)-DOI, the 5-HT2AR antagonist M100907 was used. Thirty-five minutes 
Fig. 75- Cortical DA AUC values after drug injection. Effect of intraperitoneal administration of vehicle     
(n=14), or (±)-DOI at doses of 0.1 mg/kg (n=9), 0.5 mg/kg (n=3), 1 mg/kg (n=10), 2.5 mg/kg (n=2), 5 
mg/kg   (n=5) on cortical dopaminergic modulation in 129/Sv mice. All results are expressed as means ± 
SEM. **p<0.01, ***p<0.001 (one-way ANOVA followed by Dunnett’s post hoc test). 
Fig. 76- Cortical NE AUC values after drug injection. Effect of intraperitoneal administration of vehicle      
(n=17), or (±)-DOI at doses of 0.1 mg/kg (n=9), 0.5 mg/kg (n=8), 1 mg/kg (n=13), 2.5 mg/kg (n=2), 5 
mg/kg   (n=6) on cortical noradrenergic modulation in 129/Sv mice. All results are expressed as means ± 
SEM. *p<0.05, **p<0.01 (one-way ANOVA followed by Dunnett’s post hoc test). 
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prior to the acute administration of (±)-DOI (1 mg/kg i.p.) a single dose of M100907 (0.5 mg/kg 
i.p.) was administered. 
 
This dose has already been described to be sufficient to antagonize systemic (±)-DOI-evoked 
extracellular serotonergic alterations in FC (Martín-Ruiz et al., 2001). 
 
Dopamine 
The decrease in the extracellular DA concentration in the FC induced by (±)-DOI was reverted 
by the administration of the antagonist. M100907 not only was fully effective in blocking the 
inhibitory effect of (±)-DOI, but also increased DA output (Emax=131 ± 10%) (Figure 77). In these 
experiments - with double injection, the first one administering saline - the inhibitory effect 
triggered by systemic (±)-DOI was lower (Emax=-13 ± 8%), compared to the groups where only 
one injection of (±)-DOI was carried out (Emax=-26 ± 3%) (Figure 69). This lack of inhibitory 
effect could be due to a rise in DA output induced by the stress caused by subjecting the 
animal to a double injection. 
 
 Statistically significant differences were revealed by two-way repeated measures ANOVA 
analysis between saline + (±)-DOI, and M100907 + (±)-DOI groups (Fi[12, 168]=3.68; p<0.0001).  
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Fig. 77- Effect of systemic administration of (±)-DOI (1 mg/kg i.p.) alone ( n=9) or in presence of 
M100907 (0.5 mg/kg i.p.)  ( n=7) on cortical extracellular DA concentrations in 129/Sv mice. 
The arrows indicate the time of drug injections: the first arrow represents VEH or M100907 
administration; the second arrow represents (±)-DOI administration. Data are means ± SEM of 
DA expressed as a percentage of basal values (100%). **p<0.01 versus VEH + (±)-DOI-treated 
group (two-way repeated measures ANOVA followed by Bonferroni’s post hoc test). 
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Norepinephrine 
The previous presence of M100907 (0.5 mg/kg) abolished the (±)-DOI-induced inhibitory 
noradrenergic effect in the FC (Fi[12, 216]=3.041; p<0.001) (Figure 78). Once again, the 
inhibitory effect triggered by systemic (±)-DOI was lower (Emax=-8 ± 5%), as compared to the 
groups where only one injection - of (±)-DOI - was administered (Emax=-26 ± 4%) (Figure 70). 
These findings suggest that the lack of inhibitory effect could be a stress-induced response to 
the exposure to two consecutive injections. 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2.7. Effect of the 5-HT2CR antagonist SB242084 on (±)-DOI-induced attenuation of 
extracellular DA and NE release in frontal cortex of 129/Sv mice 
 
SB242084 is primarily a 5-HT2CR antagonist, displaying 100- and 158-fold selectivity over the 
closely related 5-HT2B and 5-HT2A receptors respectively (Bromidge et al., 1997; Kennett et 
al., 1997; Gobert et al., 2000; Knight et al., 2004). A dose of 1 mg/kg was selected to be 
injected into the mice according to previous microdialysis studies (Calcagno et al., 2009, 
Calcagno & Invernizzi, 2010). 
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Fig. 78- Effect of systemic administration of (±)-DOI alone (1 mg/kg i.p.) ( n=11) or in presence 
of M100907 (0.5 mg/kg i.p) ( n=9) on cortical extracellular NE concentrations in 129/Sv mice. 
The arrows indicate the time of drug injections: the first arrow represents VEH or M100907 
administration; the second arrow represents (±)-DOI administration. Data are means ± SEM of 
NE expressed as a percentage of basal values (100%) (two-way repeated measures ANOVA). 
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Dopamine 
Acute injection of SB242084 (1 mg/kg i.p.) 35 minutes before the systemic administration of 
(±)-DOI (1 mg/kg i.p.) fully blocked the inhibitory effect induced by the hallucinogen alone. The 
5-HT2CR antagonist not only significantly blocked the effect, but also rendered a stimulatory 
effect on DA release (Emax=148 ± 11%). Two-way repeated measures ANOVA revealed a 
statistically significant difference between saline + (±)-DOI, and SB242084 + (±)-DOI groups 
over time (Fi[12, 144]=2.270; p<0.05) (Figure 79). Taken together, these data and those under 
the presence of M100907, it is suggested that both 5-HT2AR and 5-HT2CR could be involved in 
the (±)-DOI-induced inhibitory effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
The presence of the 5-HT2CR antagonist SB242084 (1 mg/kg i.p.) did not block the slight 
noradrenergic response exerted by (±)-DOI (1 mg/kg i.p.) in wild-type 129/Sv strain mice. 
Two-way repeated measures ANOVA failed to reach significance in the interaction between 
treatments over time (Fi[12, 204]=1.331; p=0.203) (Figure 80). 
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Fig. 79- Effect of systemic administration of (±)-DOI (1 mg/kg i.p.) alone ( n=9) or in presence of 
SB242084 (1 mg/kg i.p.) ( n=5) on cortical extracellular DA concentrations in 129/Sv mice. 
Arrows indicate the time of drug injections: the first arrow represents VEH or SB242084 
administration; the second arrow represents (±)-DOI administration. Data are means ± SEM of 
DA levels expressed as a percentage of basal values (100%). **p<0.01 versus VEH + (±)-DOI-
treated group (two-way repeated measures ANOVA followed by Bonferroni’s post hoc test). 
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4.1.2.8. Effect of systemic administration of the preferential 5-HT2C receptor agonist 
Ro 60-0175 on extracellular DA and NE release in frontal cortex of 129/Sv mice 
 
To further discern whether the inhibitory effect on dopaminergic and noradrenergic activities 
was the result of 5-HT2AR or 5-HT2CR activation, experiments using a preferential 5-HT2CR 
agonist were performed. Ro 60-0175 has been described as an agonist at the 5-HT2CR, with 
roughly 10-fold higher affinity at the 5-HT2C receptor compared to the 5-HT2A subtype, and 
equivalent affinity for the 5-HT2B receptor (Porter et al., 1999; Higgins et al., 2001; Hemrick-
Luecke & Evans, 2002; Knight et al., 2004). In vitro studies have shown reasonable affinity and 
efficacy for human 5-HT2AR and particularly human - and rat - 5-HT2B receptors (Porter et al, 
1999). Nonetheless, reported findings suggest an apparent in vivo selectivity of this drug, 
because its properties as 5-HT2CR agonist inhibit the expression of 5-HT2A receptor-mediated 
behaviours, most notably wet-dog shakes, back muscle contractions and hyperactivity 
(Higgings et al., 2001). Dose of 3 mg/kg is commonly used to elicit 5-HT2CR related behaviors 
(Martin et al., 1998; Millan et al., 1998; Kennett et al., 2000), consistent with the relative 
potencies of Ro 60-0175 at human 5-HT2AR and 5-HT2CR (Porter et al., 1999). In addition, 
effects indicative of 5-HT2CR activation induced by Ro 60-0175 - e.g. hypolocomotion and 
penile grooming - are blocked by antagonists at the 5-HT2CR (Millan et al., 1998; Kennett et 
al., 2000). SB242084 (1 mg/kg) is reported to be able to antagonize dopaminergic inhibitory 
Fig. 80- Effect of systemic administration of (±)-DOI (1 mg/kg i.p.) alone ( n=11) or under 
presence of SB242084 (1 mg/kg i.p.) ( n=8) on cortical extracellular NE concentrations in 129/Sv 
mice. Arrows indicate the time of drug injections: the first arrow represents saline or SB242084 
administration; the second arrow represents (±)-DOI administration. Data are means ± SEM of 
NE expressed as a percentage of basal values (100%).  
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effects elicited by Ro 60-0175 (1-3 mg/kg) in the NAcc (Di Matteo et al., 2000; De 
Deurwaerdère et al., 2004). 
 
Dopamine 
Intraperitoneal administration of 3 mg/kg of Ro 60-0175 elicited a significant decrease in DA 
efflux in the FC (Emax=-21 ± 4%). Significant differences between treatments were found after 
analyzing with two-way repeated measures ANOVA, compared to vehicle-treated group (Fi[11, 
132]=5.098; p<0.0001) (Figure 81).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
Acute intra-peritoneal administration of Ro 60-0175 (3 mg/kg) significantly evoked an 
inhibitory effect on cortical NE output (Emax=-21 ± 3%) (Figure 82). Two-way repeated measures 
ANOVA revealed a statistically significant effect on noradrenergic modulation depending on 
treatments over time (Fi[11, 143]=4.670; p<0.0001). 
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Fig. 81- Effect of systemic administration of VEH or Ro 60-0175 (3 mg/kg i.p.) on cortical 
extracellular DA concentrations in 129/Sv mice ( n=6,  n=8). The arrow indicates the time of 
drug injection. Data are means ± SEM of DA levels expressed as a percentage of basal values 
(100%). *p<0.05, **p<0.01, ***p<0.001 versus vehicle-treated group (two-way repeated 
measures ANOVA followed by Bonferroni’s post hoc test). 
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4.1.3. Influence of the 5-HT2AR/mGluR2 heterocomplex in the responses triggered 
by systemic administration of the hallucinogenic 5-HT2A/2C receptor agonist (±)-DOI 
The potential functional existence of the heterocomplex in mouse frontal cortex has been 
previously addressed (section 4.1.1.; see introduction for further details). An impairment in the 
cortical stimulatory response of DA and NE to local administration of (±)-DOI was elicited in    
mGluR2-/-, as compared to its wild-type counterparts (Figures 38 and 40). Overexpression of 
mGluR2, mediated by viral transduction, was able to restore the (±)-DOI-induced stimulatory 
response toward similar values to those observed in mGluR2+/+ mice (Figures 60 and 62). 
In order to establish potential differences between genotypes in the effect induced by 
intraperitoneal administration of (±)-DOI, the response in mGluR2-/- mice and wild-type 
mGluR2+/+ mice was evaluated. 
 
4.1.3.1. Dose-dependent effects of systemic administration of (±)-DOI on extracellular DA and 
NE release in the frontal cortex of mGluR2
-/-
 129/Sv mice 
 
Modulation of extracellular DA and NE concentrations after the administration of three doses 
of (±)-DOI (0.1, 1, and 5 mg/kg i.p.) were studied. Surprisingly, the lowest dose (0.1 mg/kg) was 
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Fig. 82- Effect of systemic administration of VEH or Ro 60-0175 (3 mg/kg i.p.) on cortical 
extracellular NE concentrations in 129/Sv mice ( n=5,  n=10). The arrow indicates the time of 
drug injection. Data are means ± SEM of NE levels expressed as a percentage of basal values 
(100%). **p<0.01, ***p<0.001 versus vehicle-treated group (two-way repeated measures 
ANOVA followed by Bonferroni’s post hoc test). 
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able to significantly rise extracellular DA (AUC mean=6962 ± 1131) and NE concentrations (AUC 
mean=3172 ± 1120) in the FC. However, (±)-DOI induced an overall inhibitory effect of cortical 
DA (F[3, 46]=14.11; p<0.0001, one-way ANOVA), reaching a maximal inhibitory effect at 
1 mg/kg i.p. (AUC mean=-1173 ± 952) (Figure 83). Doses of 1 mg/kg and 5 mg/kg also induced a 
decrease in cortical NE efflux (F[3, 50]=7.701; p<0.001, one-way ANOVA), with a maximal 
inhibitory response at a dose of 1 mg/kg (AUC mean=-2132 ± 757) (Figure 84).  
 
 
Fig. 83- Cortical DA AUC values after drug injection. Effect of intraperitoneal administration of VEH        
(n=19), or (±)-DOI at doses of 0.1 mg/kg (n=10), 1 mg/kg (n=10) and 5 mg/kg (n=8) on cortical 
dopaminergic modulation in mGluR2
-/-
 129/Sv mice. All results are expressed as means ± SEM. *p<0.05, 
**p<0.01 (one-way ANOVA followed by Dunnett’s post hoc test). 
Fig. 84- Cortical NE AUC values after drug injection. Effect of intraperitoneal administration of VEH        
(n=21), or (±)-DOI at doses of 0.1 mg/kg (n=9), 1 mg/kg (n=14) and 5 mg/kg (n=7) on cortical 
noradrenergic modulation in mGluR2
-/-
 129/Sv mice. All results are expressed as means ± SEM. *p<0.05
(one-way ANOVA followed by Dunnett’s post hoc test). 
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4.1.3.2. Effect of systemic administration of (±)-DOI (1 mg/kg) on extracellular DA and NE 
release in the frontal cortex in mGluR2
-/-
 and mGluR2
+/+
 129/Sv strain mice 
 
Dopamine 
As mentioned above (see 4.1.1.1. section), basal dialysate concentrations of DA, by pooling 
from different experiments, collected from five-six consecutive samples from the FC, did not 
differ across genotype:  1.637 ± 0.115 nM (n=99) in mGluR2+/+ mice and 1.799 ± 0.204 nM 
(n=71) in mGluR2-/- mice (t=0.738; p=0.461). 
 
As previously stated, (±)-DOI (1 mg/kg i.p.) was able to reduce extracellular DA output in the FC 
of 129/Sv wild-type mice (Emax=-26 ± 3%) (Figure 69). Their mGluR2 knock-out counterparts 
seemed to display the same inhibitory pattern, exerting a significant inhibitory response when 
compared to saline administration (Fi[11, 157]=2.881; p<0.01) (Emax=-21 ± 7%). Two-way 
repeated measures ANOVA failed to reach significant interaction in the response to (±)-DOI 
between genotypes over time (Fi[11, 198)=0.725; p=0.714) (Figure 85). 
 
 
 
 
 
 
 
 
 
 
 
 
When analyzed the magnitude of the effects induced by systemic administration of (±)-DOI, a 
decrease in DA outflow in the FC in both genotypes, compared to the respective vehicle-
treated groups, was observed (AUC mean=-3043 ± 642 in (±)-DOI-treated mGluR2+/+; AUC 
mean=-1773 ± 952 in (±)-DOI-treated mGluR2-/-). Two-way ANOVA only showed that (±)-DOI 
Fig. 85- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
DA concentrations in mGluR2
+/+
 ( n=7,  n=10) and in mGluR2
-/-
 ( n=9,  n=10) 129/Sv mice. 
The arrow indicates the time of drug injection. Data are means ± SEM of DA expressed as a 
percentage of basal values (100%).  
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was exerting an inhibitory effect, compared to vehicle (Ftreatment[1, 32]=14.19; p<0.001). 
However, the effect was similar between genotypes (Fi[1, 32]=0.38; p=0.540) (Figure 86). 
 
 
 
 
 
 
 
 
 
 
 
 
Norepinephrine 
As mentioned above (see 4.1.1.1. section), pre-drug basal concentrations of extracellular NE in 
the FC under CSF infusion, by pooling dialysates from various experiments, were significantly 
higher in mGluR2-/- mice when compared to mGluR2+/+ group: 1.420 ± 0.065 nM (n=125) versus 
1.690 ± 0.106 nM (n=77) (t=2.302; p<0.05). Intra-cortical CSF infusion did not alter cortical 
extracellular NE concentrations in either genotype. 
 
As previously shown, acute administration of (±)-DOI (1 mg/kg i.p.) triggered an inhibitory 
effect, reducing the extracellular NE release noticeably in wild-type mice (Emax=-26 ± 4%) 
(Figure 70) (Fi[11, 231]=4.466; p<0.0001). 
 
Acute intraperitoneal dose of (±)-DOI (1 mg/kg), dissolved in saline as vehicle, also evoked a 
statistically significant inhibition of extracellular NE output in the FC of mGluR2-/- mice 
(Emax=-21 ± 6%) (Fi[11, 242]=2.125; p<0.05) (Figure 87). There were no differences between 
genotypes in the effect of (±)-DOI administration, as assessed by ANOVA analysis (Fi[11, 
275]=1.176; p=0.304). 
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Fig. 86- Cortical DA AUC values after drug injection. Effect of intraperitoneal administration of 
saline or (±)-DOI (1 mg/kg i.p.) on cortical dopaminergic modulation in mGluR2
+/+
 ( n=7, 
 n=10) and in mGluR2
-/-
 mice ( n=9,  n=10). All results are expressed as means ± SEM. 
*p<0.05, **p<0.01 (two-way ANOVA followed by LSD’s post-hoc test). 
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Regarding the magnitude of the effects displayed after saline or (±)-DOI injection, AUC values 
showed that there was an inhibitory effect in NE release subsequently to (±)-DOI 
administration (Ftreatment[1, 43]=14.78; p<0.001), but the magnitude was not 
genotype-dependent (AUC mean=-2458 ± 638 in mGluR2+/+, AUC mean=-2132 ± 757 in 
mGluR2-/-) (Fi[1, 43]=0.12; p=0.728) (Figure 88). 
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Fig. 87- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
NE concentrations in mGluR2
+/+
 ( n=10,  n=13) and in mGluR2
-/-
 ( n=10,  n=14) 129/Sv mice. 
The arrow indicates the time of drug injection. Data are means ± SEM of NE expressed as a 
percentage of basal values (100%). 
Fig. 88- Cortical NE AUC values after drug injection. Effect of intraperitoneal administration of 
saline or (±)-DOI (1 mg/kg i.p.) on cortical noradrenergic modulation in mGluR2+/+ ( n=10, 
 n=13) and in mGluR2
-/- 
mice ( n=10,  n=14). All results are expressed as means ± SEM. 
*p<0.05, **p<0.01 (two-way ANOVA followed by LSD’s post hoc test). 
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4.2. FUNCTIONAL REGULATION OF CORTICAL NE RELEASE BY 5-HT2A/2C RECEPTORS. 
NEUROCHEMICAL PATHWAYS EVALUATION BY IN VIVO MICRODIALYSIS IN AWAKE, 
FREELY MOVING RATS  
Subsequent microdialysis studies were carried out in order to elucidate the pathways involved 
in the noradrenergic modulation exerted by (±)-DOI. As shown above, (±)-DOI evoked opposite 
noradrenergic responses in mouse frontal cortex after intra-cortical or systemic 
administration. A noradrenergic stimulation can be seen after intra-cortical administration of 
(±)-DOI, whereas no effect or an inhibitory response can be noted after its systemic 
administration in C57BL/6 or 129/Sv strain mice, respectively. 
 
The LC is the major source of NE in the CNS and is widely known that there are projections 
arising from LC to the FC. In this regard, the implantation of two probes - one in the LC and the 
other one in the FC - allowed us to evaluate NE modulation in somatodedritic and terminal 
noradrenergic areas. LC in mouse brain is too tiny to ensure the dialysis in that specific area, 
and the overall brain size is not big enough to lodge two probes at the same time. Therefore, 
we decided to perform the study in rats.  
 
Dual-probe microdialysis experiments were undertook without the presence of desipramine 
dissolved in the CSF. Basal extracellular NE concentrations are higher in rats than in mice and 
enough to detect them by HPLC. Moreover, these dialysates were measured using a very 
sensitive Ultra-High Performance Liquid Chromatography (UHPLC) equipment. 
 
4.2.1. Effect of cortical infusion of the 5-HT2A/2C receptor agonist (±)-DOI on 
extracellular NE output in frontal cortex and locus coeruleus 
Basal extracellular NE concentrations, obtained by pooling the basal values of the different 
experimental groups, were substantially higher in the LC (0.299 ± 0.04 nM, n=30) than in the 
FC (0.140 ± 0.02 nM, n=30) (t=3.554; p<0.001). 
 
We characterized the cortical noradrenergic effect after intra-cortical (±)-DOI administration 
(300 µM) in rats. CSF infused as vehicle did not exert any effect. As previously shown in mice 
(Figures 40 and 41), the cortical infusion of the 5-HT2A/2C receptor agonist increased 
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extracellular NE release in the FC (Emax=376 ± 39%) (Figure 89). Two-way repeated measures 
ANOVA revealed a statistically significant stimulatory effect over time when compared to 
vehicle group (Fi[10, 40]=14.07; p<0.001). 
 
Conversely, no modulation in NE efflux was experience in the LC after intra-cortical infusion of 
(±)-DOI (300 µM). Repeated measures two-way ANOVA failed to reach significance over time, 
when compared to vehicle-treated group (Fi[10, 130]=0.492; p=0.892) (Figure 90). 
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Fig. 89- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular 
concentrations of NE in rat FC ( n=4,  n=12). Data are means ± SEM of NE expressed as a 
percentage of basal values (100%). The line shows the period of drug application. **p<0.01, 
***p<0.001 versus vehicle-treated group (two-way repeated measures ANOVA followed by 
Bonferroni’s post hoc test). 
Fig. 90- Effect of cortical administration of VEH or (±)-DOI (300 µM) on extracellular NE
concentrations in rat LC ( n=4,  n=11). Data are means ± SEM of NE expressed as a percentage 
of basal values (100%). The line shows the period of drug application.  
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4.2.2. Effect of systemic administration of the 5-HT2A/2C receptor agonist (±)-DOI on 
extracellular NE output in frontal cortex and locus coeruleus 
Saline injection did not modify extracellular NE concentrations neither in the FC, nor in the LC. 
Acute administration of (±)-DOI (1 mg/kg i.p.) elicited a significant decrease of NE release in 
the FC (Emax=-28 ± 7%), reaching the maximal inhibition value 175 minutes after injection. 
Extracellular NE concentrations returned to basal values at the end of the procedure (Figure 
91). Repeated measures two-way ANOVA showed a significant interaction in the noradrenergic 
modulation between vehicle-treated group and (±)-DOI-treated group over time (Fi[9, 
117]=4.283; p<0.001).  
 
On the contrary, right after (±)-DOI injection, a high noradrenergic stimulation was elicited in 
the LC (Emax=234 ± 24%) (Figure 92). Statistically significant differences were found by two-way 
repeated measures ANOVA analysis compared to the saline group (Fi[9, 126]=9.539; p<0.0001). 
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Fig. 91- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on cortical extracellular 
NE concentrations in rat ( n=7,  n=8). The arrow indicates the time of drug injection. Data are 
means ± SEM of NE expressed as a percentage of basal values (100%). *p<0.05, **p<0.01, versus
vehicle-treated group (two-way repeated measures ANOVA followed by Bonferroni’s post hoc 
test). 
I. Mollinedo Gajate 
 
160 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3. Effect of intra-locus coeruleus infusion of the 5-HT2A/2C receptor agonist 
(±)-DOI on extracellular NE output in locus coeruleus and frontal cortex 
As a decrease in extracellular NE efflux in the FC, and an increase in the LC were observed after 
a systemic administration of (±)-DOI, the stimulation occurring in the LC could be responsible 
for the decrease in the FC. To address this hypothesis, two increasing doses were locally 
perfused in the LC, and extracellular NE modulations were simultaneously analyzed in both 
areas. 
 
At the lowest dose (100 µM), local administration of (±)-DOI displayed a trend to increase 
extracellular NE output in the LC (Emax=192 ± 21%). This stimulation did not reach statistical 
significance.  On the other hand, extracellular NE concentrations were gradually decreasing in 
the FC versus basal values, reaching statistical significance 210 minutes after the (±)-DOI 
infusion (Emax=-56 ± 3%) (p<0.01) (Figure 93 and 94). The highest dose (300 µM) of (±)-DOI 
evoked a greater extracellular NE release in the LC (Emax=278 ± 58%), following by a dramatic 
fall in NE efflux in the FC (Emax=-89 ± 3%) (Figure 93 and 94). Statistically significant effects were 
shown by two-way repeated measures ANOVA analysis in both areas when compared to 
vehicle perfusion (Fi[13, 78]=7.486; p<0.0001, in LC; Fi[13, 65]=14.77; p<0.001, in FC). 
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Fig. 92- Effect of systemic administration of VEH or (±)-DOI (1 mg/kg i.p.) on extracellular NE
concentrations in the rat LC ( n=7,  n=9). The arrow indicates the time of drug injection. Data 
are means ± SEM of NE expressed as a percentage of basal values (100%). ***p<0.001, versus
vehicle-treated group (two-way repeated measures ANOVA followed by Bonferroni’s post hoc 
test). 
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Additionally, the existence of a linear correlation between extracellular NE concentrations in 
the LC and the FC of the same rats was also evaluated (Figure 95). A significant negative 
correlation was observed between both areas (p<0.05, r=-0.508, n=21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 93- Effect of intra-LC administration of VEH or (±)-DOI (100 and 300 µM) on extracellular 
concentrations of NE in rat LC ( n=4,  n=4). Data are means ± SEM of NE expressed as a 
percentage of basal values (100%). The lines show the period of drug application. *p<0.05, 
**p<0.01, ***p<0.001 versus vehicle-treated group (two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test). 
Fig. 94- Effect of intra-LC administration of VEH or (±)-DOI (100 and 300 µM) on extracellular 
concentrations of NE in rat FC ( n=4,  n=3). Data are means ± SEM of NE expressed as a 
percentage of basal values (100%). The lines show the period of drug application. ***p<0.001
versus vehicle-treated group (two-way repeated measures ANOVA followed by Bonferroni’s post 
hoc test). 
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4.2.4. α2-Adrenoceptors in the modulation of NE by (±)-DOI  
As stated above, FC is an area innervated by noradrenergic projections arising from the LC. 
Presynaptic α2-adrenoceptors are located on noradrenergic nerve terminals as well as on cell 
bodies and dendrites of the LC neurons. It has been previously demonstrated that 
somatodendritic α2-adrenoceptors in the LC exert an inhibitory tonic modulation on NE release 
in noradrenergic terminal areas (Fernández-Pastor & Meana, 2002) and on the firing activity of 
noradrenergic neurons in the LC (Mateo et al., 1998). The presence of the α2-adrenoceptor 
antagonist RX821002 (1 µM) into the LC, despite not altering extracellular NE concentrations, 
is able to abolish the inhibition of NE release in FC subsequent to the increased NE release 
occurred in LC (Mateo et al., 1998). 
 
In this regard, we sought to elucidate the influence of somatodendritic α2-adrenoceptors 
located in the LC in the cortical inhibition of NE release induced by systemic administration of 
(±)-DOI (Figure 91 and 92). 
 
Vehicle-treated group displayed absolute NE basal values of 0.121 ± 0.030 nM (n=5) in FC and 
0.277 ± 0.091 nM (n=8) in LC. In the presence of RX821002 (1 µM) locally into the LC, basal 
Fig. 95- Correlation between extracellular NE concentrations in rat LC and FC, following the local 
administration of (±)-DOI (100-300 µM) into the LC. Each point represents the percentage of NE 
baseline values obtained in the same animal, from samples collected every 35 minutes (n=3).
The regression equation was y=80.74-0.17x. 
100 200 300 400 500
0
50
100
150
NE in LC (% of baseline)
N
E 
in
 
FC
 
(%
 
o
f b
as
e
lin
e
)
Results 
 
163 
 
values were 0.450 ± 0.065 nM (n=5) in FC and 0.355 ± 0.041 nM in LC (n=9). There were no 
significant differences between groups. 
 
As shown in Figure 96, the presence of RX821002 (1 µM) in the LC blocked the (±)-DOI-induced 
NE decrease in the FC. Indeed, a stimulatory effect in that area was found (Emax=156 ± 19%). 
Two-way repeated measures ANOVA  comparing (±)-DOI versus RX821002+(±)-DOI groups over 
time, revealed statistically significant differences (Fi[9, 126]=5.437; p<0.0001). 
 
In LC, (±)-DOI injection significantly induced a rise in NE efflux in the group with RX821002 
(1 µM) (Emax=210 ± 26%). However the maximal value, magnitude and duration of the effect 
were lower compared to the group where only CSF was perfused. Two-way repeated measures 
ANOVA revealed a significant interaction between drug group - (±)-DOI versus 
RX821002+(±)-DOI - over time (Fi[9, 144]=3.270; p<0.01) (Figure 97). 
 
Figure 98 and 99 represents AUC values in FC and LC triggered by the administration of saline, 
(±)-DOI (1 mg/kg i.p.) alone, or (±)-DOI (1 mg/kg i.p.) with previous and continuous infusion of 
RX821002 (1 µM) into the LC. There were statistically significant differences in the responses 
exerted by treatments in both areas (Fi[2, 20]=44.61; p<0.0001 in FC; Fi[2, 22]=8.544; p<0.01 in 
LC; one-way ANOVA). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 96- Effect of the perfusion of RX821002 (1 µM) into the LC, on the (±)-DOI-induced 
extracellular NE variations in rat FC ( n=7,  n=8,  n=8). The arrow indicates the time of drug 
injection. Data are means ± SEM of NE expressed as a percentage of basal values (100%). 
*p<0.05, ***p<0.001 versus (±)-DOI-treated group (two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test). 
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Fig. 97- Effect of the perfusion of RX821002 (1 µM) into the LC, on the (±)-DOI-induced 
extracellular NE variations in rat LC ( n=7,  n=9,  n=9). The arrow indicates the time of drug 
injection. Data are means ± SEM of NE expressed as a percentage of basal values (100%). 
*p<0.05, **p<0.01 versus (±)-DOI-treated group (two-way repeated measures ANOVA followed 
by Bonferroni’s post hoc test). 
Fig. 98- NE AUC values after drug injection in rat 
FC. Effect of intraperitoneal administration of 
saline, (±)-DOI (1 mg/kg i.p.) alone or in continuous 
presence of RX821002 (1 µM) in the LC ( n=7, 
 n=8,  n=8). All results are expressed as means ± 
SEM. **p<0.01, ***p<0.001 (one-way ANOVA 
followed by Bonferroni’s post hoc test). 
Fig. 99- NE AUC values after drug injection in rat LC. 
Effect of intraperitoneal administration of saline, 
(±)-DOI (1 mg/kg i.p.) alone or in continuous 
presence of RX821002 (1 µM) in the LC ( n=7, 
 n=9,  n=9). All results are expressed as means ± 
SEM. **p<0.01 (one-way ANOVA followed by 
Bonferroni’s post hoc test). 
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4.2.5. Effect of intra-locus coeruleus infusion of the glutamate receptor antagonist 
kynurenic acid on NE release response to systemic administration of (±)-DOI in locus 
coeruleus and frontal cortex 
The receptors implicated in the (±)-DOI-induced increase in NE output in the LC after acute 
administration remained to be clarified. In an effort to elucidate the role of glutamartergic 
excitatory inputs arising from other areas to the LC, kynurenic acid (KYN) was perfused into the 
LC. KYN is a metabolite physiologically present in the CSF at nanomolar concentrations. It 
displays a broad spectrum of action as a glutamatergic antagonist, being able to block the 
glutamate receptors NMDA and AMPA, among others (Moroni et al., 2012).  
 
In this section, kynurenic acid (1 mM) was perfused into the LC from the beginning of the 
experiment. Following the collection of 3 basal samples, (±)-DOI was intraperitoneally injected 
(1 mg/kg). 
 
The administration of kynurenic acid (1 mM) into the LC did not modify basal NE 
concentrations in the FC (0.217 ± 0.06 nM, n=4 in CSF group; 0.134 ± 0.02 nM, n=9 in KYN 
group; t=1.526; p=0.155). Interestingly, KYN induced a markedly decrease of extracellular NE 
concentrations in the LC (0.599 ± 0.11 nM, n=5 in CSF group; 0.048 ± 0.01 nM n=10 in KYN 
group; t=7.382; p<0.001). 
 
Systemic administration of (±)-DOI in the continuous presence of KYN in the LC evoked a 
stimulatory effect of NE release in FC 35 minutes after (±)-DOI administration (likely due to 
handling stress), followed by a gradual decrease in NE release (Emax=66 ± 14%) (Figure 100). 
Two-way repeated measures ANOVA indicated a significant interaction (±)-DOI versus KYN + 
(±)-DOI over time (Fi[9, 99]=2.351; p<0.05). 
 
As Figure 101 shows, KYN did not blunt the stimulatory effect of (±)-DOI seen in LC, exerting 
again a rise in NE efflux in LC (Emax=251 ± 25%). No statistical differences between (±)-DOI and 
KYN + (±)-DOI responses over time were found by analysis with two-way repeated measures 
ANOVA (Fi[9, 126]=1.634; p=0.112).  
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Fig. 100- Effect of the perfusion of kynurenic acid (KYN, 1 mM) into the LC, on the systemic 
(±)-DOI-induced extracellular NE variations in rat FC ( n=7,  n=8,  n=5). The arrow indicates 
the time of drug injection. Data are means ± SEM of NE expressed as a percentage of basal 
values (100%).  
Fig. 101- Effect of the perfusion of kynurenic acid (KYN, 1 mM) into the LC, on the systemic 
(±)-DOI-induced extracellular NE variations in rat LC ( n=7,  n=9,  n=7). The arrow indicates 
the time of drug injection. Data are means ± SEM of NE expressed as a percentage of basal 
values (100%).  
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4.2.6. Effect of intra-locus coeruleus infusion of the glutamate receptor antagonist 
kynurenic acid on the response of NE release exerted by local administration of (±)-
DOI into the frontal cortex 
In order to assess the existence on an indirect loop (FC  LC  FC) responsible for the increase 
of extracellular NE release in the FC after the intra-cortical administration of (±)-DOI, the 
glutamatergic antagonist was perfused into the LC.  
 
As mentioned in 4.2.5. section, KYN in LC (1 mM) did not modify basal NE concentrations in the 
FC (0.217 ± 0.06 nM, n=4 in CSF group versus 0.134 ± 0.02 nM, n=9 in KYN group; t=1.526; 
p=0.155). In contrast, KYN induced a markedly decrease of extracellular NE concentrations in 
the LC (0.599 ± 0.11 nM, n=5 in CSF group versus 0.048 ± 0.01 nM n=10 in KYN group; t=7.382; 
p<0.001). 
 
The continuous perfusion of KYN (1 mM) in LC not only failed to antagonize the cortical 
stimulation mediated by (±)-DOI (300 µM in FC), but also enhanced that stimulation (Emax=500 
± 70%) (Figure 102). Two-way repeated measures ANOVA showed a statistically significant 
interaction between treatments - (±)-DOI alone, or KYN + (±)-DOI - over time (Fi[10, 
140]=3.295; p<0.001). 
 
The intra-LC infusion of KYN was not able to alter the response of extracellular NE 
concentrations in LC by (±)-DOI administration in the FC (Figure 103). Hence, no significant 
interactions were found regarding treatment and time (Fi[10, 120]=0.410; p=0.940). 
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Fig. 102- Effect of the perfusion of kynurenic acid (KYN, 1 mM) into the LC on the intra-cortical 
(±)-DOI-induced extracellular NE variations in rat FC ( n=4,  n=12,  n=4). Data are means ± 
SEM of NE expressed as a percentage of basal values (100%). The line shows the period of drug 
application. **p<0.01 versus (±)-DOI-treated group (two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test). 
 
Fig. 103- Effect of the perfusion of kynurenic acid (KYN, 1 mM) into the LC on the intra-cortical 
(±)-DOI-induced extracellular NE variations in rat LC ( n=4,  n=11,  n=3). Data are means ± 
SEM of NE expressed as a percentage of basal values (100%). The line shows the period of drug 
application.  
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4.2.7. Effect of cortical infusion of the glutamate receptor antagonist kynurenic acid 
on the response of NE release exerted by local administration of (±)-DOI into the 
frontal cortex 
Martín-Ruiz and co-workers (2001) raised the hypothesis that local administration of (±)-DOI 
could increase the 5-HT release in FC indirectly, through the stimulation of glutamate release 
and subsequent activation of AMPA-KA receptors. In order to asses if in the case of NE 
regulation, (±)-DOI proceeds the same way as for 5-HT, the non-selective glutamatergic 
antagonist KYN (1 mM) was locally administered into the FC from the beginning of the 
experiment. 
 
KYN perfused into FC did not alter basal NE concentrations in FC (0.217 ± 0.06 nM, n=4 in CSF 
group versus 0.160 ± 0.05 nM, n=6 in KYN group; t=0.712; p=0.496). Likewise, in LC no changes 
in baseline NE values derived from to KYN infusion were observed (0.599 ± 0.11 nM, n=5 in CSF 
group versus 0.678 ± 0.12 nM, n=5 in KYN group; t=0.489; p=0.638). 
 
Intra-cortical infusion of KYN impaired the NE stimulation evoked by local administration of 
(±)-DOI (300 µM) in the FC, shown in Figure 89, to a maximal effect of 257 ± 51% (Figure 104). 
Two-way repeated measures ANOVA highlighted a statistically significant interaction 
treatment x time between (±)-DOI and KYN + (±)-DOI groups (Fi[10, 170]=4.036; p<0.0001), and 
between CSF and KYN + (±)-DOI groups (Fi[10, 90]=4.310; p<0.0001). 
 
Conversely, no modifications in NE efflux were observed in the LC (Figure 105). Two-way 
repeated measures ANOVA revealed non-significant differences between treatments over time 
(Fi[10, 150]=0.866; p=0.567). 
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Fig. 104- Effect of the perfusion of kynurenic acid (KYN, 1 mM) into the FC on the intra-cortical 
(±)-DOI-induced extracellular NE variations in rat FC ( n=4,  n=12,  n=4). Data are means ± 
SEM of NE expressed as a percentage of basal values (100%). The line shows the period of drug 
application. ***p<0.001 versus (±)-DOI-treated group (two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test). 
Fig. 105- Effect of the perfusion of kynurenic acid (KYN, 1 mM) into the FC on the intra-cortical 
(±)-DOI-induced extracellular NE variations in rat LC ( n=4,  n=11,  n=3). Data are means ± 
SEM of NE expressed as a percentage of basal values (100%). The line shows the period of drug 
application. 
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4.3. DETERMINATION OF THE TYPE OF G-PROTEIN SUBTYPE INVOLVED IN 
THE HALLUCINOGENIC-LIKE BEHAVIOR AND TEMPERATURE VARIATION 
INDUCED BY (±)-DOI IN MICE  
4.3.1. Evaluation of the optimal dose of (±)-DOI to induce a head-twitch response in 
129/Sv mice 
In order to determine the efficacy of (±)-DOI (i.p.) to induce a head-twitch response, as well as 
to establish the optimal dose to trigger the maximal number of head-shakes, a dose-effect trial 
was carried out. 129/Sv mice were subjected to intraperitoneal (±)-DOI injections at doses of 
0.5 mg/kg and 1 mg/kg. As illustrated in Figure 106, treatment with saline did not exert any 
response. In contrast, the maximal effect was achieved at a dose of 0.5 mg/kg (p<0.001). One-
way ANOVA showed a statistically significant effect of treatment (Fi[2, 15]=25.47; p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2. Role of 5-HT2A receptor in the head twitch response induced by (±)-DOI in 
C57B L/6 mice  
To confirm that (±)-DOI elicited head twitch response by acting through 5-HT2ARs, both 
C57BL/6 wild type and 5-HT2AR knock-out mice were intraperitoneally single-treated with 0.5 
Fig. 106- Head twitch response to (±)-DOI (0.5 mg/kg or 1 mg/kg i.p.) in 129/Sv mice ( n=6, 
 n=9,  n=3). Data are means ± SEM. *p<0.05, ***p<0.001 versus saline group (one-way 
ANOVA followed by Bonferroni’s post hoc test). 
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mg/kg of (±)-DOI. As Figure 107 shows, (±)-DOI was only able to induce a significant head 
twitch response in wild-type mice, while this response was absent in 5-HT2AR knock-out mice 
(t=11.28; p<0.0001). 
 
 
 
 
 
 
 
 
 
4.3.3. Role of mGluR2 in the head twitch response induced by (±)-DOI in 129/Sv mice 
As mentioned in the introduction, mGluR2 forms a functional heterocomplex with 5-HT2AR in 
human and mouse brain (González-Maeso et al., 2008). It has been demonstrated that such 
heterocomplex is necessary for the hallucinogenic properties derived from hallucinogenic 
5-HT2AR agonist drugs. The absence of mGluR2 has been reported to abolish the 
hallucinogenic-like response exerted by the 5-HT2A/2C receptors agonist (±)-DOI in mice 
(Moreno et al., 2011a; Moreno et al., 2012).  
To assess the involvement of mGluR2 in the (±)-DOI-induced hallucinogenic-like responses, 
HTR was scored in mGluR2+/+ and mGluR2-/- mice. Mice were intraperitoneally single-treated 
with saline or 0.5 mg/kg of (±)-DOI. As Figure 108 shows, (±)-DOI induced a significant head 
twitch response in wild-type animals, whereas the absence of mGluR2 blunted that response, 
as seen in mGluR2-/- mice. Two-way ANOVA revealed significant interaction genotype x 
treatment (Fi[1, 21]=28.62; p<0.0001). 
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Fig. 107- Head twitch response induced by (±)-DOI (0.5 mg/kg i.p.) in 5-HT2AR
+/+
 ( n=5) and 
5-HT2AR
-/-
 mice ( n=4). Data are means ± SEM. ***p<0.001 (Student’s t-test). 
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4.3.4. Effect of i.c.v.-administered PTX on 129/Sv mice weight variation 
PTX induces several systemic effects that include a constitutive stimulation of lipid degradation 
in adipose tissue. This biological response is frequently used to assess that treatment with this 
toxin is effectively working. Therefore, after the i.c.v. administration, weight was measured 
daily, and its variation was calculated using the following equation: 
    ∆Weight = Weightday n – Weightday 0 
PTX pre-treated animals displayed a marked weight loss the first days after the injection of the 
toxin (0.4 µg), particularly at the second day after PTX administration (Figure 109). Afterwards, 
animals gained weight gradually, although they never recovered the initial weight. Meanwhile, 
animals pre-treated with vehicle did not show that drastic weight reduction and displayed a 
more progressive and slighter weight loss curve that was not different from baseline values 
(Figure 109). Two-way repeated measures ANOVA revealed a significant difference in weight 
loss between animals pre-treated with toxin and vehicle (Fi[8, 184]=12.22; p<0.0001). 
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Fig. 108- Head twitch response induced by saline or (±)-DOI (0.5 mg/kg i.p.) in mGluR2
+/+
( n=7,  n=6) and mGluR2
 -/-
 mice ( n=5,  n=4). Data are means ± SEM. *p<0.05, 
***p<0.001 (two-way ANOVA followed by Bonferroni’s post hoc test). 
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4.3.5. Effect of i.c.v.-administered pertussis toxin on (±)-DOI-induced head twitch 
response in 129/Sv mice 
Based on weight loss, evaluation of HTR was decided to be performed two days after PTX 
administration. To evaluate whether pertussis toxin was capable of inhibiting the HTR in 
129/Sv mice, animals were intracerebroventricularly injected with 0.4 µg of the neurotoxin or 
its vehicle. Two days after PTX administration, 0.5 mg/kg of (±)-DOI was intraperitoneally 
administered and the HTR was scored. As Figure 110 shows, (±)-DOI evoked a significant 
increase in the number of head shakes in animals pre-treated with vehicle. Lower (roughly 50% 
of the response displayed in vehicle-pretreated group) but still significant increase HTR was 
displayed in those animals pre-treated with PTX. Therefore, two-way ANOVA showed that, 
despite (±)-DOI somehow elicited HTR in both pre-treated groups, there was a significant 
inhibition of head twitch behavior in those mice which were PTX administered (Fi[1, 20]=10.38; 
p<0.01). 
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Fig. 109- Daily weight variation compared to day 0, when vehicle ( n=12) or PTX ( n=13) were 
intracerebroventricularly injected. **p<0.01, ***p<0.001 versus vehicle group (two-way 
repeated measures ANOVA followed by Bonferroni’s post hoc test). 
Results 
 
175 
 
 
 
 
 
 
 
 
 
 
 
 
 
In an attempt to assess the time span of PTX inhibition over the HTR induced by (±)-DOI, a 
similar protocol was also followed at fourth, sixth, and eleventh day post-i.c.v. injection, with 
both PTX- and vehicle-pre-treated 129/Sv mice. Note that distinct animals were evaluated at 
these time points. Results of these experiments are represented in Figure 111.  
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Fig. 110- Head twitch response induced by saline or (±)-DOI (0.5 mg/kg i.p.) two days after pre-
treatment with vehicle ( n=6,  n=6) or with 0.4 µg of PTX ( n=6,   n=6). Data are means ± 
SEM. **p<0.01, ***p<0.001 (two-way ANOVA followed by Bonferroni’s post hoc test). 
Fig. 111- Head twitch response after (±)-DOI administration (0.5 mg/kg i.p.) 2, 4, 6 or 11 days 
after i.c.v. pre-treatment with vehicle (: n=6, n=10, n=6, n=2; respectively) or pertussis toxin
(: n=6, n=11, n=7, n=3; respectively). **p<0.01 (Student’s t-test versus vehicle). 
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4.3.6. Role of 5-HT2A receptor in the hyperthermia induced by (±)-DOI in C57BL/6 
mice  
Basal temperature value was 37.00 ± 0.09°C (n=18) in 5-HT2A+/+ mice and 37.28 ± 0.08°C 
(n=16) in 5-HT2A-/- mice. Knock-out mice presented slightly higher basal body-core 
temperature, compared to its wild-type littermates (t=2.350; p<0.05). 
 
Saline injections did not exert any change in body temperature. In contrast, 0.5 mg/kg of      
(±)-DOI induced a marked hyperthermia in wild-type mice (∆max=0.68 ± 0.11°C) that was not 
observed in 5-HT2AR-/- mice (Figure 112). Three-way repeated measures ANOVA revealed a 
statistically significant interaction between genotype x treatment x time (Fi[6, 180]=7.78; 
p<0.001) (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Num. df F-value p-value 
GENOTYPE 1 57.95 <0.0010 
TREATMENT 1 26.86 <0.0010 
TIME 6 12.9 <0.0010 
GENOTYPE:TREATMENT 1 20.15 <0.0010 
GENOTYPE:TIME 6 10.11 <0.0010 
TREATMENT:TIME 6 4.54 0.0003 
GENOTYPE:TREATMENT:TIME 6 7.78 <0.0010 
Residuals 180   
Table 3- Statistical values derived from the three-way repeated measures ANOVA of the VEH or (±)-DOI-induced 
temperature variation in 5-HT2AR
+/+
 and 5-HT2AR
-/-
 mice. 
Fig. 112- Time-course for the effects of saline or (±)-DOI (0.5 mg/kg i.p.) on rectal temperature in 
5-HT2AR
+/+
 ( n=7,  n=11) or 5-HT2AR
-/-
 ( n=7,  n=9) C57BL/6 mice. Values are expressed as 
mean temperature variation ± SEM of the mean of three basal temperatures. **p<0.01 versus
5-HT2AR
+/+
 saline-treated group; ##p<0.01 versus 5-HT2AR
-/-
 (±)-DOI-treated group (three-way 
repeated measures ANOVA followed by Bonferrroni’s post hoc test). 
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4.3.7. Effect of i.c.v. administration of PTX on the hyperthermia induced by (±)-DOI in 
C57BL/6 mice  
Saline injections did not alter body-core temperature. Intraperitoneal injection of the 
hallucinogen 5-HT2A/2C receptors agonist (±)-DOI (0.5 mg/kg i.p.) induced a substantial and 
similar increase in body temperature in both vehicle- or PTX-pre-treated mice (∆max=0.61 ± 
0.07°C, 0.56 ± 0.06°C, respectively) (Ftreatment[1, 48]=35.89; p<0.001) (Figure 113). Three-way 
repeated measures ANOVA showed non-significant differences between PTX or VEH 
pre-treatment, (±)-DOI or saline treatment, and time (Fi[6, 288]=0.34; p=0.914) (Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Num. df F-value p-value 
GENOTYPE 1 0.10 0.7592 
TREATMENT 1 35.89 <0.0010 
TIME 6 45.61 <0.0010 
GENOTYPE:TREATMENT 1 0.04 0.8439 
GENOTYPE:TIME 6 0.81 0.5667 
TREATMENT:TIME 6 20.42 <0.0010 
GENOTYPE:TREATMENT:TIME 6 0.34 0.9140 
Residuals 288   
Table 4- Statistical values derived from the three-way repeated measures ANOVA of the VEH or (±)-DOI-induced 
temperature variation in vehicle-pretreated and PTX-pretreated mice. 
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Fig. 113- Time-course for the effects of saline or (±)-DOI (0.5 mg/kg i.p.) on rectal temperature in 
vehicle-pre-treated ( n=10,  n=16) or PTX-pre-treated ( n=9,  n=17) C57BL/6 mice. Values 
are expressed as mean temperature variation ± SEM of the mean of three basal temperatures. 
**p<0.01 vehicle-pre-treated (±)-DOI versus saline; ##p<0.01 PTX-pre-treated (±)-DOI versus
saline (three-way repeated measures ANOVA followed by Bonferrroni’s post hoc test). 
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4.3.8. Implication of the mGluR2/5-HT2AR heterocomplex on (±)-DOI-induced 
hyperthermia  
mGluR2 is necessary for the behavioral effects induced by hallucinogenic 5-HT2A receptor 
agonists, accordingly to the activation of Gi subtype proteins (Moreno et al., 2011a). Data from 
4.3.7. section, seem to suggest that (±)-DOI-induced hyperthermia is not elicited through Gi 
proteins. In order to double check whether Gi proteins were involved in this response, wild-
type 129/Sv and mGluR2 knock-out mice were injected (±)-DOI (0.5 mg/kg i.p.) and rectal 
temperature was monitored. 
 
No differences in basal body temperature were found between genotypes (37.80 ± 0.22°C in 
mGluR2+/+ mice, 37.66 ± 0.09°C in mGluR2-/- mice; t=0.562; p=0.58). Intraperitoneal injection of 
(±)-DOI induced marked hyperthermia in both mGluR2+/+ (∆max=0.850 ± 0.32°C) and mGluR2
-/- 
mice (∆max=0.856 ± 0.15°C) (Ftreatment[1, 147]=21.83; p<0.0001) (Figure 114). Three-way 
repeated measures ANOVA revealed no statistically significant differences between genotype x 
treatment x time (Fi[6, 147]=0.09; p=0.997) (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 114- Time-course for the effects of saline or (±)-DOI (0.5 mg/kg i.p.) on rectal temperature in 
mGluR2
+/+
 ( n=7,  n=6) or mGluR2
-/-
 ( n=5,  n=7) 129/Sv mice. Values are expressed as 
mean temperature variation ± SEM of the mean of three basal temperatures. **p<0.01
mGluR2
+/+
 (±)-DOI versus saline; ##p<0.01 mGluR2
-/-
 (±)-DOI versus saline (three-way repeated 
measures ANOVA followed by Bonferrroni’s post hoc test). 
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 Num. df F-value p-value 
GENOTYPE 1 0.18 0.6684 
TREATMENT 1 21.83 <0.0010 
TIME 6 9.29 <0.0010 
GENOTYPE:TREATMENT 1 0.11 0.7444 
GENOTYPE:TIME 6 0.20 0.9753 
TREATMENT:TIME 6 4.06 0.0008 
GENOTYPE:TREATMENT:TIME 6 0.09 0.9970 
Residuals 147   
Table 5- Statistical values derived from the three-way repeated measures ANOVA of the VEH or (±)-DOI-induced 
temperature variation in mGluR2
+/+
 and mGluR2
-/-
 mice. 
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Despite much research has been undertaken to develop new antipsychotic drugs for treating 
effectively the intrinsic positive, negative and cognitive impairments characteristic of 
schizophrenia, none of the medications currently available on the market has stood out for its 
long-lasting marked efficacy without detrimental side effects. This is partially due to the poorly 
understood neurobiology of schizophrenia. 
 
Animal models have become important tools for investigating the aetiology and 
pathophysiology of schizophrenia, and enable progress towards the development of effective 
therapeutic targets for its treatment. The main obstacle in modeling psychiatric disorders has 
been the limited information about their origin and underlying neural mechanisms. Recently, 
due to the rapid growing knowledge about the neurobiology and genetics of these disorders, 
animal models of these diseases are gaining popularity in psychiatric research. New models of 
schizophrenia mimic biological phenomena associated with the clinical condition, particularly 
developmental changes in the cortex, abnormalities of catecholamines neurotransmission, and 
genetic characteristics of selected behavioral traits. The FC plays a crucial role in working 
memory, attention, decision making, sensorimotor gating, and impulse control, all of them 
features impaired in schizophrenia. Those higher-order brain functions performed by the FC 
are supposed to rely on rhythmic electrical activity generated by neural network oscillations 
determined by an excitation and inhibition balance resulting from the recurrent excitation, and 
feedback and feedforward inhibition. The altered cortical functions seen in schizophrenics are 
in part due to neurotransmission pathways disruption. Among the neurotransmitter pathways, 
monoamine systems represent precise modulators of cortical activity, and dysfunctions of 
these systems have been associated with the pathophysiology of schizophrenia. DA, NE and 
5-HT release in the FC are dependent on firing activity of brainstem nuclei but also are under 
local control of axon terminal activities. Previous literature suggests that 5-HT2ARs are able to 
modulate monoamine release in FC (Gobert & Millan, 1999; Pehek et al., 2001; Bortolozzi et 
al., 2003; Bortolozzi et al., 2005; Pehek et al., 2006). This fact makes the use of changes in 
extracellular monoamine concentrations after 5-HT2AR stimulation or inhibition as a functional 
indicator of this receptor activity. 
 
 5-HT2ARs are key players in hallucinations and represent the main target of atypical 
antipsychotic drugs. On the other hand, activation of mGluR2 evokes antipsychotic-related 
phenotypes in preclinical models of schizophrenia (Moghaddam & Adams, 1998; Patil et al., 
2007; Lavreysen et al., 2015). It has been convincingly demonstrated that 5-HT2AR is 
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assembled with mGluR2 in humans and rodents FC, forming a heteromer. Neuroanatomical, 
biophysical, genetic, epigenetic and cellular trafficking assays have demonstrated that both 
receptors co-localize and crosstalk in layer V mouse cortical pyramidal neurons, specifically at a 
postsynaptic level (González-Maeso et al., 2008; Fribourg et al., 2011; Kurita et al., 2012; 
Moreno et al., 2012; Moreno et al., 2016). Cellular trafficking assays have confirmed the 
crosstalk between both receptors, and the activation of 5-HT2AR signaling pathways distinct 
from those induced by the monomeric structure, potentially implicated in hallucinogenic 
effects (González-Maeso et al., 2008; Fribourg et al., 2011; Moreno et al., 2011a; Moreno et 
al., 2016). Moreover, behavioral studies also confirm that the presence of mGluR2 in the FC 
and the subsequent crosstalk with 5-HT2AR seems to be necessary for the hallucinogenic 
responses evoked by psychedelic 5-HT2AR agonist drugs in mice (Moreno et al., 2011a; 
Moreno et al., 2012).  
 
Although such crosstalk has been extensively studied over the past few years from different 
biological levels, the existence of in vivo functional information about the effect of this 
heterocomplex on cortical catecholamine release regulation by the heterocomplex is still 
unknown. Therefore, the hallucinogenic 5-HT2AR agonist drug (±)-DOI was administered to 
rodents in order to elicit hallucinogenic states that resemble symptoms seen in schizophrenia, 
as well as to gain insight into the neurochemical effects triggered by this drug in the FC and LC. 
The involvement of the functional role of 5-HT2AR/mGluR2 heterocomplex in such responses 
was further evaluated using mGluR2- and 5-HT2AR-null mice. DA and NE release was 
quantified in the FC, which have been reported to be altered in schizophrenia and 
hallucinations. The NE pathways underlying (±)-DOI responses were further studied.  
 
Within this context, the results compiled in the present work could provide new insights for 
the better understanding of pharmacological mechanisms, neurotransmission alterations, as 
well as circuits involved in hallucinations, and point to new targets for future antipsychotic 
treatments. 
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5.1. EFFECT OF THE CORTICAL ADMINISTRATION OF (±)-DOI ON THE 
CATECHOLAMINE RELEASE IN THE FRONTAL CORTEX  
 
5.1.1. Cortical (±)-DOI-induced DA release is mediated by 5-HT2ARs activation 
The present work found that intra-cortical infusion of the hallucinogenic 5-HT2A/2C receptors 
agonist (±)-DOI increased DA output in the FC (Figure 38 and 39, grayscale lines and bars), in 
good agreement with previous reports (Pehek et al., 2001; Bortolozzi et al., 2005). (±)-DOI acts 
preferentially as an agonist of 5-HT2AR, but also displays close affinity to 5-HT2CR (May et al., 
2003; Pigott et al., 2012). The (±)-DOI-induced DA output enhancement was apparently, at 
least in part, evoked via an activation of 5-HT2ARs in cortical areas, inasmuch as the 
co-perfusion with the selective 5-HT2AR antagonist M100907 throughout the entire 
experiment was able to significantly attenuate such increase (Figure 43 and 45). However, the 
response was not fully abolished, but a remaining effect was still visible. To further ascertain 
the involvement of 5-HT2ARs in the (±)-DOI-induced DA release, the same procedure was 
repeated in 5-HT2AR-/- mice and their corresponding wild-type control littermates. 5-HT2AR+/+ 
animals displayed a substantially higher stimulatory effect, when compared to 5-HT2AR-/- mice 
(Figure 65 and 66), suggesting that the majority of the stimulation elicited by (±)-DOI is 
mediated by 5-HT2AR activation. 
 
It should be noted that in the latter two cases - wild-type animals in continuous presence of 
M100907, and 5-HT2AR-/- mice -, there was some remaining dopaminergic stimulatory effect, 
presumably 5-HT2AR-independent. It is unlikely that this remaining effect is a result of a 
hyperactivation of 5-HT2CRs in animals lacking 5-HT2ARs, since there are not altered 
compensatory changes in the 5-HT2CR mRNA or protein expression (Popa et al., 2005; 
Bortolozzi et al., 2010). The concentration of (±)-DOI used in the present work was chosen on 
the basis of a dose-effect study carried out by Bortolozzi and co-workers (2003), where the 
optimal concentration of (±)-DOI to elicit the greatest release of 5-HT in the FC was 300 µM. 
They also reported that co-administration with 300 µM M100907 fully blocked such 
stimulation. However, the assumption of an overestimated concentration of (±)-DOI used in 
this study, lacking to some extent selectivity for 5-HT2ARs, and therefore responsible for the 
remaining effect, cannot be ruled out. Indeed, a recent report has shown that (±)-DOI displays 
some affinity for certain additional receptors and transporters (Ray, 2010), which could be 
responsible for such remaining effect.  
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It has been described that the expression and activation of 5-HT2AR in the cortex is enough to 
induce hallucinogenic-specific behavioral and signaling effects (Willins & Meltzer, 1997; 
González-Maeso et al., 2007). As pointed out in the introduction, the two major cell types in 
the FC are glutamate-containing pyramidal neurons and GABAergic interneurons. Pyramidal 
neurons represent approximately 70-80% of the neurons in the cortex, while the remaining 
20-30% are mostly inhibitory interneurons (Markram et al., 2004; Espuny-Camacho et al., 
2013). 5-HT2AR and 5-HT2CR can downstream stimulate PLC, via Gq/11 subtype protein 
activation (Garcia et al., 2007). Nonetheless, both receptors display opposite behavioral and 
neurochemical effects within the medial FC (Alex & Pehek, 2007). In the FC, 5-HT2ARs are 
primarily located on apical dendrites of glutamate-containing pyramidal neurons (López-
Giménez et al., 1997; Fiorica-Howells et al., 2002; Miner et al., 2003; Alex & Pehek, 2007), but 
can also be found on GABAergic interneurons, as well as the closely related 5-HT2CR (Willins et 
al., 1997; Jakab & Goldman-Rakic, 2000; Carr et al., 2002; Santana et al., 2004; Alex & Pehek, 
2007; Liu et al., 2007; Puig & Gulledge, 2011; Santana & Artigas, 2016). A small percentage of 
5-HT2CRs also co-localize with 5-HT2AR on pyramidal neurons (Nocjar et al., 2015). Thus, the 
activation of cortical 5-HT2AR/2C receptors leads to the pyramidal and GABAergic neurons 
excitation and c-fos expression in the FC (Zhai et al., 2003; Zhang et al., 2010), and 
subsequently increases glutamate and GABA output (Araneda & Andrade, 1991; Aghajanian & 
Marek, 1997; Abi-Saab et al., 1999; Aghajanian & Marek, 2000; Scruggs et al., 2003). 
Glutamatergic neurons can modulate DA release (Lodge, 2011) likely through serotonergic 
regulation (Puig & Gulledge, 2011; Meunier et al., 2017). GABA interneurons may regulate 
prefrontal DA release by the interaction with GABAA and GABAB receptors (Santiago et al., 
1993). It is unclear if the effect of (±)-DOI on GABAergic interneurons is direct or mediated by 
activation of pyramidal cell collaterals. Electrophysiological studies in the neocortex suggest 
that the major effect of serotonin is on pyramidal cells, via 5-HT2AR agonism (Aghajanian & 
Marek, 1997). However, in the piriform cortex, (±)-DOI directly depolarizes interneurons 
predominantly via 5-HT2AR (Marek & Aghajanian 1994).  
 
Taken together, as the FC is a region denser populated by excitatory pyramidal neurons than 
inhibitory GABAergic interneurons (Markram et al., 2004; Espuny-Camacho et al., 2013), and 
5-HT2ARs are present in both types of neurons but mostly on the former ones (Nocjar et al., 
2015), it is plausible that the overall effect evoked by (±)-DOI in the FC is an enhancement of 
DA release mediated by the activation of 5-HT2 receptors expressed on pyramidal neurons. 
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On the other hand, the merely intra-cortical perfusion of 300 µM M100907 dramatically 
decreased extracellular DA concentrations up to 65% (Figure 42, grayscale lines), reflecting a 
presumably tonic stimulatory 5-HT2AR-dependent effect of 5-HT on pyramidal neurons (Pehek 
et al., 2001).  
 
5.1.1.1. DA basal dialysate concentrations 
 
As described in the previous paragraph, DA baseline concentrations were reduced up to 57% 
with the cortical perfusion of M100907 in wild-type animals. Accordingly, 5-HT2AR-/- animals 
showed lower DA basal values than their wild-type counterparts. Previous research has also 
found lower baseline DA concentrations in 5-HT2AR-/- mice compared to their wild-type 
counterparts, although the difference did not reach significance (Bortolozzi et al., 2010). 
 
Since the administration of 5-HT2AR agonists enhances DA release in the FC, it would be 
conceivable that its blockade triggers the decrease of such release. These observations could 
indicate that 5-HT2AR may tonically activate DA release in the FC or VTA.  
 
5.1.1.2. Assessing the possible pathways involved in the (±)-DOI-induced effects 
 
The (±)-DOI-induced DA release in the FC after cortical perfusion may be explained by the 
activation of different long-loop or direct pathways: 
 
Indirect FC → VTA → FC loop: The activation of cortical 5-HT2ARs triggers the excitation of 
pyramidal cells and GABAergic interneurons in the FC (Araneda & Andrade, 1991; Aghajanian & 
Marek, 1997). Moreover, the activation of 5-HT2ARs on pyramidal neurons increases the firing 
rate of descending fibers projecting to the VTA, that may result in enhanced glutamate efflux 
in the latter area, which subsequently activates glutamate receptors on VTA DA mesocortical 
neurons projecting back to the FC (Pehek & Hernan, 2015), increases DA neural activity and 
induces DA release in VTA and FC (Murase et al., 1993; Overton & Clark, 1997; Bortolozzi et al., 
2005; Alex & Pehek, 2007). In support of this interpretation, the blockade of NMDA and AMPA 
receptors in the VTA blocks the (±)-DOI-induced DA efflux in the FC (Alex & Pehek, 2007). 
Electrical stimulation mimics such increase of DA release in FC, whilst the 5-HT2AR antagonist 
M100907 blocks these stimulatory effects (Bortolozzi et al., 2005). These findings reinforce the 
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existence of anatomical connections between the FC and VTA (Carr & Sesack, 2000; Sesack et 
al., 2003) that can be excited after the activation of 5-HT2ARs on cortical pyramidal cells (Puig 
et al., 2003), as well as the presence of DA fibers from the VTA projecting back to the FC 
(Sesack et al., 2003).  
 
Indirect FC → PPT → VTA → FC loop: Glutamate innervations of the VTA derive from two 
major inputs, the FC and the laterodorsal/pedunculopontine tegmentum (LDT/PPT). Both 
sources activate bursts in DA cells of the SN and VTA. The SN receives an additional glutamate 
input from the subthalamic nucleus, but whether there is an excitatory source for VTA is so far 
unknown (Sesack et al., 2003). Hence, more complex indirect pathways to explain the raise in 
cortical DA output cannot be excluded; for instance: FC → PPT → VTA → FC, or FC → NAcc → 
ventral pallidum → VTA → FC (Bortolozzi et al., 2005). Both pathways could be involved 
inasmuch as they have been proven to modulate DA neuron activity, via phasic and tonic 
inputs, respectively (Floresco et al., 2003).  
 
Direct FC pathway: Another plausible explanation restricted to a merely local stimulation 
would involve the presence of presynaptic 5-HT2ARs on cortical dopaminergic axon terminals, 
which would facilitate the release of DA from the storage vesicles. Miner and co-workers 
(2003) showed the presence of a small percentage of 5-HT2ARs on axon terminals of cortical 
monoaminergic inputs, and those appear not to be neither serotonergic nor noradrenergic, 
positing dopaminergic fibers as the main candidates. Furthermore, moderate mRNA 
expression for the 5-HT2AR has been shown in dopaminergic-rich areas of the rat midbrain 
(Pompeiano et al., 1994) including cells projecting to the FC (Berger et al., 1976).  
 
Alternatively, regulation by iGluRs in FC may be implicated, extending the outcomes observed 
in striatum. Presynaptic iGluRs are present on striatal dopaminergic nerve terminals. Activation 
of NMDA, kainate and AMPA receptors in synaptosomes by NMDA or non-NMDA agonists, 
evoke an increased release of DA. The endogenous transmitter glutamate could activate both 
NMDA and non-NMDA receptors, because its effect is partially blocked by both the NMDA and 
the AMPA/kainate receptors antagonists MK-801 or CNQX, respectively. NMDA or kainate 
receptor activation could increase Ca2+ influx and lead to transmitter release (Wang, 1991). 
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5.1.2. Cortical (±)-DOI-induced NE release is mediated by 5-HT2ARs activation 
Intra-cortical perfusion of (±)-DOI enhanced local NE release likely through a 5-HT2AR-
dependent mechanism (Figure 40 and 41, grayscale lines), since such effect was completely 
blunted in the local presence of M100907 (Figure 47 and 49). Supporting evidence was found 
when cortical perfusion of (±)-DOI in 5-HT2AR-/- mice failed to modulate NE output, while in 
wild-type animals a substantial NE release was yielded (Figure 52 and 53).  
 
Once again, intra-cortical perfusion of M100907 (300 µM) led to a slight inhibition of NE 
release (Emax=-13 %) in the FC (Figure 46, grayscale), potentially reflecting a tonic stimulatory 
effect of 5-HT, mediated by 5-HT2ARs on pyramidal neurons.  
 
5.1.2.1. NE basal dialysate concentrations 
 
In the same way as DA, the presence of M100907 (300 µM) slightly decreased extracellular 
basal NE concentrations, approximately 11% from baseline. On the other hand, NE baseline 
concentrations in 5-HT2AR-/- animals did not differ from those seen in 5-HT2AR+/+ control mice. 
That absence of changes might suggest that circuits regulating NE and DA release in the FC are 
distinct between them in response to M100907 administration. 
  
5.1.2.2. Assessing the possible pathways involved in the (±)-DOI-induced effects 
 
As there is little (if any) research into the cortical 5-HT2AR-induced NE output after (±)-DOI 
perfusion into the FC, we sought to investigate the noradrenergic pathways that could underlie 
such effects. The LC contains the majority of NE neurons in the brain. These neurons possess 
ramified axons that project to a broad array of areas, including the FC (Foote et al., 1983). In a 
bidirectional way, cortical neurons provide inputs toward the peri-LC that can modulate LC 
neurons activity (Cedarbaum & Aghajanian, 1978; Luppi et al., 1995). It was of great interest to 
gain insight into the potential implication of both areas - FC and LC - to explain the cortical 
(±)-DOI-induced NE release. 
 
Indirect FC → LC → FC loop: In order to assess the existence of an indirect loop (FC → LC → FC) 
responsible for the increase of extracellular NE release in the FC after the intra-cortical 
administration of (±)-DOI, dual-probe microdialysis experiments were performed. One of the 
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limitations of the animal models in which the previous findings were discovered is that mouse 
brain is too tiny to accomplish dual-probe microdialysis assays. Thus, the use of rats for 
conducting the following experiments was required. Probes were inserted into the FC and LC, 
and extracellular NE concentrations were simultaneously measured in both areas. 
 
There is some controversy regarding the influence of FC activation on the activity of NE LC 
neurons. While Sara & Hervé-Minvielle (1995) support an inhibitory effect of cortical neurons, 
other researchers stand up for an excitatory influence (Jodo et al., 1998). Both assays were 
performed in anesthetized rats.  
 
The following goal of the present work was to evaluate the implication of excitatory inputs, 
involving EAA in the LC, in the (±)-DOI-induced increase of NE release in the FC. The potential 
glutamatergic influence in the LC was pharmacologically studied by administration of the 
non-selective iGluRs antagonist drug KYN (1 mM). NMDA and non-NMDA (AMPA/kainate) 
excitatory  amino acid receptors are localized on somatodendritic sites of LC NE neurons (Olpe 
et al., 1989; Wisden & Seeburg, 1993; Luque et al., 1995; Van Gaalen et al., 1997; Kawahara et 
al., 1999; Samuels & Szabadi, 2008). Simultaneous perfusion of KYN into the LC and (±)-DOI 
into the FC enhanced somewhat the (±)-DOI-induced NE release in the FC (Figure 102). Similar 
or even higher effects compared to the sole administration of (±)-DOI were found in the FC 
(Figure 102), without altering NE concentrations in the LC (Figure 103).  
 
KYN administration (1 mM) into the LC evoked a non-significant reduction of NE basal 
concentrations in the FC (38%), and a dramatic reduction in the LC (92%). These results might 
dismiss the assumption of a loop involving cortical glutamatergic pyramidal neurons activation 
projecting to the LC that via iGluRs activates noradrenergic projections toward the FC. On the 
other hand, these data suggest that the LC somatodendritic release as well as LC neural firing is 
under control of EAA, although this excitatory input does not seem to be regulated by cortical 
5-HT2AR. 
 
Direct cortical pathway: The feasibility of a direct cortical effect mediating the (±)-DOI-induced 
NE release in the FC is conceivable, inasmuch as subcortical pathways seem not to be involved 
in that effect, regarding the findings explained above. In fact, co-perfusion of KYN and (±)-DOI 
both into the FC markedly attenuated the intra-cortical (±)-DOI-induced NE release in the FC 
(Figure 104) without affecting NE levels in the LC (Figure 105). iGluRs have been reported to be 
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presynaptically located on NE nerve terminals in cortical areas and hippocampus (Pittaluga et 
al., 2005; Luccini et al., 2007; Nomura et al., 2014). Most NMDAR functions have been ascribed 
to postsynaptic sites of action. Moreover, it is currently known that NMDARs can be 
presynaptically located and modulate neurotransmitter release in many brain regions, 
including the neocortex (Kunz et al., 2013), albeit the molecular mechanisms by which these 
receptors can affect such release are not well-established. Stimulatory presynaptic NMDA and 
AMPA receptors on noradrenergic axon terminals in the spinal cord have also been found to 
evoke NE release (Sundström et al., 1998). It is probable that the activation of 5-HT2ARs on 
cortical layer V pyramidal neurons could lead to an enhancement of extracellular glutamate 
concentrations which act at iGluRs on pyramidal and non-pyramidal neurons (Martin et al., 
1993), including NE axons in the FC, which eventually could facilitate the release of NE from 
storage vesicles. Therefore, the (±)-DOI-induced NE release could be restricted merely and 
primarily to local cortical pathways and mediated via 5-HT2ARs activation through the action 
of NMDA/AMPA/kainate receptors (Figure 115). In good agreement with this scenario, Fink 
and co-workers (1990) demonstrated that presynaptic NMDA receptors are able to facilitate 
the NE release in slices of rat cortex and synaptosomes preparations from hippocampus, 
olfactory bulb and cerebral cortex (Wang et al., 1992).  
 
The local presence of KYN in the FC did not significantly modify NE basal concentrations. This 
suggests that the tonic control exerted by iGluRs over NE only happened after stimulation of 
glutamate-containing pyramidal neurons. This assumption would be in good agreement with 
the low inhibitory effect of M100907 on NE release in the FC (Figure 46). 
 
Finally, it is unlikely that 5-HT2ARs presynaptically located on noradrenergic terminals in the FC 
mediate the observed NE release, since the LC is devoid of 5-HT2AR mRNA expression 
(Pompeiano et al., 1994; López-Giménez et al., 2001a; Miner et al., 2003). However, the 
existence of presynaptic 5-HT2CRs on NE axon terminals cannot be discarded, since LC express 
mRNA for 5-HT2CR (Pompeiano et al., 1994) and could travel along the axon up to terminal 
areas.  
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5.1.3. Influence of the presence of mGluR2 on the cortical (±)-DOI-induced 
catecholamine release. Does a functional neurochemical crosstalk between 
5-HT2AR/mGluR2 in the FC exist? 
The existence of a crosstalk between 5-HT2AR and mGluR2 has been broadly discussed 
throughout the present work (see introduction). Compelling evidence at multiple 
neurobiological levels has demonstrated the existence of a heteromer formation between the 
Gq/11-coupled 5-HT2AR and the Gi/o-coupled mGluR2 in cortical neurons of human and mouse 
brain (González-Maeso et al., 2008): 
 
- Biophysical approaches such as BRET, microscope-based FRET, fluorescent in situ 
hybridization (FISH) or immunohistochemistry assays, among others, have determined that 
5-HT2AR and mGluR2 co-localize in layer V mouse cortical pyramidal neurons (González-Maeso 
et al., 2008) and suggest the existence of a crosstalk mechanism between these two receptors 
that requires their physical association. Electron microscopy approaches have enabled to 
determine the subcellular proximity of these receptors, particularly at or near synaptic 
junctions (Moreno et al., 2012). Three residues at transmembrane domain 4 of mGluR2 were 
identified as necessary for the heteromerization (Moreno et al., 2012). Recent studies suggest 
that 5-HT2AR and mGluR2 could form a part of a protein complex at the postsynaptic density 
in mouse FC (Moreno et al., 2016; Gaitonde & González-Maeso, 2017). 
 
- Biochemical studies have revealed that the Gq/11-coupled 5-HT2AR and the Gi/o-coupled 
mGluR2 form a heterocomplex through which ligands that bind to the 5-HT2AR modulate 
Gi/o-dependent signaling, whereas ligands that bind to the mGluR2 modulate Gq/11-dependent 
signaling (González-Maeso et al., 2008; Fribourg et al., 2011). 
 
Under basal conditions, hallucinogenic LSD-like 5-HT2AR agonists such as (±)-DOI are able to 
activate Gq/11 and Gi/o proteins through the 5-HT2AR/mGluR2 heteromer (González-Maeso et 
al., 2007; Fribourg et al., 2011). Thus, the presence of mGluR2 interacting with 5-HT2AR 
confers to the latter receptor the ability to signal via Gi/o proteins and not only through the 
canonical Gq/11 proteins as a result of the 5-HT2AR activation by hallucinogenic, but not by non-
hallucinogenic, 5-HT2AR agonist drugs. In fact, [35S]GTPγS SPA binding assays revealed that 
mGluR2 is necessary and regulate (±)-DOI 5-HT2AR-mediated signaling through Gαi1, Gαi3, and 
Gαz subunits (Miranda-Azpiazu, Doctoral Thesis 2014). These findings spawn the necessity of 
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mGluR2 so that 5-HT2AR can mediate hallucinogenic effects via Gi/o proteins. Supporting 
evidence demonstrates that postmortem FC of schizophrenic patients has alterations in the 
allosteric crosstalk between 5-HT2AR and mGluR2 as a receptor heterocomplex (Moreno et al., 
2012). 
 
As previously mentioned, the assembly of mGluR2 and 5-HT2AR into a functional 
heterocomplex allows hallucinogenic drugs to cross-signal to Gi-dependent proteins (González-
Maeso et al., 2008). A meticulous study reported that the heterocomplex functions to 
establish a Gi-Gq balance for the response to glutamate and 5-HT, the endogenous ligands. 
Psychedelic drugs, acting through the heterocomplex, decreases Gi-dependent signaling while 
increases Gq-dependent signaling, tipping the Gi-Gqbalance in favor of Gq signaling 
(propsychotic) (Fribourg et al., 2011). 
 
- Genetic and epigenetic studies also reveal the crosstalk between 5-HT2AR and mGluR2. 
Schizophrenia patients who are homozygous (T/T) at single nucleotide polymorphism 
rs7330461 in the Htr2a gene showed better treatment response to pomaglumetad 
(LY2140023, prodrug of the mGluR2/3 agonist LY404039) compared to A/A homozygous 
patients (Liu et al., 2012; Nisenbaum et al., 2016). Among the epigenetic changes, it has been 
observed that chronic treatment with atypical antipsychotics induces repressive covalent 
histone modifications at the promoter region of Grm2 gene in mice FC (Kurita et al., 2012). 
These epigenetic changes induced at the Grm2 promoter requires 5-HT2AR signaling, as they 
were absent in 5-HT2AR knock-out mice (Kurita et al., 2012). 
 
- Behavioral studies have also revealed that the crosstalk between 5-HT2AR and mGluR2 in 
mice FC is necessary to display behavioral effects derived from hallucinogenic 5-HT2AR agonist 
drugs. mGluR2 knock-out mice do not exhibit HTR after systemic administration of (±)-DOI. In 
the same way, the virus-mediated overexpression of mGluR2 in the FC of mGluR2 knock-out 
mice rescues the head twitch behavioral response induced by (±)-DOI, whereas overexpression 
of mGluR2 with the three residues necessary for the assembly modified with the 
corresponding residues of mGluR3 does not (Moreno et al., 2012). Therefore, the absence of 
the three amino acidic residues at TM4 of mGluR2, which leads to the disruption of a 
5-HT2AR/mGluR2 complex formation, abolish the (±)-DOI-induced hallucinogenic-likes states in 
rodents. 
 
I. Mollinedo Gajate 
194 
 
Much research has been reported about this heterocomplex, but its influence in cortical 
monoamine release at basal conditions and after administration of 5-HT2AR agonist 
psychedelic drugs was still a mystery. In order to address that issue, intra-cortical perfusion of 
the 5-HT2A/2C receptor agonist (±)-DOI was administered to animals lacking mGluR2 and the 
wild-type controls. 
 
5.1.3.1. Tackling the involvement of the heteromer in dopaminergic (±)-DOI-induced response 
 
There was no difference in DA basal dialysate concentrations between mGluR2-/- and 
mGluR2+/+ animals. This finding might reflect that DA baseline levels are not under mGluR2 
regulation.  
 
mGluR2-/- mice displayed lower (±)-DOI-induced DA release in the FC than mGluR2+/+ animals 
(Figure 38 and 39). The small stimulatory effect in mGluR2-/- mice was insensitive to co-
perfusion with M100907 (Figure 44 and 45), suggesting that most of the (±)-DOI-induced 
enhancement of DA output is mediated by 5-HT2ARs, and the absence of mGluR2s hampers 
the DA release stimulation. Possibly, the minor M100907-insensitive remaining effect could be 
yielded by the action of other undetermined receptors or transporters which does not interact 
with mGluR2. In support of this, 5-HT2AR-/- mice also display a remaining effect after (±)-DOI 
cortical perfusion.  
 
Increasing evidence over the last years has proven that the heterocomplex formation is made 
up of 5-HT2AR and mGluR2 but not the mGluR3 (González-Maeso et al., 2008; Moreno et al., 
2012). In order to further elucidate the potential implication of the mGluR2 receptor and not 
the mGluR3, the same procedure was undergone in animals lacking mGluR3. As expected, the 
absence of the mGluR3 receptor did not modify the (±)-DOI-induced DA increase (Figure 54 
and 55). The present work shows that the absence of mGluR2 hampers to some extent the 
stimulatory effects on catecholamine release induced by (±)-DOI.  
 
Previous data from the literature mention that cortical co-perfusion of (±)-DOI with the 
mGluR2/3 agonist 1S,3S-ACPD was able to attenuate the 5-HT release in the rat FC mediated 
by (±)-DOI (Bortolozzi et al., 2003). In line with this finding, (±)-DOI produces cortical c-fos 
expression in a number of cortical regions, including the FC (Scruggs et al., 2000). c-Fos is 
considered a marker of neuronal activity in the brain. The mGluR2/3 agonist LY379268 is able 
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to attenuate the (±)-DOI-induced increase in c-fos mRNA and that suppression is blocked by 
the mGluR2/3 antagonist LY341495 (Zhai et al., 2003).  
 
Within this context, an apparent paradoxical situation should be noted, since animals lacking 
mGluR2 and the administration of a mGluR2 agonist would both block the (±)-DOI-induced 
effects on catecholamine release derived from its intra-cortical administration. However, both 
conditions are not contradictory. On the one hand, it seems that 5-HT2AR requires the 
presence and crosstalk with mGluR2 for its proper functioning as pro-hallucinogenic pathway. 
On the other hand, a mGluR2/3 agonist could lead to conformational changes in the 5-
HT2AR/mGluR2 heterocomplex that hampers some of the responses mediated by 5-HT2AR 
activation. 
 
The merely perfusion of the 5-HT2AR antagonist M100907 into the FC of mGluR2+/+ and 
mGluR2-/- displayed similar extent of inhibitory responses regarding DA concentrations (Figure 
42), discarding the contribution of the heterocomplex to such effect. A conceivable 
explanation for this finding is that cortical 5-HT2ARs exert a tonic control on DA release, which 
relies on the activation of its canonical signaling pathway, Gq/11 proteins. The canonical 
5-HT2AR Gq/11 proteins signaling pathway is not disrupted in the absence of the 
heterocomplex. Thus, M100907 could block Gq/11 proteins-dependent tonic DA release in 
wild-type mice, and in mGluR2-/- mice, displaying similar responses independently of the 
genotype. On the other hand, M100907 blocks the enhancement of DA release induced by (±)-
DOI in the FC only in mGluR2+/+ (Figure 43), but not in mGluR2-/- animals (Figure 44). This 
outcome indicates that the phasic control of 5-HT2AR on DA release requires the presence of 
mGluR2. Therefore, this phasic control could be mediated through Gi/o proteins, and is 
speculated that M100907 primarily blocks the Gi/o protein-dependent effect. Thus, the 
coexistence of two 5-HT2AR populations in FC, with only one contributing to the 
heterocomplex, is suggested. 
 
5.1.3.2. Tackling the involvement of the heteromer in noradrenergic (±)-DOI-induced response 
 
Looking at the NE basal values, mGluR2-/- mice possess higher values when compared to 
mGluR2+/+ animals. As mentioned in the introduction, glutamate is the main EAA 
neurotransmitter in the brain and can bind both ionotropic (NMDA, AMPA and KA receptors) 
and metabotropic receptors (coupled to G proteins, mGluR1-mGluR8). Activation of 
I. Mollinedo Gajate 
196 
 
presynaptic group II mGluRs depresses excitatory synaptic transmission and glutamate release 
in the cortex (Pin & Duvoisin, 1995). It has been reported a firing rate suppression of neurons 
in the LC subsequently to the administration of the mGluR2/3 agonist LY354740, leading to a 
significant decline in NE release in terminal areas such as the FC (Vandergriff & Rasmussen, 
1999). Previous findings by Dubé & Marshall (1997) also suggest the inhibitory role of group II 
metabotropic receptors on excitatory postsynaptic potentials arising from the LC, acting as 
autoreceptors to block the activation of LC neurons. Conversely, animals lacking mGluR2 could 
conceivably prompt the opposite effect. In this way, a hyperactivation of NE neurons due to 
the absence of the inhibitory Gi/o-coupled mGluR2 receptor might trigger higher extracellular 
NE basal values, as observed in the present work. 
 
After cortical (±)-DOI perfusion, mGluR2+/+ mice displayed higher NE release than their mutant 
counterparts (Figure 40 and 41). Furthermore, perfusion of M100907 into the FC was able to 
fully block the NE stimulation triggered by intra-cortical infusion of (±)-DOI in mGluR2+/+ and 
mGluR2-/- mice (Figure 47, 48 and 49). In this case, it seems that the majority of the (±)-DOI-
induced effect on NE release in the FC depends on 5-HT2AR activation, but as the response is 
lower in mGluR2-/- mice, mGluR2 seems to be also necessary for the proper release. On the 
other hand, as the small (±)-DOI-evoked NE release in mGluR2-/- mice was sensitive to the 
presence of M100907, it is likely that a certain population of 5-HT2ARs exists without forming 
a heteromer with mGluR2, and would be responsible for the lower extracellular NE 
enhancement triggered by (±)-DOI in mGuR2-/- animals. 
 
 Again, the present work shows additional evidence supporting a functional crosstalk between 
5-HT2AR and mGluR2, but not mGluR3, since mGluR3-/- mice displayed similar NE stimulatory 
effects elicited by (±)-DOI than their wild-type littermates (Figure 56 and 57). These data might 
reflect that 5-HT2AR requires the presence of mGluR2 for the proper NE release evoked by 
(±)-DOI.  
 
In analogy to the other catecholamine, the sole perfusion of M100907 into the FC elicited in 
both mGluR2+/+ and mGluR2-/- similar extent of inhibitory responses regarding NE release 
(Figure 46). A conceivable explanation is that the tonic stimulatory effects of the cortical 
5-HT2AR on NE release are mediated by activation of its canonical Gq/11 proteins signaling 
pathway. Thus, the presence of the 5-HT2AR/mGluR2 heteromer and the 5-HT2AR monomer 
would coexist in FC.  
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In a similar way, previous findings investigating the crosstalk between α2-adrenoceptors, 
bradykinin (B2) and angiotensin (AT1) receptors already suggested that the activation of Gi/o 
proteins could conceivably be necessary for raising the effects mediated by Gq/11 proteins on 
NE release (Cox et al., 2000). 
 
Collecting the interpretations speculated in section 5.1.2.2. for the (±)-DOI-induced effects on 
cortical NE release and the results included in this section, we suggest a plausible and more 
complex mechanism of (±)-DOI when administered cortically. This mechanism would have its 
roots in the activation of 5-HT2AR/mGluR2 heteromers on pyramidal neurons that could lead 
to glutamate release in the FC, able to interact with iGluRs located on NE axon terminals, and 
thus facilitating the release of NE in that area. 5-HT2ARs and 5-HT2CRs on GABAergic 
interneurons would be also excited and would mediate inhibitory effects. However, since the 
proportion of pyramidal neurons is substantially higher in the FC, the overall effect of cortical 
administration of (±)-DOI would be predominantly excitatory (Figure 115). 
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Fig. 115- Schematic picture of the plausible cortical mechanism of action of (±)-DOI on NE release in the FC. Activation of 
5-HT2AR/mGluR2 heteromers on pyramidal neurons could excite glutamate neurons and promote glutamate release. This 
neurotransmitter could act at iGluRs (NMDA/AMPA/kainate) receptors on noradrenergic axon terminals facilitating the release of NE 
from the storage vesicles. 5-HT2ARs and 5-HT2CRs on GABAergic interneurons would be also excited and mediate inhibitory effects. 
However, since the proportion of pyramidal neurons is substantially higher in the FC, the overall effect of cortical administration of 
(±)-DOI would be predominantly excitatory.  
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5.1.3.3. Rescuing the (±)-DOI-induced catecholamine release after mGluR2 virus-mediated gene 
transfer in the frontal cortex of mGluR2
-/-
 mice 
 
In this work, it is demonstrated that the overexpression of mGluR2 in frontal cortical neurons 
of mGluR2-/- mice, via virus-mediated gene transfer (HSV-mGluR2), rescues the high 
(±)-DOI-induced extracellular DA and NE release. In contrast, the sole overexpression of the 
control protein (HSV-GFP) does not. These data provide supporting evidence for the necessity 
of the existence of mGluR2 in frontocortical neurons to induce the rise in DA and NE output in 
that area, subsequently to local (±)-DOI perfusion. The elegant study undertaken by Moreno 
and co-workers (2012) already revealed similar extendable results when head twitch behavior 
yielded by systemic injection of (±)-DOI was evaluated. (±)-DOI is unable to induce the 
psychotic-like HTR in mGluR2-null animals, leading to the assumption that mGluR2 is necessary 
for the behavioral effects induced by hallucinogens as (±)-DOI or LSD in mouse models 
(Fribourg et al., 2011; Moreno et al., 2011a).  
 
The three amino acidic residues located in the TM4 (Ala-6774.40, Ala-6814.44 and Ala-6854.48) of 
mGluR2 are known to be necessary for the allosteric binding mediating functional crosstalk 
between the components of the 5-HT2AR/mGluR2 heterocomplex (Moreno et al., 2012). The 
administration of virus-mediated plasmids substituting these three residues with the ones 
located at equivalent positions in the TM4 of the highly related mGluR3 leads to a disruption of 
the heteromeric assembly with the 5-HT2AR in living cells (Moreno et al., 2012).  
 
The rescue of mGluR2 exclusively in the FC by stereotaxic injection of HSV-mGluR2 allowed 
mGluR2-/- mice to recover the high (±)-DOI-induced DA and NE release in the FC, to similar 
extent to those observed in wild-type animals (Figure 59 and 60 for DA; Figure 61 and 62 for 
NE). Such striking outcome led us to speculate that this virus-mediated gene transfer could 
conceivably be rescuing the functional crosstalk via the receptor heterocomplex that finally 
mediate the DA and NE efflux after cortical administration of (±)-DOI. Here again it should be 
noted that the remaining effect on DA in mGluR2-/- mice transfected with control virus (HSV-
GFP) is visible, as expected, in this new set of experiments.  
 
The main findings of this section can be summarized as follows: (i) the hallucinogen primarily 
5-HT2AR agonist (±)-DOI, when administered locally in the FC, elicits a stimulatory effect on 
cortical DA and NE release in 129/Sv and C57BL/6 strain mice as well as in rats. (ii) mGluR2 
seems to play a key role in facilitating such neurotransmitter release enhancement, since 
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mGluR2-null mice displayed stimulations of much lower degree. The previous statement was 
further assessed transfecting into the FC of mGluR2-/- mice, a virus-mediated gene to rescue 
the mGluR2 solely in the medial FC. After the rescue of the receptor, animals lacking mGluR2 
recovered the neurochemical response with similar magnitudes to the ones observed in wild-
type animals. (iii) Whereas cortical (±)-DOI-induced DA release might be a consequence of an 
activation of indirect loops involving the activation of cortical and subcortical areas, the 
cortical (±)-DOI-induced NE release might be restricted to local pathways in the FC inasmuch as 
the LC, the main source of NE in the brain, appears not to be implicated in the latter effect. 
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5.2. REGULATION OF DOPAMINERGIC AND NORADRENERGIC 
NEUROTRANSMISSION IN THE FC BY ACUTE SYSTEMIC ADMINISTRATION 
OF (±)-DOI  
 
5.2.1. 5-HT receptors playing a role in systemic (±)-DOI-induced DA release in FC 
In C57BL/6 mice, a moderate dose of (±)-DOI (1 mg/kg) intraperitoneally administered 
significantly increased DA release in the FC (Figure 63). It is likely that such DA increase is 
mediated by 5-HT2ARs, since that response was absent in 5-HT2AR knock-out animals (Figure 
65). When similar experiments were carried out in rats and 129/Sv mice, it was observed that 
(±)-DOI mildly boosted DA release in rat FC, but in contrast, diminished DA release in the FC of 
129/Sv mice. 
 
The LSD-like hallucinogens-induced monoamine modulation has been an issue of high interest 
in the last two decades. There is a body of evidence reporting the ability of systemic (±)-DOI 
administration to enhance dialysate concentrations of DA in the FC and VTA of freely-moving 
rats. This is likely via activation of 5-HT2ARs inasmuch as the injection of the 5-HT2AR 
antagonists M100907 and MDL 11,939 blocked that effect without modifying basal levels 
(Gobert & Millan, 1999; Pehek et al., 2001; Pehek et al., 2006; Bortolozzi et al., 2005). 
Additionally, that stimulatory effect is increased by the co-injection of the 5-HT2B/2C 
receptors antagonist SB 206,553 (Gobert & Millan, 1999).  
 
Pehek and co-workers (2001) investigated the potential presence of 5-HT2AR in the FC, and 
they reinforced the existence of 5-HT2ARs in cortical areas, since co-administration with 
M100907 (10 µM) perfused into the FC prevented the increased DA output induced by (±)-DOI 
(2.5 mg/kg s.c.). Cornea-Hebert and co-workers (1999) revealed by immunohistochemical 
assays with conventional microscopy, a weak presence of 5-HT2AR in the VTA; as earlier 
described by Pazos and co-workers (1985). Later, more sophisticated studies using 
immunohistochemistry with confocal microscopy techniques, demonstrated that 5-HT2AR are 
distributed on TH positive DA neurons in VTA and a sparse number on non-TH-positive cells in 
the VTA, probably GABAergic interneurons located in that latter area (Nocjar et al., 2002). In 
this way, the hypothesis that (±)-DOI injection may be able to enhance DA release in the FC 
through the activation of 5-HT2AR in VTA and in the FC seems plausible. 
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Herein, 5-HT2ARs in the VTA may be involved in facilitating the phasic release of frontocortical 
DA. Doherty & Pickel (2000) observed in C57BL/6 mice that agonism at 5-HT2ARs located on 
DA neurons in the VTA could stimulate DA projection fibers and finally a rise in DA output in 
terminal areas would be aroused. Moreover, it has been suggested that 5-HT2AR, which 
regulate cortical DA release, could be located in the FC. Thus, blockade of prefrontocortical 
5-HT2ARs prevents the evoked release of DA from the mesocortical pathway. The application 
of the NMDA receptor antagonist MK-801 in the VTA suppressed the FC-evoked stimulation of 
DA release, supporting the involvement of NMDA-dependent inputs (Bortolozzi et al., 2005). 
NMDA and AMPA receptors within the VTA (Paquet et al., 1997) can excite DA neurons in this 
area (Rodríguez et al., 2000). In this sense, a rise in FC DA release following acute injection of 
(±)-DOI could be mediated by activation of 5-HT2AR on cortical neurons, which would induce 
burst firing in VTA DA neurons through a NMDA-dependent mechanism. Finally, such burst 
firing would be associated with a greater DA release in the FC.  
 
However, there is some controversy regarding the effects elicited by systemic (±)-DOI in the 
FC. In this sense, Kuroki and co-workers (1999a) did not observe any (±)-DOI-induced (2.5 
mg/kg i.p.) DA modulation in the FC of awake freely moving rats. 
 
On the other hand, acute administration of non-selective 5-HT2AR antagonists have generally 
rendered increased cortical extracellular DA levels in a similar way to the one proposed by 
(±)-DOI. For instance, amperozide, ritanserin, risperidone, olanzapine, and clozapine have all 
been shown to increase cortical DA dialysate levels (Moghaddam & Bunney, 1990; Pehek et al., 
1993; Nomikos et al., 1994; Pehek, 1996; Kuroki et al., 1999b; Kaminska et al., 2013; Kaminska 
et al., 2017). However, systemic administration of M100907 do not exert any modulation on 
DA release (Gobert et al., 2000). Antagonism at 5-HT2CRs slightly increases dialysate levels of 
DA in the FC, suggesting the existence of a tonic inhibitory regulation mediated by 5-HT2CRs 
(Nomikos et al., 1994). On the other hand, systemic administration of the preferential 5-HT2CR 
agonist Ro 60-0175 (3 mg/kg) decreases DA release in the FC (Ichikawa et al., 2001). In order to 
explain this paradoxical effect of antipsychotics on DA release in the FC, it has been suggested 
that the activation of 5-HT1AR is required (Bortolozzi et al., 2010). In apparent contradiction 
with this finding, (±)-DOI (2.5 mg/kg) but not Ro 60-0175 (3 mg/kg) when given systemically, is 
able to attenuate clozapine injection-induced DA release in FC, suggesting that the effect is 
mediated by 5-HT2ARs (Ichikawa et al., 2001). 
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In an attempt to evaluate the DA modulation in the FC underlying systemic (±)-DOI injection in 
129/Sv mice, (±)-DOI (1 mg/kg i.p.) was injected in wild-type mice. Surprisingly, (±)-DOI evoked 
an inhibitory effect on DA release in the FC of 129/Sv mice (Figure 69), an effect antagonized 
by systemic administration of the 5-HT2AR antagonist M100907 (0.5 mg/kg i.p.) (Figure 77), 
and by the 5-HT2CR antagonist SB242084 (1 mg/kg i.p.) (Figure 79).  
 
In view of this opposite effects mediated by 1 mg/kg of (±)-DOI in both strains, a dose-
response assay was performed in 129/Sv mice, using (±)-DOI at five increasing doses (0.1, 0.5, 
1, 2.5, 5 mg/kg i.p.). None of these doses was able to mimic the stimulatory effects on DA 
release shown in C57BL/6 mice (Figure 75). Only an upward trend was shown at the lowest 
dose, but it did not reach significance. Overall, there was a significant dose-dependent 
decrease in cortical DA efflux, reaching the maximal inhibitory values between 1 mg/kg and 2.5 
mg/kg. The highest dose (5 mg/kg) did not exert that marked inhibitory effect, but only a mild 
inhibitory trend was evoked. The dose of 1 mg/kg was chosen to perform the following 
experiments in 129/Sv mice and rats.  
 
(±)-DOI is able to induce excitatory effects on interneurons in the FC, an effect blocked with 
the 5-HT2A/2CRs antagonist ritanserine, and partially by SB242084, suggesting that both 
receptors are involved in the modulation of DA activity via excitation of interneurons in the FC 
(Zhang et al., 2010).  
 
In order to determine if the effect observed in our assay would be mediated by 5-HT2AR 
and/or 5-HT2CRs activation, the preferential 5-HT2CR agonist Ro 60-0175 was systemically 
administered. Ro 60-0175 exerted an inhibitory effect on DA release in the FC of 129/Sv mice 
(Figure 81), similar to the one previously observed by (±)-DOI injection (Figure 69). This finding 
is in line with previous studies showing that systemic Ro 60-0175 reduces DA release in the FC 
(Ichikawa et al., 2001). Thus, it is conceivable that Ro 60-0175 decreases DA firing rate via 
GABAergic synapses onto DA neurons by stimulating 5-HT2CRs on GABAergic neurons. 5-
HT2CRs have been localized, among others, on GABAergic neurons in the VTA (Pessia et al., 
1994; Eberle-Wang et al., 1997; Theile et al., 2009), and its activation inhibits dopaminergic 
pathways (Goldstein et al., 1989; Prisco et al., 1994; Prisco & Esposito, 1995; Shi et al., 1995; Di 
Matteo et al., 2000) via activation of inhibitory GABAergic interneurons (Pessia et al., 1994).  
5-HT2CRs have also been found on DA neurons as well (Bubar & Cunningham, 2007). 
Therefore, the inhibitory role that (±)-DOI (1 mg/kg i.p.) elicited in cortical DA release is likely 
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mediated by 5-HT2CRs. However, the selective 5-HT2AR antagonist M100907 also abolished 
the effect induced by (±)-DOI. This response seems consistent with a previous study suggesting 
that 5-HT2ARs directly excite dopaminergic cell bodies (Pessia et al., 1994). Nonetheless, the 
effect described in these conditions is a stimulation but not an inhibition, as the one shown in 
the present work. 
 
The present findings could have the following interpretations: (i) GABAergic neurons in VTA 
express 5-HT2AR, since 5-HT2AR is natively resident within DA and non-DAergic (GABA- or 
possibly glutamate-containing) neurons in the VTA (Doherty & Pickel, 2000; Nocjar et al, 2002). 
Stimulation of 5-HT2AR on dopaminergic neurons in VTA could lead to enhanced DA release in 
FC - as observed in C57BL/6 mice -, whereas stimulation of 5-HT2AR or 5-HT2CR on GABAergic 
neurons in VTA could release GABA in this area, and synapse onto DA neurons diminishing DA 
release in FC - as observed in 129/Sv mice -; (ii) another explanation for the inhibitory effect 
observed in the FC of 129/Sv mice is that M100907 at a dose of 0.5 mg/kg could lack selectivity 
for 5-HT2AR (Ki=1.92 nM for 5-HT2AR; Ki=88 nM for 5-HT2CR, see on-line database: 
https://kidbdev.med.unc.edu/databases/kidb.php). This dose might partially block 5-HT2CRs 
as well. 
 
5.2.2. 5-HT receptors playing a role in systemic (±)-DOI-induced NE release in FC 
As explained above, activation of 5-HT2ARs located in the FC by intra-cortical perfusion of 
(±)-DOI led to a notable increase in extracellular NE output in the FC. Based on the unique 
published microdialysis study evaluating NE modulation in the rat FC after systemic (±)-DOI 
injection undertook by Gobert & Millan (1999), it was expected to observe an increase in 
cortical extracellular NE in the FC after administration of (±)-DOI systemically. However, doses 
from 0.5 to 5 mg/kg decreased NE efflux in FC, and the highest inhibitory effect was reached at 
1 mg/kg (Figure 76). (±)-DOI (1 mg/kg) induced a slight but significant inhibitory effect on the 
FC NE release in both 129/Sv strain mice (Figure 70) and rats (Figure 91), although it did not 
exert any effect in C57BL/6 mice (Figure 64). Such striking outcome led to reconsider the initial 
scenario, suggesting that subcortical areas could conceivably be yielding the inhibitory effect 
on the FC. 
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Intriguingly, the inhibitory effect was antagonized by previous administration of the 5-HT2AR 
antagonist M100907 (0.5 mg/kg i.p.) (Figure 78), as well as by the selective 5-HT2CR antagonist 
SB242084 (1 mg/kg i.p.) (Figure 80). These data suggest that the activation of both 5-HT2AR 
and 5-HT2CRs could be mediating such inhibitory effect. 5-HT2ARs and 5-HT2CRs are located 
on GABAergic cells within the FC (Willins et al., 1997; Carr et al., 2002; Santana et al., 2004; Liu 
et al., 2007; Puig & Gulledge, 2011), and on GABAergic projections to LC (Pazos et al., 1985; 
Chiang & Aston-Jones, 1993; Pompeiano et al., 1994). Activation of these receptors in the LC 
could drive to an increase in extracellular GABA, which could finally diminish the firing rate of 
NE neurons projecting to the FC, and would decrease NE release in the FC.  
 
In order to clarify whether 5-HT2AR or 5-HT2CR are responsible for the inhibitory effect on NE 
release induced by (±)-DOI, experiments were accomplished using 5-HT2AR-/- and 5-HT2AR+/+ 
mice. These assays were performed in C57BL/6 strain mice. (±)-DOI (1 mg/kg i.p.) did not 
modulate NE concentrations in 5-HT2AR+/+ mice, but neither in 5-HT2AR-/- mice (Figure 67).  
 
These findings support the existence of variable effects between mouse strains (see discussion 
later). The involvement of 5-HT2AR and/or 5-HT2CR was further explored in 129/Sv mice by 
systemic administration of the preferential 5-HT2CR agonist Ro 60-0175. Ro 60-0175 (3 mg/kg 
i.p.) elicited a significant inhibitory response on cortical NE release (Figure 82), positing 
5-HT2CRs as the main candidates involved in such inhibition. These data agree with those 
obtained by Gobert and co-workers (2000), showing that Ro 60-0175 (2.5 mg/kg i.p.) 
diminished DA and NE output in the rat FC. 
 
Then, it was raised the question about the anatomical localization of 5-HT2AR, and/or 5-HT2CR 
responsible for the inhibitory effect seen in the FC. Bearing in mind the potential critical 
presence of 5-HT2ARs and/or 5-HT2CRs in subcortical areas underlying such inhibitory effect 
on FC, dual-probe microdialysis was performed in rats. Probes were inserted into the LC and 
the ipsilateral FC. Extracellular NE levels were simultaneously monitored in both regions. In 
this context, assays were carried out to assess to what extent the LC, which is major source of 
NE in the FC, was affected by 5-HT2AR and/or 5-HT2CR activation. Baseline NE concentration 
values in LC were higher than in the FC, as previously reported (Mateo et al., 1998; Mateo et 
al., 2000; Fernández-Pastor et al., 2005).  
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5.2.2.1. Assessing the potential role of LC NE neurons in the inhibitory effects displayed in the 
FC. Is the LC steering the ship? 
 
It was previously reported that 5-HT2CRs in the LC tonically inhibit the firing activity of cortical 
neurons likely via activation of GABAergic interneurons in the area (Chiang & Aston-Jones, 
1993). In the present study, a marked somatodendritic NE release in the LC was found after 
systemic administration of (±)-DOI (Figure 92). In the same animals, a simultaneous decrease 
of NE in the FC was yielded (Figure 91). Therefore, it can be suggested that systemic (±)-DOI 
could act on 5-HT2CR expressed on GABAergic neurons in the LC, and these neurons would 
contribute to the enhancement of NE release in the terminal area. The increase of NE output 
in the somatodendritic area would contribute to inhibit the tonic firing activity of LC NE 
neurons (Mateo et al., 1998). To date, there are not microdialysis data regarding the effect 
induced by (±)-DOI on the NE release in the LC, but electrophysiology studies have revealed 
that (±)-DOI attenuates the firing rate of LC NE neurons through a GABAA receptor activation, 
since the microiontophoretic application of a GABAA receptor antagonist on LC neurons is able 
to blunt that decrease (Chiang & Aston-Jones, 1993). Future microdialysis experiments using 
bicuculline in the LC would be necessary to evaluate the role of GABA receptors expressed on 
LC neurons, to elucidate whether the GABAergic system is responsible for the increments of 
NE release in the LC after systemic (±)-DOI administration, and its subsequent role in the 
regulation of the NE release in the FC. 
 
In order to further establish the role of NE neurons in the LC in the regulation of NE release in 
the FC, (±)-DOI was locally perfused into the LC, and extracellular NE concentrations were 
measured simultaneously in LC and FC. Once again, a rapid dose-dependent stimulatory effect 
was found in the LC (Figure 93) and a slower but marked inhibition of NE release in the FC 
(Figure 94). A negative correlation between extracellular NE concentrations in LC and FC was 
observed (Figure 95). These findings confirm the crucial role of somatodendritic NE release in 
LC in the regulation of NE release in the FC. In other words, (±)-DOI could promote NE release 
in the LC or the peri-LC area, and such NE increase could exert a negative feedback mechanism 
on the firing rate of NE neurons in the LC projecting to the FC.  
 
The ability of LC to modulate NE release in projecting noradrenergic areas such as the FC is not 
new. It has been previously reported that (±)-DOI suppresses the firing rate of noradrenergic 
neurons in the LC and decreases dialysate concentrations of NE in the hippocampus (Done & 
Sharp, 1992). Furthermore, systemic injection of the (±)-DOI analogues, DOM and DOB, as well 
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as LSD and mescaline, inhibits the firing rate of spontaneously active neurons in the LC 
(Rasmussen & Aghajanian, 1986; Gorea & Adrien, 1988).  
 
α2-Adrenoceptors present in the LC (Nicholas et al., 1993) have been highlighted as key players 
in the regulation of the firing activity of LC neurons (Svensson & Usdin, 1978; Meana et al., 
1997; Van Gaalen et al., 1997; Mateo et al., 1998; Jedema et al., 2008). Agonists at 
α2-adrenoceptors in the LC inhibit the firing activity and release of NE in terminal areas 
(Pudovkina et al., 2001; Jedema et al., 2008). The microiontophoretic administration of the 
α2-adrenoceptor agonist clonidine in the LC inhibits the firing rate of these noradrenergic 
neurons, and also the intra-LC perfusion of this agonist commonly decreases the NE dialysate 
levels in the FC (Svensson et al., 1975; Van Gaalen et al., 1997; Mateo & Meana, 1999). 
Clonidine perfusion into the LC dramatically decreases NE in the ipsilateral FC, suggesting that 
the vast majority of the NE levels in the FC are derived from LC innervations, and highlighting 
the crucial role of α2-adrenoceptors on noradrenergic neurons in the LC (Van Gaalen et al., 
1997). Supporting evidence has been found inasmuch as α2-adrenoceptor antagonists in the LC 
blunt both effects. The local administration of the α2-adrenoceptor antagonist RX821002 
perfused in the LC abolished the inhibition of the firing activity and the subsequent release of 
NE in the FC induced by the presence of an α2-adrenoceptor agonist in the LC (Meana et al., 
1997; Mateo et al., 1998; Mateo & Meana, 1999). Similar responses can be triggered by the 
action of the endogenous ligand in the LC through the blockade of NE reuptake in the LC 
(Mateo et al., 1998). Presynaptic α2A-adrenoceptors are likely the receptor subtype involved is 
these inhibitory effects (Callado & Stamford, 1999; Mateo & Meana, 1999).  
 
To assess the role of α2-adrenoceptors on LC NE neurons in mediating the inhibition of NE 
release observed in the FC, systemic (±)-DOI was injected in presence of the α2-adrenoceptor 
antagonist RX821002, perfused locally into the LC. RX821002 fully blocked the inhibitory effect 
in the cortical NE release (Figure 96), suggesting that α2-adrenoceptors on NE neurons in the 
LC play a crucial role in the modulation of NE cell firing and release, as stated by Mateo and co-
workers (1998). Moreover, in presence of RX821002, systemic (±)-DOI increased NE release in 
the FC. This stimulatory effect could probably correspond to the local effect of (±)-DOI in the 
FC.  
 
According to previous findings (Mateo et al., 1998; Fernández-Pastor & Meana, 2002), 
RX821002 perfusion in the LC induced roughly a three-fold increase of basal NE concentrations 
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in the FC, although statistical significance was not reached, potentially due to insufficient 
number of animals in each group. 
 
The effect induced by (±)-DOI (1 mg/kg i.p.) was antagonized by the preferential 5-HT2AR 
antagonist M100907 (0.5 mg/kg i.p.) as well as by the preferential 5-HT2CR antagonist 
SB242084 (1 mg/kg i.p.). We can interprete these findings regarding that both 5-HT2AR and 
5-HT2CR co-localize on GABAergic cells and both could be activated by (±)-DOI. Moreover, it 
has been recently reported that both receptors are present alone and forming homo and 
heterodimers, and this heterodimerization makes 5-HT2CR blunt the 5-HT2AR-mediated 
signaling (Moutkine et al., 2017). Supporting evidence shows that the inactivation of 5-HT2CR 
in the LC correlates with decreased 5-HT2AR-dependent NE transmission. In this sense, 
inactivation of 5-HT2CR suppresses the decrease of noradenergic tone caused by activation of 
5-HT2AR expressed on LC GABAergic interneurons (Moutkine et al., 2017). Moreover, it is 
difficult to determine whether this effect is mediated by the 5-HT2AR or the 5-HT2CR, since 
the response observed could be the combination of a 5-HT2AR- and 5-HT2CR-dependent 
effects, inasmuch as M100907 and (±)-DOI at the selected doses could also bind 5-HT2CRs. 
 
Since the expression of 5-HT2CR is substantially higher in LC than of 5-HT2AR, it is more likely 
that this effect is mediated by 5-HT2CR (Pompeiano et al., 1994). However, more recent 
studies stand up for a preferential role of 5-HT2AR on the serotonergic modulation of NE 
neurons in the LC (Szabo & Blier, 2002). Underpinning that theory, Millan and co-workers 
(2003) observed that agomelatine (S20098), which acts as melatonin agonist and 5-HT2CR 
antagonist, was able to potentiate the electrical activity of noradrenergic neurons in the LC, via 
an antagonism of 5-HT2CRs, and also rise DA and NE concentrations in the FC. Supporting 
evidence to the hypothesis stated above is found by electrophysiological approaches, where it 
is observed that the preferential 5-HT2CRs agonist Ro 60-0175 is able to decrease the firing 
rate of noradrenergic neurons in the LC (Gobert et al., 2000). Conversely, the 5-HT2CR 
antagonist SB242084 enhances noradrenergic transmission (Gobert et al., 2000). In the 
present study, a similar inhibition was observed in the FC after systemic administration of Ro 
60-0175 (3 mg/kg i.p.). 
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5.2.2.2. Considering other pathways potentially implicated in the (±)-DOI-induced inhibitory 
effects displayed in the FC 
 
PGi → LC → FC: The major excitatory innervation of the LC derives from the PGi (Aston-Jones 
et al., 1986). Electrical stimulation of PGi activates most LC neurons through the EAA 
glutamate, since the excitatory transmission is completely abolished by the EAA antagonists 
KYN and γ-D-glutamylglycine (Ennis & Aston-Jones, 1988; Olpe et al., 1989). Kainate-type 
receptors seem to be the primary contributors, since the NMDA antagonist 2-amino-7-
phosphonoheptanoic acid (AP7) and the preferential quisqualate receptor antagonist 
glutamate diethyl ester (GDEE) did not block LC responses to PGi stimulation (Ennis & Aston-
Jones, 1988). Furthermore, bath application of kainate, NMDA, quisqualate and L-glutamate 
excited LC neurons in a concentration-dependent manner (Olpe et al., 1989). Indeed, the rank 
order for stimulation of LC neurons appears to be kainate ≈ quisqualate > NMDA > L-glutamate 
(Olpe et al., 1989). PGi is a region of high expression of 5-HT2ARs (Pazos et al., 1985; 
Pompeiano et al., 1994) and 5-HT2CRs (Molineaux et al., 1989; Pompeiano et al., 1994; López-
Giménez et al., 2001a). Therefore, systemic administration of (±)-DOI could activate such 
excitatory nucleus projecting to the LC, and subsequently promote NE release from the LC. 
 
Against this possibility is the fact that local administration of (±)-DOI in LC elicits similar effects 
to the ones observed after systemic injection. 
 
In order to gain insight into the contribution of glutamate release from the excitatory input 
projections arising from PGi to evoke such (±)-DOI-induced NE release via activation of iGluRs, 
systemic injection of (±)-DOI was co-administrated with perfusion of KYN into the LC. No 
differences were found among the group treated merely with an acute injection of systemic 
(±)-DOI, and the group co-treated with perfusion of KYN locally into the LC, neither in the FC, 
nor in the LC (Figure 100 and 101). These findings also suggest that (±)-DOI-induced NE release 
in the LC is unlikely prompted by glutamate acting at iGluRs on LC NE neurons. 
 
DR → LC → FC: As broadly stated in the literature, there are serotonergic inputs arising from 
the DR that synapse onto LC NE neurons and can modulate noradrenergic transmission (Pickel 
et al., 1977; Done & Sharp, 1994; Chiu et al., 1995; Haddjeri et al., 1997; Szabo et al., 1999; 
Szabo & Blier, 2001a). These serotonergic innervations could play a role in the increase of NE 
release in the LC. Biochemical and electrophysiological data implicate specific 5-HT receptor 
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subtypes in the inhibitory action of 5-HT on noradrenergic activity (Rasmussen & Aghajanian, 
1986; Gorea & Adrien, 1988). Systemic administration of 5-HT2 receptor agonists in 
anesthetized rats decreases the firing rate of noradrenergic neurons in the LC (Rasmussen & 
Aghajanian, 1986; Gorea & Adrien, 1988).  
 
It has been suggested that DR inervates the LC, playing a role in the modulation of NE neurons 
(Chiu et al., 1995; Szabo et al., 1999). The increase of 5-HT concentrations in LC is able to 
inhibit the electric activity of NE neurons through the boosting of somatodendritic NE release. 
Thus, the presence of the selective serotonin reuptake inhibitor (SSRI) citalopram locally 
administered, enhances the somatodendritic release of NE and reduces the firing activity of NE 
neurons and the subsequent release in cortical regions (Mateo et al., 2000; Ortega et al., 
2010). As expected, α2-adrenoceptors antagonists administered into the LC block this effect 
observed in the FC (Mateo et al., 2000). 
 
On the other hand, it has been reported that the serotonergic receptor that could regulate the 
somatodendritic release of NE is the 5-HT3R (Ortega et al., 2012; Fernández-Pastor et al., 
2013). The increase of NE output that silences the LC could be triggered by enhanced 
extracellular concentrations of 5-HT in LC (Chiu et al., 1995; Szabo et al., 1999). But 
discrepancies have been reported, since (±)-DOI inhibits the firing activity of DR neurons 
through the activation of 5-HT2AR on GABAergic neurons within the DR (Wright et al., 1990; 
Garratt et al., 1991; Boothman & Sharp, 2005), triggering an inhibitory effect on 5-HT release 
in terminal projection areas such as the frontal cortex (Martin-Ruiz et al., 2001). It has been 
suggested that part of the inhibitory effect of (±)-DOI on DR neurons depends directly on the 
LC inasmuch as the DSP4 noradrenergic toxin abolish that effect (Quesseveur et al., 2013). 
 
 
 
PrH → LC → FC: Together with PGi, PrH is the other nucleus that provides LC with the major 
innervation inputs. Inhibitory GABAergic inputs can reduce the firing activity of LC NE neurons 
(Gervasoni et al., 1998; Szabo et al., 2004). Chiang & Aston-Jones (1993) support that (±)-DOI 
induces a decrease in spontaneous firing in LC noradrenergic neurons via activation of GABA 
receptors, since the GABA antagonists bicuculline or picrotoxin administered into the LC block 
that decrease. Hence, the influence of GABAergic pathways to explain the inhibition of the LC 
NE cell firing and therefore, the inhibition of the NE release in the FC cannot be ruled out. 
Regardless of the existence of this pathway, the local effect of (±)-DOI points out a major 
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influence of GABAergic neurons in the LC than more distant regions such as the PrH. Even 
much more complicated pathways have been postulated to mediate the decreased LC NE 
neurons firing rate, involving 5-HT1ARs, GABAA receptors and 5-HT2ARs (Szabo & Blier, 2001b). 
As previously mentioned, future experiments using the GABA receptor antagonist bicuculline 
or picrotoxine locally administered into the LC could be accomplished in order to better 
elucidate the implication of the GABAergic pathways in (±)-DOI effects on NE concentration 
reductions in the LC. 
 
5.2.3. Are the strain differences accounting for the opposite effects on cortical 
catecholamine release induced by systemic administration of (±)-DOI?  
There is growing evidence demonstrating that certain intrinsic physiological properties, 
conditioning factors, and pharmacological approaches can induce distinct responses 
depending on the background genotype of each species or strain. Thus, a broad number of 
articles have been published during the past decades concerning these genetic differences in 
drug-evoked behavioral responses among different species (Sei et al., 1992; Bolivar et al., 
2001; Rikke et al., 2003; Nosek et al., 2008; Mack et al., 2013; Almeida Silva et al., 2016; Gioia 
et al., 2016; Séguret et al., 2016; Zimmermann et al., 2016; Halladay et al., 2017). Even quite a 
few articles have been published so far regarding distinct drug-induced neurochemical 
responses depending on the rat or mouse strain (Shoaib et al., 1995; He & Shippenberg, 2000; 
Fernandez et al., 2003; Calcagno et al., 2007). According to He & Shippenberg (2000), the 
response of striatal DA neurons to cocaine is enhanced in 129/Sv, as compared to C57BL/6, 
DBA/2, and Swiss-Webster mice. This finding is of interest as it might reflect a certain degree 
of hypersensitivity of 129/Sv mice at DAT blockade.  
 
In the present work no differences were found in DA and NE basal values from 129/Sv and 
C57BL/6 strain mice, consistent with previous reports (He & Shippenberg, 2000). However, 
completely opposite effects were found following systemic (±)-DOI administration (1 mg/kg 
i.p.) in both strains. Whereas the drug yielded an inhibition of DA and NE release in the FC of 
129/Sv mice, it elicited a stimulation of DA release, and no changes in NE output, in C57BL/6 
mice. Speculating that such inhibitory effect is mediated by 5-HT2CR in subcortical areas (likely 
VTA for DA and LC for NE), it seems that both strains possess different sensitivity to 5-HT2CRs 
agonism.  
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Regarding NE modulation, as the outcomes obtained in rats are more similar to those observed 
in 129/Sv strain mice, it appears that C57BL/6 mice display some resistance to 5-HT2CR 
activation. In line with these findings, a very interesting study carried out in C57BL/6 and 
DBA/2 mice showed also some differences of sensitivity at 5-HT2CRs between both strains 
(Calcagno & Invernizzi, 2010). The 5-HT2CR agonist Ro 60-0175 increased extracellular GABA 
levels and reduced 5-HT levels in the DR of DBA/2 mice, and to a much lesser extent, in 
C57BL/6 mice. Indeed, C57BL/6 mice need higher doses of 5-HT2CR agonist to exert these 
effects and, even at higher doses, the magnitude of the effect does not reach the one showed 
in DBA/2 mice at lower doses. These supporting findings show a different sensitivity at 
5-HT2CRs among strains, so C57BL/6 could conceivably be more resistant to 5-HT2CRs than 
DBA/2, and probably than 129/Sv mice. 
 
5.2.4. Influence of the presence of mGluR2 on the systemic (±)-DOI-induced 
catecholamine release. Is the 5-HT2AR/mGluR2 heteromer involved in this response? 
Systemic (±)-DOI injection (1 mg/kg i.p.) induced similar inhibitory effects on DA and NE 
release in the FC of animals lacking mGluR2, and their respective wild-type controls (Figure 85 
and 86 for DA, Figure 87 and 88 for NE). Therefore, the 5-HT2AR/mGluR2 heterocomplex does 
not seem to be implicated in the systemic effect of (±)-DOI. Two possible alternatives could 
explain this finding. Firstly, since evidence of heterocomplex expression in extracortical brain 
areas has not been provided, the 5-HT2AR involved in the (±)-DOI effect is located in other 
brain regions that are not the FC, as previously discussed, where it does not form 
heterocomplex with the mGluR2. Secondly, the receptor implicated in the (±)-DOI effect is the 
5-HT2CR, which is not assembled in heterocomplex with the mGluR2 (González-Maeso et al., 
2008). 
 
In conclusion, (±)-DOI induces opposite effects on DA and NE release in the FC depending on 
the route of administration. When (±)-DOI is administered by reversal dialysis into the FC, DA 
and NE concentrations increase. However, when (±)-DOI is administered systemically, distinct 
patterns of DA and NE release in the FC are revealed depending on mouse strains and animal 
species. In this sense, systemic (±)-DOI administration enhances catecholamine release in 
C57BL/6 mice, whereas decreases it in 129/Sv mice, and rats. 5-HT2ARs may be responsible for 
the stimulatory effect. By contrast, the inhibitory effect is likely mediated via 5-HT2CRs 
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activation. Thus, strain-dependent opposite effects could reflect a resistance toward 5-HT2CRs 
activation in C57BL/6 mice. 
 
Diving deeper into the noradrenergic mechanisms involved in the opposite NE release effects 
induced by (±)-DOI depending on the route of administration, it is suggested that the LC is the 
area of greater influence on the cortical noradrenergic effects. In this regard, although intra-
cortical (±)-DOI enhances NE output in the FC via 5-HT2ARs activation, the regulation exerted 
by the LC is more influential than the cortical one. Thus, the stimulatory effect is offset by 
activation of 5-HTRs in the LC, which leads to decreased NE levels in the FC after (±)-DOI 
injection. On the basis of these data, the inhibition of NE release in the FC after systemic 
(±)-DOI administration is suggested to be the result of a feedback inhibition induced by the 
increase of endogenous NE in the LC, which would activate α2-adrenoceptors located at a 
somatodendritic level in the LC. 
 
In line with these findings, it has been reported that schizophrenic patients have lower 
dopaminergic activity in the FC (Brisch et al., 2014). In animal models using PCP, it has been 
demonstrated that DA concentrations are decreased in the FC (Marcotte et al., 2001). Data 
from this study indicate that the hallucinogenic drug (±)-DOI via activation of 5-HT2AR yields 
similar effects in the FC, verifying that administration of (±)-DOI represents a good 
pharmacological model of psychosis. This deficit of DA release in the FC could produce 
negative and cognitive impairments. In accordance with this hypothesis, antipsychotic drugs 
that antagonize 5-HT2AR increase DA and NE output in the FC.  
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5.3. INVOLVEMENT OF mGluR2 AND Gi/o PROTEINS IN (±)-DOI-INDUCED 
EFFECTS IN MICE   
5.3.1. Role of 5-HT2AR in the effects induced by (±)-DOI 
Schizophrenia and hallucinations occur uniquely in humans, however, the use of animal 
models that resembles at least some of the positive symptoms of schizophrenia is necessary to 
study the etiology and pathophysiology of the disease. In spite of the difficulty of modeling 
hallucinogen effects in nonverbal species, animal models of schizophrenia based on 
psychedelics have yielded important insights into the identification of receptor targets and 
interactions that could be exploited in the development of new therapeutic drugs.  
 
Outcomes obtained from the present work reinforced the notion that 5-HT2AR activation is 
underlying (±)-DOI-induced hyperthermia, since while 5-HT2AR+/+ mice displayed marked 
increase in body temperature, 5-HT2AR-/- mice did not (Figure 112). There is a body of 
evidence demonstrating that 5-HT2ARs activation leads to a rise in body temperature 
(Pranzatelli, 1990; Mazzola-Pomietto et al., 1995; Mazzola-Pomietto et al., 1997; Salmi & 
Ahlenius, 1998; Zhang & Tao, 2011). 5-HT2AR antagonists such as ritanserin, ketanserin, 
metergoline, mesulergine, and methysergide, while they yield no effects by their own, 
attenuate (±)-DOI- and DOM-induced hyperthermia, unmasking the contribution of 5-HT2AR to 
evoke such effect (Pranzatelli, 1990; Aulakh et al., 1994; Mazzola-Pomietto, 1995; Salmi & 
Ahlenius, 1998). 5-HT2ARs on hypothalamic neurons could presumably produce temperature 
variation, since it is a brain area implicated in the regulation of body temperature.  
 
On the other hand, there is some controversy regarding the implication of 5-HT2CR activation 
in thermogenic effects. Thus, some researchers also suggest a role of 5-HT2CR activation in 
hyperthermia (Hayashi et al., 2004; Mazzola-Pomietto et al., 1997), blunted by 5-HT2CR 
antagonistm (Hayashi et al., 2004). Interestingly, 5-HT1ARs seem to exert opposite effects. In 
this sense, systemic administration of the 5-HT1AR agonist 8-OHDPAT induces hypothermia 
(Hjorth, 1985), and co-treatment with the 5-HT1AR antagonist WAY-100635 enhances (±)-DOI-
induced hyperthermia (Salmi & Ahlenius, 1998). 
 
Several lines of evidence indicate that 5-HT2AR activation induces HTR, sensoritomor gating 
impairments, hyperthermia, and hyperlocomotion, among others (Herin et al., 2005; 
Halberstadt et al., 2009). Previous findings have reported that LSD, mescaline, psylocybin and 
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(±)-DOI are all psychedelic drugs and potent 5-HT2A/2C receptor agonists that closely 
resemble positive clinical symptoms in schizophrenia, including perceptual disturbances, 
sensory processing deficits or changes in brain metabolism. 
 
Systemic administration of the potent agonist 5-HT2A/2C receptors (±)-DOI strongly yielded 
HTR in 129/Sv mice. Two different doses were tested intraperitoneally, 0.5 mg/kg and 1 mg/kg. 
Both doses of (±)-DOI exerted HTR, but the lowest dose induced significantly higher number of 
head movements than the highest dose (Figure 106). In order to evaluate the involvement of 
5-HT2ARs in (±)-DOI-induced HTR, this behavioral response was performed in 5-HT2A+/+ and 
5-HT2AR-/- C57BL/6 strain mice. As the provision of 5-HT2AR knockout mice on a 129/Sv strain 
mice was unavailable in our laboratory, experiments were carried out using C57BL/6 strain. 
Both mouse strains showed HTR when the 5-HT2AR agonist (±)-DOI (0.5 mg/kg i.p.) was 
administered, even C57BL/6 displayed higher number of head twitch events than 129/Sv mice, 
as previously reported (Canal & Morgan, 2012). Taking into account the bell-shaped response 
exerted by increasing doses of (±)-DOI, high doses could be binding to the 5-HT2CR. In this 
sense, dose of 1 mg/kg in 129/Sv mice could be acting at least partially through 5-HT2CR. In 
line with the results shown in the present work, there is evidence suggesting that this 5-
HT2A/2CRs agonism seems to be responsible for the bell-shaped dose-response curves 
obtained at some (±)-DOI-induced HTR experiments (Pranzatelli, 1990; Willins & Meltzer, 
1997). Thus, activation of 5-HT2AR appears to be responsible for the ascending portion of this 
bell-shaped dose-response curve, and therefore eliciting higher number of head movements. 
Meanwhile, 5-HT2CR activation accounts for the descending limb of the dose-effect curve of 
(±)-DOI indicating that, at higher doses of (±)-DOI, the hallucinogenic capability of this drug is 
reversed by its 5-HT2CR agonism (Fantegrossi et al., 2010). As mentioned above, a vast 
number of publications have earmarked 5-HT2AR for such HTR, an effect fully abolished by 
antagonists with higher affinity for 5-HT2AR such as ketanserin, ritanserin, mianserin, 
metergoline, methysergide and M100907, rather than for 5-HT2CR antagonists (Schreiber et 
al., 1995; Vickers et al., 2001). Supporting evidence to establish the no involvement of 
5-HT2CR in triggering HTR can be found when the 5-HT2CR agonist Ro 60-0175 is systemically 
administered alone and no head twitch response is observed. However, in the presence of 
pretreatment with 5-HT2CRs antagonist SB 242084, there is a dose-dependent increase in the 
number of head twitches induced by Ro 60-0175, probably attributable to 5-HT2ARs 
activation, inasmuch as it is abolished by low, selective doses of 5-HT2ARs antagonists as 
ketanserin or M100907 (Vickers et al., 2001). 
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The absence of 5-HT2AR leads to the suppression of HTR in mice, indicating that HTR requires 
the activation of 5-HT2AR (Figure 107). In that sense, results shown in the present work are 
consistent with previous studies showing null HTR in 5-HT2AR-/- (González-Maeso et al., 2007). 
It seems that the ability of (±)-DOI to evoke HTR in rodents is an effect restrictively associated 
to the activation of 5-HT2ARs located on cortical neurons of the mFC. Thus, the direct bilateral 
administration of (±)-DOI into both mFCs is able to induce HTR (Willins & Meltzer, 1997), and 
loss of the HTR in 5-HT2AR-/- mice can be rescued by selective restoration of the receptor in 
cortical regions (González-Maeso et al., 2007). 
  
 
5.3.2. Role of the 5-HT2AR/mGluR2 complex in the effects induced by (±)-DOI  
Several findings have demonstrated the necessity of the mGluR2 existence to evoke 
pharmacological and behavioral effects induced by hallucinogenic 5-HT2AR agonists. The 
present work shows a much lower number of (±)-DOI-induced head twitch movements in 
mGluR2-/- than in mGluR2+/+ mice, suggesting that the absence of mGluR2 is somewhat 
impairing the hallucinogenic 5-HT2AR-dependent effects, which is consistent with previous 
reports (Moreno et al., 2011a; Moreno et al., 2012). Looking deeper into the mechanisms 
underlying such effect, the existence of a heteromer made up between 5-HT2AR and mGluR2 
receptors being able to modulate distinct G protein signaling pathways has been thoroughly 
demonstrated. Psychoactive drugs as LSD or mescaline stimulate specific conformations of this 
5-HT2AR/mGluR2 heterodimer, whereas non-psychoactive 5-HT2AR agonists lisuride and 
ergotamine do not stimulate those conformations, leading to a differential signaling (González-
Maeso et al., 2007). 
 
Moreover, it has been demonstrated that hallucinogenic 5-HT2AR agonists induce a unique 
pattern of gene expression in mouse frontal cortex that predicts the behavioral effects 
(González-Maeso et al., 2003; González-Maeso et al., 2007). Thus, 5-HT2AR agonist 
hallucinogens induce c-fos and egr-2 expression, whereas non-hallucinogens induce only c-fos 
expression. In mGluR2-/- mice, 5-HT2AR agonist hallucinogenic drugs do not induce egr-2 
expression, only c-fos, unraveling the necessity of both receptors to exert that pattern of gene 
expression (Moreno et al., 2011a). This can lead to the assumption that the hallucinogenic-
specific signaling signature is affected in the absence of mGluR2, and suggests that the 
5-HT2AR/mGluR2 heteromer is necessary for the responses induced by LSD-like drugs. 
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Noteworthy, the level of expression of 5-HT2AR in mGluR2-/- mice is unaffected in mouse FC 
(Moreno et al., 2011a). 
 
In an attempt to investigate to what extent the 5-HT2AR/mGluR2 heteromer was involved in 
non-psychotic related behavior as hyperthermia, the hallucinogenic drug (±)-DOI was injected 
in mGluR2-/- mice and their respective wild-type controls. It was found that both mGluR2+/+ and 
mGluR2-/- displayed similar magnitude of hyperthermia (Figure 114), suggesting that the 
5-HT2AR/mGluR2 heterocomplex is not necessary for this effect induced by (±)-DOI. This 
finding reinforces the notion that (i) the heterocomplex is located only in FC and not in 
hypothalamus; (ii) it is more linked to psychosis-like features of hallucinogens; (iii) or both 
reasons.  
 
 
5.3.3. Role of the Gi/o-proteins in the effects induced by (±)-DOI 
In mouse cortical primary neurons it has been discovered that the signaling elicited by 
hallucinogen and non-hallucinogen 5-HT2AR agonists requires Gq/11-dependent signaling. 
However, the signaling of hallucinogenic 5-HT2AR agonists seems to be Gi/o protein-dependent. 
In order to further investigate the role of Gi/o-dependent signaling in HTR induced by (±)-DOI, 
the Gi proteins-inhibitor PTX was intracerebroventricularly administered. One of the most 
extended approaches to test PTX activity when used in in vivo assays is weight monitoring, 
since the α subunit of PTX induces lipolysis in adipocytes, so weight loss monitoring can be use 
as a good tool to verify the Gi/o protein signaling blockade. Mice exposed to i.c.v. injection of 
PTX showed a dramatic weight loss within the first two days that was not fully recovered over 
time (Figure 109), a hallmark that did not occur in VEH-injected mice. The largest weight loss 
was achieved two days after PTX injection, correlating to the highest (±)-DOI-induced HTR 
inhibition (Figure 110). It seems that after the second day of PTX administration, the 
(±)-DOI-induced HTR is recovered as weight gain is gradually increasing (Figure 111).  
 
The explanation regarding the loss of PTX efficacy over time might be partially explained by Gi/o 
protein turnover. As PTX inhibits Gi/o proteins in an irreversible way, its effects could 
conceivably be dissipated as new Gi/o proteins are synthesized, while inhibited G proteins are 
degraded. However, previous studies showed long-lasting suppressive effects of Gi/o proteins, 
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although observations evaluated completely different effects that comprise distinct mouse 
brain areas (Self et al., 1994; Shah et al., 1997). 
 
The role of Gi/o proteins, however, seems to be only partial, since the (±)-DOI-elicited HTR was 
not fully abolished. The latter can leads to the assumption that Gi/o proteins are involved in 
HTR but not exclusively. In this sense, the involvement of other signaling pathways cannot be 
ruled out, and the remaining Gi/o-insensitive effect could be yielded by activation of other 
pathways such as Gq proteins (Garcia et al., 2007). Additional reasons could be the use of 
insufficient dose of PTX, or a lack of dissipation of this toxin through the brain from the 
ventricular space. 
 
Whereas the canonical signaling 
pathway of 5-HT2AR is mediated 
by Gq/11 proteins, it has been 
suggested the hallucinogenic 
effects evoked by (±)-DOI are 
Gi/o-dependent (González-Maeso 
et al., 2007). It has been 
indicated that this hallucinogenic 
effect evoked by the 5-HT2AR 
activation requires the crosstalk 
with mGluR2 to activate Gi/o-
dependent signaling (González-
Maeso et al., 2008). Altogether 
provide additional insights into 
the in vivo 5-HT2AR/mGluR2 
heteromer functionality. 
 
Few articles have elucidated the 
potential signaling pathways 
involve in (±)-DOI-induced 
hyperthermia. Thus, the 
hallucinogen 5-HT2AR agonists 
(±)-DOI and LSD evoke 5-HT2AR-dependent body temperature variation, whereas the non-
hallucinogen R-lisuride evoked 5-HT2AR-independent body temperature variation (González-
Fig. 116- Schematic picture of G-protein-dependent signaling and 
behavioral responses that require a GPCR heterocomplex. (±)-DOI 
acting at the 5-HT2AR/mGluR2 heteromer (mGluR2
+/+
) activates both 
Gq/11- and Gi/o-dependent signaling, triggering head twitch behavior 
responses. Conversely, when 5-HT2AR and mGluR2 are prevented 
from forming a heteromer (mGluR2
-/-
), activation of 5-HT2AR by 
(±)-DOI evokes signaling through Gq/11 protein subtypes.  
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Maeso et al., 2007). Since the hallucinogenic and non-hallucinogenic 5-HT2AR agonist drugs 
differ in the presence or absence of Gi/o-protein coupling activation through 5-HT2AR, 
hyperthermia should be considered as a pharmacological response non-dependent on Gi/o 
proteins. 
 
For this purpose, PTX was i.c.v. administered and (±)-DOI-induced temperature variation was 
monitored. Animals pretreated with PTX showed similar magnitude of hyperthermia when 
administered (±)-DOI as the VEH-pretreated mice (Figure 113), suggesting that this non-
psychosis-like functional response is not mediated via Gi/o-proteins. 
 
It should be noted that warm ambient temperature strikingly influences the magnitude of the 
evoked hyperthermia. In this sense, (±)-DOI induces higher hyperthermia when experiments 
are undertaken in a thermoneutral zone or warm ambient temperatures (27-32°C) than in 
colder or even room temperature (12-22°C) (Zhang & Tao, 2011). Therefore, experiments in 
this work were carried out at a 26-27 °C ambient room temperature. 
 
In conclusion, these findings demonstrate for the first time that activation of 5-HT2AR and 
subsequent signaling through Gi/o-proteins are a prerequisite for triggering hallucinogenic-like 
responses inasmuch as inactivation of Gi/o proteins by PTX hampers HTR in mice. 5-HT2AR 
needs the functional presence of mGluR2 to evoke such HTR (Figure 116). Moreover, PTX, 
albeit inactivating Gi/o proteins, does not affect (±)-DOI-induced non-hallucinogenic responses, 
since (±)-DOI evokes a similar degree of body core variation. This finding indirectly suggests 
that hyperthermia induced by (±)-DOI administration is mediated by Gq/11 proteins, the 
canonical pathway of 5-HT2ARs. 
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1. The cortical administration of the hallucinogenic 5-HT2A/2C receptor agonist (±)-DOI 
evokes DA and NE release in the FC through the activation of 5-HT2ARs expressed on 
cortical neurons. In animals lacking 5-HT2AR, as well as co-perfusion of (±)-DOI with 
the 5-HT2AR antagonist M100907 in the FC of control mice, the effect was null or 
attenuated, respectively.  
 
2. The cortical administration of the hallucinogenic 5-HT2AR agonist (±)-DOI evokes NE 
release through the activation of iGluRs expressed on cortical neurons. The cortical 
co-perfusion of (±)-DOI with the iGluRs antagonist kynurenic acid blunted the 
(±)-DOI-induced effects on NE release. 
 
3. The proper cortical DA and NE release following the perfusion of (±)-DOI into the FC 
requires the presence of mGluR2, but not mGluR3, in this region. Animals lacking 
mGluR2 displayed lower catecholamine release induced by cortical perfusion of 
(±)-DOI, whereas animals lacking mGluR3 displayed a similar magnitude of 
catecholamine release as the one observed in control mice. 
 
4. Systemic administration of (±)-DOI enhanced DA release in the FC of C57BL/6 mice, 
through the activation of 5-HT2ARs. Animals lacking 5-HT2AR displayed negligible 
effects on DA release following systemic (±)-DOI administration. However, (±)-DOI did 
not exert any modulation on NE output in C57BL/6 mice. 
 
5. Systemic administration of (±)-DOI decreased DA and NE release in the FC of 129/Sv 
mice. The degree of implication of 5-HT2AR and/or 5-HT2CR in triggering these 
(±)-DOI-induced effect remains to be further elucidated. In the same way, systemic 
administration of the 5-HT2CR agonist Ro 60-0175 decreases DA and NE release in the 
FC. Co-injection of (±)-DOI with the 5-HT2AR antagonist M100907, as well as with the 
5-HT2CR antagonist SB242084, antagonizes the inhibitory effects induced by (±)-DOI in 
the FC. 
 
6. The presence of mGluR2 is not required for the inhibitory effects on DA and NE release 
induced by systemic administration of (±)-DOI in the FC of 129/Sv mice. Animals 
lacking mGluR2 displayed similar magnitude of inhibition that the one observed in 
control mice. 
 
7. Systemic administration of (±)-DOI enhanced NE release in rat LC, whereas decreased 
NE output in the FC. A negative correlation between NE concentrations in FC and LC 
was revealed. Subcortical pathways seem to play a role in the effects observed in the 
FC following (±)-DOI injection. 
 
8. The α2-adrenoceptors antagonism in the LC abolished the inhibitory effects on NE 
release in the FC of rats induced by (±)-DOI. 
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9. Perfusion of the iGluRs antagonist kynurenic acid into the rat LC did not blunt either 
the inhibitory effects on NE release in the FC induced by (±)-DOI or the stimulatory 
effects observed in LC. Glutamatergic afferent projections toward the LC do not seem 
to play a role in these effects. 
 
10. Systemic administration of (±)-DOI induced head twitch response through a 
mechanism that requires the presence of 5-HT2AR and mGluR2. Animals lacking 
5-HT2AR, or mGluR2, exhibited negligible or much lower number of head movements, 
respectively. 
 
11. Gi/o proteins are involved in the head twitch response induced by (±)-DOI. The 
intracerebroventricular administration of the Gi/o protein inhibitor pertussis toxin, 
attenuated the head-twitch response induced by systemic administration of (±)-DOIin 
mice. The maximal attenuation was yielded two days after the injection of pertussis 
toxin, which correlates with the greater weight loss. 
 
12. Systemic administration of (±)-DOI induces hyperthermia through a mechanism that 
requires the presence of 5-HT2AR but not mGluR2. Animals lacking 5-HT2AR did not 
display any body temperature variation following (±)-DOI injection, but animals lacking 
mGluR2 showed increased body temperature similar to their respective controls. 
 
13. The hyperthermia evoked by systemic administration of (±)-DOI seems not to be 
Gi/o-dependent, since the intracerebroventricular injection of pertussis toxin did not 
abolish that effect. 
 
14. The findings shown in the present work suggest that modulation of DA and NE release 
in FC could represent an in vivo functional index of the mGluR2/5-HT2AR 
heterocomplex activation by hallucinogenic 5-HT2AR agonists. This activation is 
mediated by the non-canonical 5-HT2AR signaling pathway coupled to Gi/o proteins. 
Therefore, an in vivo biased agonism activation of this receptor is demonstrated. 
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